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1: Normal Heart Function 
 
The Cardiac Cycle 
The heart is a muscular pump, providing blood flow through the cardiovascular 
system, needed for normal body function. The cardiovascular system can be divided 
into a cardiac and a circulatory component. The cardiac component itself can be 
subdivided into the right heart side, supplying blood flow for the low pressure 
pulmonary circulation, and the left side, which provides blood flow for the high 
pressure coronary and systemic circulation (Figure 1). During a relaxation phase, i.e., 
diastole, the lumen of the ventricle is filled with blood. During systole, the ventricle 
wall contracts, reducing its lumen volume, and ejects the blood from the lumen into 
the arteries. 
With each contraction, 55-75% of the blood in the ventricular cavity is ejected into 
the arteries under normal workload conditions, with mean arterial pressures of 15 
mmHg and 90 mmHg developed by the right and left ventricle, respectively. This is 
sufficient to provide every organ with adequate blood flow. 
 
Excitation – Contraction Coupling 
The heart consists of several cell types, 
e.g., endothelial cells, smooth muscle 
cells, fibroblasts, pacemaker cells and 
cardiac myocytes. Cardiac myocytes are 
rod shaped cells with a diameter of 10-25 
µm and a length of 100-200 µm. They 
are arranged in series, connected by 
intercalated discs forming myofibers. The 
outer or sarcolemmal membrane of a 
myocyte has deep invaginations called T-
tubules, bordering the sarcomeres of the 
myofilaments. The sarcomeres are the 
superior
vena cava
right
atrium
tricuspid
valve
right
ventricle
inferior
vena cava
aorta
pulmonary
artery
left atrium
mitral valve
left ventricle
pulmonary vein
left semilunar
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▲Figure 1 - Heart and circulation. Within each heart cycle, blood is collected in the right 
atrium (RA) from both the superior and inferior vena cava. The right ventricle (RV) is 
subsequently filled with blood from the RA during RV diastole and during RV systole, blood is 
ejected from the RV, passing the right semilunar valves, into the pulmonary arteries. In the 
lungs, carbon dioxide (CO2) is released from the blood and oxygen (O2) is bound to the 
hemoglobin of red blood cells. Parallel to the entry into the right side of the heart, blood is 
collected from the pulmonary veins in the left atrium (LA) and released into the left ventricle (LV) 
after which the blood is pumped during LV systole, passing the left semilunar valves, into the 
aorta. The heart itself is the first organ to be perfused by oxygenated blood via the coronary 
circulation. Each heart cycle is synchronized in a way that first both atria contract 
simultaneously, releasing blood into the ventricles. After a small pause, both ventricles will 
subsequently contract.  
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smallest functional units of the myofibers, consisting of myosin, forming the thick 
filaments and actin, tropomyosin and troponins in the thin filaments. The cardiac 
myocytes comprise approximately 75% of the total heart volume and convert the 
chemical energy stored in adenosine triphosphate (ATP) into mechanical energy, i.e., 
contraction, in a process called excitation contraction coupling (ECC). Central in the 
mechanism of ECC are fluctuations in intracellular calcium concentration ([Ca2+]i)1. 
Calcium is the second messenger that relays the signal of the action potential from 
the T-tubule of the sarcolemma to the contractile elements, initiating cross-bridge 
cycling of the actin and myosin filaments. The action potential triggers a rise in 
[Ca2+]i through a calcium - induced - calcium – release (CICR) from the 
sarcoplasmatic reticulum (SR), which in turn initiates actin-myosin cross-bridge 
cycling and shortens the sarcomeres during systole (Figure 2). At end systole, [Ca2+]i 
is reduced to baseline levels, allowing for the diastolic phase. 
 
Calcium Handling 
There are several transporter systems present in cardiac myocytes that mediate the 
decrease in [Ca2+]i to baseline levels and thus terminate the ECC cycle. These 
systems balance the influx of calcium from beat to beat, maintaining a constant total 
calcium content of the myocyte. First, L-type channels (LTCC) are closed by a 
negative feedback loop responding to the increasing [Ca2+]i itself, preventing more 
calcium from entering the cells. Reduction of [Ca2+]i is driven by three routes, each 
with different contributions and transporting calcium from the cytosolic compartment 
to different locations2. A marginal percentage is handled by the sarcolemmal Ca2+-
ATPase and the mitochondrial Ca2+ uniporter, i.e., the slow systems, and these do 
not significantly contribute to the [Ca2+]i fluxes. The sodium-calcium exchanger 
(NCX) which is located in the sarcolemma, transports calcium to the outside of the 
cellular compartment. The main contribution to the reduction of [Ca2+]i, however, is 
by the sarcoplasmic-endoplasmic reticulum Ca2+-ATPase (SERCA2a), pumping 
calcium back into the SR (Figure 2, step 5). SERCA2a pump activity is increased 
when its inhibitory regulator protein phospholamban is phosphorylated by Ca-
calmodulin-dependent protein kinase (CaMK) II and protein kinase A (PKA) at high 
[Ca2+]i levels1. 
There are differences in the contribution of extracellular and SR calcium and hence 
the contribution of the different transport systems between species. Ferret, dog, cat, 
guinea-pig, rabbit and human myocytes show a similar distribution (70% SERCA2a 
vs. 28% NCX vs. 2% slow systems) in contrast to rat and mouse which are much 
more dependent on SERCA2a expression levels (92% SERCA2a vs. 7% NCX vs. 1% 
slow systems)1.  
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Beta-Adrenergic Receptor Signalling 
Cardiac output and contraction frequency can be varied by alterations in noradrenalin 
(NA) and adrenaline levels via modulation of beta-adrenergic receptor (βAR) 
signalling, allowing for acute responses to increased cardiac output demand. Of the 
subtypes of βAR expressed on cardiac myocytes, the β1 and β2 types have been 
shown to mediate positive inotropic effects in contrast to negative inotropic effects 
via β3 type signalling3, 4. Signalling through the βAR types 1 and 2 involves the 
stimulatory G protein (Gαs) cascade, resulting in increased production of cAMP via 
adenylyl cyclase activation. Subsequently activated PKA modulates myocyte 
contraction via phosphorylation of many intracellular protein targets, resulting in 
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▲Figure 2 - Calcium Handling. When the sarcolemma is depolarized (step 1), a small 
amount of calcium enters the cell through opening of the L-type calcium channels (LTCC) (step 
2). Within milliseconds, this small increase in [Ca2+]i from the LTCC triggers a calcium - induced - 
calcium - release from the sarcoplasmatic reticulum (SR) through the ryanodine receptor 
complexes located in the SR membrane (step 3). This results in an approximately 100 fold 
increase in total free [Ca2+]i. Calcium binding to troponin C (TnC) induces a conformational 
change in troponin I (TnI), allowing actin-myosin cross-bridge cycling. When TnI inhibition is 
relieved, the myosin head reaches forward and binds to actin. Chemical energy from ATP 
hydrolysis is converted into mechanical energy when the myosin head bends through a 45º 
angle, sliding the actin and myosin filaments past each other, shortening the sarcomere and thus 
muscle fibre length (step 4). The actin-myosin complex dissociates at the end of the cycle when 
new ATP is bound. Myosin returns to its resting conformation, cleaves the ATP and resets the 
system to starting conditions, ready to repeat the cycle. This will continue for as long as there is 
enough calcium present to keep TnI in the disinhibiting conformation2, allowing for relaxation 
only if the [Ca2+]i has reached baseline levels again (step 6). 
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increased Ca2+ influx via the LTCC, increased Ca2+ re-uptake in the SR via PLB / 
SERCA2a and myofilament Ca2+ sensitivity via TnI. However, the β2 receptors are 
also coupled to the inhibitory G proteins (Gαi), and thus may also reduce cAMP levels 
through inhibition of adenylyl cyclase. Consequently, the β1 to β2 receptor ratio is an 
important parameter. 
  
Myocardial Energy Metabolism 
During normal cardiac function, over 95% of all cellular ATP is produced via oxidative 
phosphorylation in the mitochondria, with only a small contribution from the 
glycolysis pathway. Approximately 60-70% of the total ATP content is used for 
sarcomere shortening during systole while the remaining 30-40% drives ion 
channels, primarily SERCA2a for calcium re-uptake into the SR.  
Under normal conditions, approximately 70% of ATP generation depends on oxidation 
of fatty acids (FA). These FA are processed in the mitochondrial matrix by the fatty 
acid beta-oxidation pathway to yield acetyl-CoA and the reduced flavin adenine 
dinucleotide (FADH2). The remaining 30% of ATP generation depends primarily on 
pyruvate derived from glucose and lactate. Acetyl-CoA is also produced from 
pyruvate by the pyruvate-dehydrogenase (PDH) complex in the inner mitochondrial 
membrane. The acetyl-CoA from both these pathways enters the tricarboxylic acid 
(TCA) cycle to generate reduced nicotinamide adenine dinucleotide (NADH). The 
NADH and FADH2 from these pathways are used in the electron transport chain to 
build an electrochemical proton-gradient across the inner mitochondrial membrane, 
which enables ATP synthesis during oxidative phosphorylation. 
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2: Cardiomyopathy 
 
Cardiac Adaptation 
Cardiac function may be compromised following an “index event” leading to pressure 
or volume overload. As a direct result, the ventricles will sense an increase in wall 
stress, triggering a compensatory response that is aimed at normalizing wall stress 
and maintaining adequate blood flow. A general mechanism of the heart to 
compensate for this increased workload is hypertrophic remodelling of the ventricular 
wall. In the setting of pressure overload, which may for instance develop during 
(pulmonary) hypertension or aortic valve stenosis, the thickness of the ventricular 
wall will increase5 due to the addition of new sarcomeres in parallel to already 
existing sarcomeres at the individual myocyte level. This is termed concentric 
hypertrophy. Cardiac hypertrophy, by definition, is the result of an abnormal increase 
in myocyte dimensions and not an increase in the number of these cells6. The 
adapted ventricle is then more capable of generating forces and pressures to cope 
with the increased workload, while the increased wall diameter normalizes wall stress 
(Figure 3). Volume overload may occur due to heart block, regurgitant mitral or 
aortic valves, atrial or ventricular septal defects, or other congenital diseases. Here 
also, new sarcomeres are added to existing ones, but in series rather than in 
parallel5. This hypertrophic response is called eccentric hypertrophy. It leads to an 
increase in end-diastolic volume of the ventricle, showing greater than normal cavity 
dimension at end-diastole, and results in an increased end-diastolic volume of the 
ventricular lumen, and a resulting rise in stroke volume, which compensates for 
excess blood remaining in the LV (Figure 3).  
 
Adaptive vs. Maladaptive Remodelling 
Cardiac hypertrophy is generally thought to be a necessary, beneficial, compensatory 
reaction in response to increased workload7. This was already recognized during the 
18th and 19th century by JB. Morgagni8, FA. 
Aran9 and R. Virchow10. Indeed, many patients 
remain free of clinical events for a long time after 
the index event has occurred. In contrast to this 
adaptive (physiological) response, cardiac 
hypertrophy may progress to heart failure when 
the overload is too high or is maintained for too 
Pressure
overload
Volume
overload
►Figure 3 – Pressure and volume overload: 
Schematic representation of sarcomere addition during 
pressure overload and volume overload (grey 
sarcomeres) to the pre-existing sarcomeres in the 
normal situation (black sarcomeres).  
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long a period of time (pathological hypertrophy).  
A substantial amount of research over the last couple of decades has lead to 
important insights into processes that govern the development of ventricular 
hypertrophy and heart failure, e.g., alterations in signal transduction cascades, 
energy metabolism and calcium handling (for a detailed description of such 
processes, see section 3 and 4). However, it still remains an enigma which signalling 
pathway or combination of pathways is critical for the development of a pathological 
hypertrophic phenotype. Furthermore, it is unclear whether the alteration of these 
processes is predominantly qualitative or quantitative in nature. 
Also, little information is available concerning the sequence in time at which these 
molecular alterations take place. For the majority of observed changes it is unknown 
whether these occur as a direct result of the pressure overload sensed by the 
myocardium, or, as a secondary response to preceding changes. Contemporary 
theory states that a compensated form of hypertrophy may either remain as a 
adaptive phenotype, or subsequently progress to a maladaptive phenotype. 
Progression to heart failure would be mediated by a deterioration of survival 
signalling, relative to the pro-hypertrophic stimuli. It remains to be seen whether a 
pathological phenotype is induced early during overload, as a function of the degree 
of mechanical overload, or, only as a secondary response when compensation is 
insufficient11-13, i.e., end point trigger vs. early origin of differences between 
phenotypes. 
 
Defining Heart Failure 
Patients who have been diagnosed with heart failure, have hearts with depressed 
contractile capabilities, leading to decreased cardiac output. Heart failure contributed 
to approximately 287.200 deaths in the year 1999 in the United States and on 
average, 5 million cases of heart failure exist in the U.S alone. Two recent 
epidemiological studies14, 15, based on two separate populations, indicated an overall 
higher incidence of heart failure in men, with no decreased incidence over time. For 
women however, one study showed decreased incidence15 while the other indicated 
no change14 during the last two decades. Both studies indicated an overall increase in 
the survival rate, in particular for men and young persons. However, this increase in 
survival rate was less prominent in women and the elderly. With an overall 5 year 
survival rate of 52% and an increasing elderly population, heart failure remains a 
major health problem. Similarly, an estimated 0.4 - 2% of the European population 
suffers from heart failure16. There is no single definition that fully describes heart 
failure in all its facets17. It is a clinical end-point of a syndrome characterized by a 
progressive loss of pump function, manifested by respiratory distress, pedal edema 
General Introduction 
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and ascites, and profound exercise intolerance. The New York Heart Association 
(NYHA) has provided a heart failure classifications framework (Figure 4), which 
classifies patients in four groups, according to the severity of the observed 
symptoms. However, heart failure may result from a wide variety of disorders, and, 
although the observed pathophysiological phenotype at end-point heart failure 
resulting from distinct etiologies may appear to be similar, the underlying changes at 
the molecular level can be profoundly different. Also, a single etiologic factor may 
result in a drastically different phenotype in individuals with a different genetic 
background. Furthermore, co-morbidities like viral infection, inflammation, 
hyperthyroidism and metabolic disease may significantly contribute to the 
progression to heart failure18-20, indicating the importance of interactions between 
disease-related factors, the environment and genetic background. Recently, a new 
classification proposal was issued, which also classifies patients according to the 
specific etiology, in addition to the stage of development20 potentially leading to a 
more specific and effective treatment of the patient. 
◄Figure 4: NYHA heart failure 
classification 
 
Class I: patients with no limitation 
of activities; they suffer no 
symptoms from ordinary activities. 
 
Class II: patients with slight, mild 
limitation of activity; they are 
comfortable with rest or with mild 
exertion. 
 
Class III: patients with marked 
limitation of activity; they are 
comfortable only at rest.  
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3: Alterations During Ventricular Hypertrophy And Heart Failure 
 
Characteristic features of hypertrophic remodelling at the cellular level, in addition to 
the aforementioned myofibrillar re-organization, are changes in calcium handling21, 
evident from decreased peak systolic [Ca2+]i, increased diastolic [Ca2+]i and 
prolonged diastolic [Ca2+]i decay. Also, extracellular matrix composition22, 23, 
cytoskeletal proteins24, β-adrenergic receptor signalling3, 4, mitochondrial energy 
metabolism25, myocyte survival26 and alterations in gene-expression patterns of both 
the messenger RNA (mRNA) and protein level can generally be observed. The main 
processes implicated in heart failure are briefly discussed in the following sections. 
 
Fetal Gene Program 
At the earliest stages of ventricular remodelling, a set of growth related genes is 
rapidly, yet transiently expressed in the myocardium. These are the first changes to 
be detected after the rise in pressure, and were subsequently called the “immediate 
early genes” (IEG). Typical members of this group of genes are members of the early 
growth response (Egr) family and the proto-onco genes c-fos and c-jun27 in addition 
to GATA-4, Nkx-2.5/Csx, myocyte enhancing factor (MEF)-2 and the HAND family28. 
These genes encode transcription factors that can subsequently stimulate alterations 
in gene-expression patterns. These changes in gene-expression are indicative for the 
initiation of a hypertrophic or fetal gene program, in which the adult protein isoforms 
are replaced by their fetal counterparts. Typical changes are increases in skeletal a-
actin with concomitant decreases in a-cardiac actin29, and a switch in the myosin 
heavy chain (MHC) α to MHCβ expression ratio30, 31. Also depressed SERCA2a23, 32 
levels and increased natriuretic peptide type A and B (ANP and BNP) expression are 
observed29.  
 
Altered Beta-Adrenergic Receptor Signalling 
Absolute cardiac βAR expression levels are at 50-70 fmol/mg membrane protein. In 
the normal heart, the β1 to β2 expression ratio is approximately 70:30, at which 
catecholamine stimulation would lead to an overall increase in cAMP production. 
During heart failure, although the β2 levels are unaffected, β1 expression levels are 
reduced to such an extent that the β1 to β2 ratio may reach 50:50. Relatively 
increased Gαi contributions in this situation, results in a decreased generation of, and 
response to, cAMP upon catecholamine stimulation. In addition, hypertrophic 
remodelling has also been associated with an increased activity of G protein receptor 
kinases (GRKs), in particular the GRK2 (βARK1). These kinases trigger the 
internalization and degradation of βARs. Both the receptor degradation and the 
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reduction of cAMP effectively lead to a desensitization to catecholamine drive. This 
appears to be an adaptive response since sympathetic activation is inversely 
correlated with survival33. Although it is generally thought that β1 and β2-ARs 
mediate pro- and anti-apoptotic signalling respectively, the precise mediators for 
these effects remain to be identified.  
 
Changes In Energy Metabolism 
In general, during the earliest stages in the development of heart failure through 
pressure overload, energy substrate distribution is relatively normal. However, in the 
advanced stages, a severe downregulation in fatty acid oxidation is observed, 
accompanied by increased glycolysis and glucose oxidation, reduced respiratory chain 
activity and impaired reserve for mitochondrial oxidative flux and reduced myocardial 
ATP content34. However, despite the strong association between the substrate switch 
and the development of heart failure, there is evidence that supports a beneficial role 
of this change35, 36. In addition, theoretically, glucose and lactate yield approximately 
11% more ATP per oxygen used than fatty acids do37. However, ATP yield will be 
decreased for both glucose / lactate and fatty acid oxidation (FAO) if the inner 
mitochondrial membrane is uncoupled, and thus is unable to take full advantage of 
the proton-gradient. This is particularly important since FA have been shown to be 
able to uncouple oxidative phosphorylation. 
The basis for this switch away from FAO can be found at both the transcription and 
protein activity level of peroxisome proliferator activated receptor-α (PPARα) and the 
transcription factor PPARα coactivator-1a (PGC-1a). In the normal postnatal heart a 
complex of PPARα, retinoid x receptor-α (RXRα) and PGC-1a, bound to a PPAR 
responsive element (PPRE) in the promotor region of a FAO related gene, functions 
as a lipid sensor switch. Upon fatty acid binding, the complex is activated and gene 
transcription can commence, in principle allowing for the simultaneous regulation of 
many related genes with PPRE motifs38. 
A decrease in both PPARα39 and PGC-1a40 has been demonstrated in the pressure-
overloaded heart and several signalling cascades have been shown to mediate these 
changes. Cardiac specific over expression of a constitutively active form of protein 
kinase B (PKB / Akt), lead to the decreased expression of both PPARα and PGC-1a41. 
In addition, PGC-1a has been shown to be inhibited via ERK1/2 signalling, while it is 
stimulated by calcineurin A, CaMK, nitric oxide / cGMP, β-adrenergic / cAMP signalling 
and p38 MAPK25. 
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Mitochondrial Structure And Biogenesis 
Mitochondria are small subcellular organelles 1-4 µm in length which comprise 30-
50% of the total cardiac myocyte volume. Their best known function is the 
generation of high energy ATP from adenosine diphosphate (ADP) through oxidative 
phosphorylation. In addition, mitochondria are involved in processes like apoptosis, 
regulation of the cellular redox state, heme synthesis, steroid synthesis and heat 
production. They consist of a highly folded inner membrane, forming cristae, 
surrounding the matrix compartment. This inner membrane contains, in addition to a 
number of highly selective transporter complexes, a crucial series of proteins needed 
for respiratory chain function, i.e., NADH dehydrogenase (Complex I), succinate 
dehydrogenase (Complex II), cytochrome-C reductase (Complex III; also known as 
the cytochrome B-C1 complex), cytochrome C oxidase (Complex IV) and ATP 
synthase (Complex V). Surrounding the mitochondrion is the outer membrane, 
containing a large number of pore-forming complexes that control transport in and 
out of the intermembrane space, however, molecules smaller than 15kD are able to 
diffuse freely in and out of the intermembrane space. The integrity of these two 
membranes is imperative for proper mitochondrial function. 
Mitochondria contain 5-10 copies of double stranded, circular mitochondrial DNA 
(mtDNA), each approximately 16.5 kb long, coding for 22 tRNAs, two rRNA and 13 
protein subunits for complexes I, III and IV of the respiratory chain. These genes 
have no introns, and the two non-coding regions contain the two promotor regions 
for transcription initiation and the origin of replication. After both strands are 
completely transcribed, strands for mRNA, rRNA and tRNA are excised and non-
coding RNA is degraded. The majority of the estimated 1000 proteins comprising 
mature mitochondria are so called nuclear-encoded mitochondrial (NEM) genes, i.e., 
respiratory chain complex subunits, membrane carriers, matrix enzymes and 
transcription-translation related proteins. Fully functioning protein complexes are 
formed with their mtDNA-encoded counterparts, after these proteins have been 
imported into mitochondria via translocator complexes of the outer and inner 
membranes, TOM and TIM, respectively, which are structured at contact sites (CS) 
which fuse the inner and outer membranes.  
PGC-1a is not only involved in transcriptional gene-expression regulation of FAO-
related proteins, it is also directly involved in mitochondrial biogenesis through 
regulation of increased nuclear respiratory factor (NRF) 1 and NRF-2 expression, 
which in turn are almost exclusively involved in the regulation of NEM genes. Of 
these genes, it is the mitochondrial transcription factor A (TFAM), which is crucial for 
the replication, maintenance, and transcription of the mitochondrial genome. 
Genetically modified mice with a cardiac-specific deletion of the TFAM gene, showed 
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severe respiratory chain deficiency in addition to characteristic gene-expression 
alterations for heart failure42, 43 and apoptosis42. Also, profound alterations in calcium-
handling genes were observed, e.g., decreased expression of Ryr, calsequestrin 2, 
LTCC, NCX and SERCA2a44. Interestingly, TFAM has been shown to be downregulated 
in a model for pressure overload at end-point heart failure, accompanied by reduced 
expression levels of nuclear and mitochondrial subunits for complex IV of the 
respiratory chain40. Furthermore, mice over-expressing human TFAM showed reduced 
LV remodelling and mortality after myocardial infarction45. 
 
Mitochondrial Dysfunction 
Altered structure, function and number of mitochondria in the cell may indicate 
mitochondrial dysfunction, which leads to impaired energy production, loss of 
contractility and cell death46. The development of heart failure may involve an 
abnormally high frequency of myocyte apoptosis that can persist for a prolonged 
period of time47, 48. Apoptosis can be triggered via various stimuli, including ischemia-
reperfusion, β1-adrenergic stimulation, stretch, angiotension II, tumor necrosis 
factor–α and oxidative stress49. One inherent by-product of normal cellular activity is 
the production of a small amount of reactive oxygen species (ROS) from 1-5% of the 
oxygen that is consumed during cellular respiration in the mitochondrial respiratory 
chain50, meaning that conditions that demand higher levels of oxygen consumption 
consequently result in higher levels of cellular ROS. Of the many possible sources of 
ROS, mitochondria, xanthine oxidase and the non-phagocytic NADPH oxidases 
(Noxs), are the predominant sources of ROS in heart failure. Under normal 
conditions, the ROS species are effectively scavenged by antioxidant systems, 
including the mitochondrial superoxide dismutase 2. Evidence exists that excess ROS 
production causes myocyte dysfunction and apoptosis51, 52. Increased mitochondrial 
ROS production may severely impair cellular and mitochondrial function, by 
damaging proteins, lipids and mtDNA, which in turn may lead to increased generation 
of ROS. In contrast to genomic DNA, mtDNA is relatively unprotected and resides in 
close proximity to the inner mitochondrial membrane where ROS is generated. It is 
therefore much more susceptible to ROS damage than the nuclear genome. 
Mutations in the mtDNA may lead to non-functional respiratory-chain proteins and 
impaired mitochondrial replication.  
Increased cellular ROS, but also long chain fatty acids and calcium, may lead to the 
opening of the mitochondrial permeability transition pore (mtPTP), which is a 
channel, with the adenine nucleotide translocase 1 (ANT1) and the voltage 
dependent anion channel 1 (VDAC1) located on the inner and outer membranes, 
respectively, as part of the membrane contact sites. mtPTP opening leads to the loss 
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of the membrane potential (Δψ) and cytochrome-C release from the intermembrane 
space into the cytosol, activation of caspase3 and subsequently to apoptosis.  
 
Extracellular Matrix Composition 
The extracellular matrix (ECM) is crucial for maintaining the integrity and normal 
geometry of the heart. It does not merely provide a supportive scaffold by 
surrounding and interconnecting the cardiac myocytes, aligning them in muscle 
fibers, but the matrix also plays a complex and divergent role in influencing cell 
behaviour, e.g., cell migration, proliferation, adhesion, and cell-to-cell signalling53. 
The primary constituents are elastin and collagen fibers, of which five forms are 
expressed in the heart, i.e., collagens I, III, IV, V and VI. Collagen type I, comprising 
approximately 85% of the total collagen content, has a tensile strength close to iron, 
enabling the heart to resist deformation, while collagen type III (11% of the total 
content) displays more flexible properties. Collagen types IV and VI are involved in 
cellular adhesion via integrins as components of the basal lamina. Other constituents 
of the ECM are adhesive proteins (fibronectin and laminin), anti-adhesive proteins 
(tenascin, thrombospondin and osteopontin) as well as proteoglycans, integrins and 
metalloproteinases54, 55. 
There is a balance between ECM degradation and formation. Matrix 
metalloproteinases (MMP) are endopeptidases, predominantly produced by 
fibroblasts56 and mast cells57, that degrade elements of the ECM. Four groups of 
MMPs can be discerned, based on their primary specificity for matrix components, 
i.e., collagenases (MMP-1 and MMP-13), gelatinases (MMP-2 and MMP-9), 
stromelysins (MMP-3), and membrane-type MMPs (MT1-MMP)58. They are secreted 
into the ECM in an inactive state zymogen, and are activated by cleavage by serine 
proteases like cathepsin G, trypsin and plasmin. MMPs induce collagen degradation 
by cleavage of these proteins at a site near the C-terminal domain. The remaining 
fragments are unstable and are denatured, leaving them susceptible to degradation 
by non-specific proteases. A family of four endogenous proteins called the tissue 
inhibitors of metalloproteinases (TIMP1 to TIMP4) inhibit MMP activity by binding 
MMPs in a 1:1 ratio, completely abolishing their activity to degrade their substrates. 
Examinations of failing hearts, provided evidence of abnormal ECM turnover, e.g., 
alterations in the amount, type, stability, and organization of fibrillar collagen. More 
specifically, MMP dysregulation appears to be associated with heart-failure 
development56, 58-60. Also, MMPs produced by mast cells have been implicated in the 
development of heart failure61. Moreover, the use of an MMP inhibitor was able to 
significantly reduce LV dilatation and preserve systolic function in a study using SHHF 
rats62.   
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4: Signal Transduction Cascades Involved In Myocardial Hypertrophy 
 
Hormones from autocrine/paracrine or neuroendocrine origin and different forms of 
stress, e.g., altered hemodynamic loading, toxic insults and infections, initiate and 
activate signal transduction cascades that can lead either to acute responses, or on 
the longer term, to alterations in gene-transcription activity. Multiple signal 
transduction cascades, with considerable cross-talk, have been shown to be involved 
in hypertrophic remodelling and heart failure12, 63-65.  
 
Mitogen-Activated Protein Kinase Cascades 
The mitogen-activated protein kinase (MAPK) pathways represent three parallel 
branches of successive, serine threonine kinases named after their terminal effector 
kinases, i.e., the extracellular signal-regulated protein kinases (ERK), c-Jun NH2-
terminal kinases (JNK) and p38, which are activated by dual phosphorylation on a 
threonine and a tyrosine residue lying within a T–X–Y motif. Unambiguous roles for 
each of these three signalling branches have yet to be defined, however, reports 
indicate both pro and anti-apoptotic effects for JNK and p38 while ERK appears to be 
predominantly involved in survival signalling65, 66.  
 
Calcineurin/NFAT Signalling 
Calcineurin (Cn), a serine threonine protein phosphatase, is activated during 
sustained elevations in [Ca2+]i, essentially linking impaired calcium handling to 
alterations in gene-expression. Activated Cn dephosphorylates a family of 
transcription factors called the nuclear factors of activated T-cells (NFAT), which 
subsequently translocate to the nucleus and, in cooperation with other active 
transcription factors, are involved in the regulation of transcription initiation of 
various genes. Activation of the Cn/NFAT pathway manifests itself as a “two-edged 
sword”. While a transient activation antagonizes myocyte apoptosis, prolonged 
activation induced myocyte hypertrophy with deleterious effects ultimately leading 
the heart failure65, 67, 68. 
 
PI3K / Akt / Gsk3β Cascades 
The phosphatidylinositol 3-kinase / protein kinase B (PI3K/Akt) signalling cascade is 
implicated in adaptive cardiac hypertrophy. Overexpression of either constitutively 
active PI3K or Akt leads to concentric hypertrophy with preserved function and 
without signs of fibrosis69-71. Glycogen synthase kinase 3β (Gsk3β), an ubiquitously 
expressed and constitutively active serine/threonine kinase, is involved in processes 
like development, cytoskeletal turnover, apoptosis, cell cycle, metabolism and gene-
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expression. Under normal, un-stimulated conditions, it is active and serves as a 
negative regulator of cardiac hypertrophy by actively inhibiting downstream signalling 
cascades72-75. Gsk3β is able to interfere with the activity of specific transcription 
factors through the triggering of a nuclear exit signal, e.g., GATA4, NFAT and STAT, 
or, by attenuation of DNA binding, e.g., CREB, c-Jun, junD and HSF-172. 
Phosphorylation at the Ser9 residue, which may occur due to multiple upstream 
kinases, including Akt, disinhibits its negative regulatory actions, allowing for 
hypertrophic signals to continue uninterrupted.  
 
GATA4 Transcription Factor 
GATA4 is one of the earliest transcription factors expressed in developing cardiac 
myocytes76. Both the ERK and p38 MAPK cascades regulate the activity of the GATA4 
transcription factor, by phosphorylation of Ser10577, 78 and mediates gene-expression 
alterations during cardiac hypertrophy through interaction with several other 
transcription factors and/or nuclear co-factors, e.g., p300, serum response factor 
(SRF), Nkx2.5, MEF2 and NFAT79. Moreover, GATA4 appears to mediate anti-
apoptotic effects, making it a myocyte survival factor80, 81. 
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5: Controlled Induction Of Adaptive Or Maladaptive Hypertrophy  
 
Many animal models are available of human myocardial hypertrophic responses due 
to pressure overload. Although interspecies differences are known to exist, e.g., 
calcium handling, action potential, heart rate and MHC α to β ratio, animal studies 
are necessary to define the essential mechanisms underlying myocardial disease 
states82. 
One frequently used animal model to study the processes associated with myocardial 
dysfunction is the monocrotaline (MCT) model for pulmonary hypertension and 
subsequent RV hypertrophy due to pressure overload83-86. MCT is a pyrrolizidine 
alkaloid derived from Crotolaria spectabilis and after a single subcutaneous injection, 
the MCT is biotransformed in the liver to its active metabolite monocrotaline-pyrrole 
(MCTP) by the cytochrome P-450 3a system87, 88. The MCTP has a very short half-life 
in aqueous solutions and only through stabilisation and transportation via red blood 
cells is the MCTP able to reach the pulmonary vascular endothelium89. In the lungs, 
the MCTP injures the vascular endothelium and induces pulmonary vasculitis with a 
subsequent increase in vascular resistance and pulmonary arterial pressure, resulting 
in RV hypertrophic remodelling. Alterations characteristic of hypertrophic remodelling 
were shown at the gene-expression level, e.g., a progressive down-regulation of 
SERCA2a83, 84, an increase in MHC β to α84 expression ratio83 and increased ANP 
expression levels90. Also a decrease in noradrenalin transporter density as well as 
activity and a reduction in βAR receptor density was reported91-93. 
With the MCT doses generally used in rats (40-60 mg/kg body weight) the developed 
hypertrophy progressed to heart failure and death at around day 25-28 after 
injections, with typically a 1.6 and 2 fold increase in lung and RV weight, 
respectively. However, in up to 50% of the animals, the hypertrophic response 
resulted in a compensated phenotype with no signs of heart failure21, 83, 84, 91, 93-97. 
Although compensated or decompensated hypertrophic phenotypes do emerge, they 
cannot reliably be discerned until around day 25-28. Hence, early events occurring 
during the development of either phenotype cannot be studied. A recently introduced 
modification to the standard MCT model does allow for the controlled induction of a 
compensated or decompensated hypertrophic phenotype by using a dose of either 30 
or 80 mg/kg bw, respectively. Both doses lead to an initial phase of compensated RV 
hypertrophy (day 14-19). From day 19 on, the low dose continues to remain 
compensated. However, the high dose progresses towards decompensated 
phenotype and premature death around days 25-2898. This model provides the 
unique opportunity to study, and define, critical factors for the development of either 
phenotype. 
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6: Rationale For Genomics Research 
 
One should realize that during the development of stable ventricular hypertrophy or 
heart failure, the activation of the aforementioned signal transduction routes and 
subsequent changes in structure and function of the myocardium may occur 
simultaneously. Moreover, even if the contribution of each of these alterations to the 
overall phenotype is relatively small, the sum of all known and unknown factors 
involved will amount to a very complex system indeed. Also, it is a false assumption 
that a pathological phenotype consists solely of detrimental processes, as is the 
assumption that a non-pathological phenotype will be driven only by beneficial 
events. Rather, in both these conditions, adaptive and maladaptive processes will 
manifest, and, depending on the prevalence of either, the compensated or 
decompensated phenotype will eventually “prevail”. Furthermore, it is unknown 
whether the drive of detrimental signals initiates the development of a pathological 
phenotype early during myocardial remodelling or at a late event during hypertrophic 
remodelling. 
The ability to dissect specific molecular and cellular events that distinguish between 
putative hypertrophic events and events that underlie the development of either 
maladaptive or adaptive myocardial hypertrophy, will be crucial for our 
understanding of key signalling cascades involved in processes leading to either of 
these phenotypes. A reductionsts approach of one, or a few, genes at a time is not 
sufficient for the analysis of the complex parallel cellular events that characterize the 
hypertrophic response. Consequently, to achieve these goals there is a pressing need 
for novel techniques that are capable of accurately assessing a significant portion of 
cellular events, occurring either at the transcriptome, proteome or metabolome level, 
in combination with the analysis of patho-physiological parameters. 
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7: Large Scale Screening Methods 
 
The large scale analysis of the genome and transcriptome of a given tissue in 
combination with functional data constitutes the field of functional genomics. The 
DNA in the nucleus of each cell contains a full set of information for the estimated 
32.000 - 38000 genes of a typical mammalian genome. However, only a subset of 
these genes is expressed in each cell under a given condition at a certain time, which 
determines the unique properties of each cell type. The transcriptome is the full 
collection of activated genes, mRNAs and transcripts present in a cell. It is thought 
that the cardio-vascular system expresses approximately 70% of the total number of 
genes99.  
 
Gene Expression Alterations 
A series of interdependent events regulate the processes that are needed from the 
initial signal to change gene-expression, commence protein synthesis and the 
emergence of a fully functional protein100. Transcription regulation of protein-coding 
genes depends on a complex interplay between gene-specific regulators, signal-
transduction pathways, general transcription factors, RNA polymerase II (RNAPII) 
and co-regulatory protein complexes as well as chromatin modification101, 102. This 
regulation of chromatin structure has serious implications in gene-expression 
modulation, i.e., a gene and its regulatory elements may no longer be regarded as a 
stand alone unit. Rather, it may be viewed as part of a larger context, in which 
neighbouring genes influence each others expression103. This complex control of 
gene-expression regulation allows for dynamic cellular responses to changes in 
▲Figure 5: Transcription-initiation complex. Schematic representation of the formation and 
activation of the transcription-initiation complex of a gene. Left: The DNA-binding domains of 
activated transcription factors associate with their corresponding short specific DNA motifs within 
the promotor sequence. Co-activators, e.g., PGC1a, may mediate and enhance the activity of the 
transcription factors via protein-protein interactions. Right: Binding of the activation domains of 
the transcriptions factors with the RNApolII complex stabilizes the initiation complex and 
facilitates its positioning on the TATA box. 
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environmental conditions and/or developmental alterations, not only by acting as an 
on/off switch, but also by enabling increases and decreases in gene-expression to 
occur.  
Gene-expression alterations can often be considered a primum mobile, i.e., both the 
origin and the effector of a response, in which the information stored in the genome 
is interpreted and employed to provide the means required for an appropriate 
response. Monitoring gene-expression alterations may thus provide insights into 
cellular responses to specific patho-physiological stimuli.  
 
Formation And Activation Of The Transcription Initiation Complex  
The whole process of transcription can be divided into three steps, i.e., initiation, 
elongation and termination, with transcription initiation by the activation of the 
RNAPII holoenzyme complex being the most important control point in gene-
expression. This 2MDa holoenzyme is a complex consisting of at least 50 proteins 
and is thought to exist in a preassembled state in the nuclear compartment. Central 
to the function of this complex are the TATA-binding protein (TBP), several general 
transcription factors (TF) and the RNAPII with its C-terminal domain (CTD). 
Transcription initiation of a gene will only commence when a specific set of signals 
reach, and activate, the appropriate set of transcription factors that are needed. The 
DNA binding domain of these transcriptions factors will then associate with short 
specific DNA motifs in the gene’s enhancer and promotor regions. In general, such 
regulatory regions contain binding motifs for several TF, allowing multiple signal 
transduction cascades to activate one single gene. Interaction of the TF’s activation 
domains with the holoenzyme complex in concert with alterations in the DNA 
condensation status, and looping of the DNA strands, facilitates the positioning of the 
RNAPII complex on the transcription start site (Figure 5). The RNAPII reads the DNA 
sequence when moving along the DNA sense strand from the 3’-end to the 5’-end, 
and builds the mRNA strand according to normal Watson-Crick base-pairing 
principles, with the exception that the thymidine base is substituted by uracil in the 
mRNA strand. The finished mRNA strand is bound by specific proteins that facilitate 
its translocation from the nuclear compartment to the cytosol, where it is translated 
and further processed to yield a fully functioning protein. 
 
Micro-Array Methodology 
Methods to determine gene-expression have been available for over two decades, 
e.g., polymerase chain reaction introduced by Kary Mullis in 1985104 and northern 
blotting by E.M. Southern in the 1970s. Although many assays may be run in 
parallel, these techniques basically process one gene at a time. It was in 1995 that a 
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large scale gene-expression method was described by Velculescu et al. termed Serial 
analysis of gene-expression (SAGE)105, that allowed the quantitative and 
simultaneous analysis of a large number of transcripts.  
Micro-arrays also have the potential to simultaneously perform transcription analysis 
on thousands of genes. A micro-array essentially consists of a glass slide, which acts 
as a solid support surface material, upon which gene-specific DNA sequence strands, 
either DNA, cDNA, or oligonucleotides, have been accurately deposited as distinct 
spots in a well defined grid, using high speed robotics. Three types of arrays can be 
discerned, i.e., those used in comparative genome hybridization (CGH) to assay 
genomic gains and losses106, SNP-chips that are able to detect single nucleotide 
polymorphisms107 and expression arrays that can be used to assess global 
transcriptome profiles. The latter are used to compare expression-profiles between 
phenotypes resulting from different experimental conditions108. 
The first micro-array experiments were performed by Schena et al. at Stanford 
University in 1995108, using arrays representing 45 Arabidopsis genes. From then on, 
the micro-array technology has undergone rapid development, leading to the 
contemporary arrays, with the potential to perform genome-wide transcription 
analyses, in a wide variety of biological samples. Arrays are available for several 
species, including Arabidopsis thaliana109, Saccharomyces cerevisiae110, Mus 
Musculus111, Rattus Norvegicus112 and Homo Sapiens113. 
 
Simple Steps To Perform A Micro-Array Experiment 
In the Nature Genetics supplement issue of 1999, a standard nomenclature system 
was introduced referring to the hybridization pairs which interact during 
hybridization114. The definitions are based upon the principle that a micro-array is a 
reversed dot-blot, in which the probe, with a known sequence, is essentially used to 
identify and quantify the target. Conversely, in a standard micro-array setup, the 
probe is the gene-specific DNA sequence which is immobilized on the micro-array 
surface and the target is the labelled cDNA strand in the hybridization mixture. Micro-
arrays intrinsically exploit the ability of the probe and target strands to form a 
sequence specific DNA-DNA hybrid complex by standard Watson-Crick base pairing. 
The laboratory aspects of performing micro-array experiments consists of a set of 
relatively simple and straightforward steps (Figure 6). First, experimental conditions 
of interest need to be defined, appropriate samples collected and handled to allow 
the extraction of high quality total RNA or mRNA. Per array, the expression levels of 
each gene can be compared for two experimental conditions. For each experimental 
condition the mRNA pool needs to be reverse transcribed into complementary DNA 
(cDNA) strands, with incorporation of the standard dATP, dCTP, dGTP and dTTP 
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nucleotides as well as an aminoallyl-modified dUTP nucleotide (aa-dUTP). To allow 
the expression levels of each gene per sample to be differentiated within each array 
in subsequent steps, each of the two conditions is labelled with a different fluorescent 
tag at the aa-dUTP, e.g., Fluorolink Cy3 or Cy5 mono-functional dyes. The two 
samples can than be mixed and applied onto the micro-array for hybridization, 
without loss of information concerning the expression levels of the genes in the 
separate conditions. The labelled cDNA stands, e.g., the targets, bind to the gene-
specific, immobilized, probe strands on the array surface. After a series of washing 
steps to remove all non-specific binding from the arrays, the total amount of 
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+
▲Figure 6: Micro-array labeling and hybridization. See accompanying text in section 
Simple Steps To Perform A Micro-Array Experiment. 
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specifically bound cDNA at each spot can be measured by confocal laser scanning 
microscopy for both fluorescent tags. A micro-array experiments thus yields two 
individual images representing the spot abundance intensities for each fluorescent 
tag used. Specialized image analysis software is able to determine and extract the 
total fluorescent signal intensity per spot. A fundamental assumption is that the 
measured signal intensity is proportional to the original mRNA abundance in the 
biological sample, which allows the comparison of gene-expression levels between 
different biological samples by comparing the level of fluorescent intensities per gene 
per array. 
Figure 7A illustrates a typical example of the two separate channel images in addition 
to the combined overlay image resulting from a single array experiment where the 
control and treatment group were labelled with Cy5 and Cy3, respectively. These 
images show circular spots with homogenous intensity and low background signals. 
The colours in the Cy5-Cy3-overlay image can be easily interpreted. A highly 
expressed gene results in a spots with high colour intensity, and conversely, low 
expression genes result in low intensity spots, while genes that are not expressed at 
all, yield black spots. Green spots are indicative for genes that have increased 
expression levels in the treatment sample relative to the control situation, i.e., Cy3 > 
Cy5, while the red spots, represent genes with lower expression levels in the 
treatment sample, i.e., Cy3 < Cy5. Yellow spots represent genes with similar 
expression levels in both samples, i.e., the Cy3 and Cy5 spot intensities are equal.  
A scatter plot is a simple way to visualize the gene-expression differences between 
the two biological samples used in each array experiment. It is compiled by plotting 
the expression ratio for each individual spot against a measure for the total spot 
intensity, e.g., log2(Cy3/Cy5) vs. log10(Cy3*Cy5) or log2(Cy3+Cy5 / 2). A whole 
spectrum of ratios can be appreciated from figure 7B, most of which can be found 
between the +1 and -1 ratio boundaries. The lower intensities display a higher 
variation in ratios due to detection limitations for the lower gene-expression levels, 
while at the high intensity levels variation is relatively small. This means that one 
cannot simply apply a standard ratio cut-off to determine differential expression, 
which may prove to be biased at low and too conservative at high expression levels. 
Scatter plots are also generally used to examine the arrays for potential artefacts, 
such as systemic intensity-dependent effects, which are characterized by a structural 
deviation from the Y=0 axis of the spots in the plot at the lower intensity range. 
When such artefacts are observed, specific within-array transformation algorithms 
are available to correct for these artefacts in order to avoid biased results in the 
subsequent analysis steps, which are generally called within-array transformations. 
Between-array transformations, standardization and normalization steps are 
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subsequently needed to allow all separate arrays to be incorporated into a single 
dataset and to be reliably analysed 115-121.  
 
Experiment Design 
In the simple experimental setup described in the previous paragraph of a direct 
comparison on one slide of a control sample vs. a treatment sample, a systemic error 
may be introduced due to the different excitation-emission properties of the Cy3 and 
Cy5 fluorescent dyes. These errors appear as systemic differences in the Cy3 and 
Cy5 signal intensities, leading to biased results, even when the two different channels 
originated from an identical source sample, i.e., a self vs. self experiment. These 
biases may be corrected for by imposing specific transformation and/or normalization 
procedures, though whether these manipulation are able to completely correct for 
these dye-biases remains questionable. This dye-bias may also be compensated for 
by performing dye-swap experiments, in which the control and treatment samples on 
the first array are labelled using the Cy5 and Cy3 dyes, respectively, while on the 
second array, the labels are switched.  
The experiment described in the previous section of a direct comparison between 
samples, lacks the ability to efficiently compare gene-expression between samples 
representing more than two biological phenotypes. To handle the comparison for 
multiple biological samples two alternative approaches are available, i.e., 
experimental designs that employ a common reference or those that use a loop 
design, both of which have advantages as well as disadvantages. Figure 8 displays 
▲Figure 7: Array channel images and scatter plot. See accompanying text in section 
Simple Steps To Perform A Micro-Array Experiment. 
A B 
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characteristics for both the loop and reference designs. At a first glance, if enough 
sample material is available, the loop design appears to be the best choice. However, 
when more than three samples are to be compared, the loop designs may become 
very complex, making deconvolution of the data structure into comprehensible 
results complicated. Also, if one of the arrays in the loop is of dubious quality, it may 
seriously affect the accuracy of the whole experiment. 
For experimental designs that employ a common reference, high quality RNA of 
standardized composition may be obtained commercially, though it is costly. This is 
an RNA pool that represents all of the target organisms’ genes, yielding a signal in 
almost all of the spots on the array. Conversely, one can prepare a custom pool of 
RNA from various tissue sources, both physiological and pathological in origin, 
preferably related to the samples of interest. This approach ensures that at least all 
targets of potential biological interest are present in the reference sample. In this 
experimental setup, all subsequent samples are hybridized against an aliquot of the 
reference sample. A disadvantage of the reference design is that one needs a large 
pool of high-quality RNA to ensure all samples of interest can be included in the 
experiment. Dye-swaps may be incorporated to reduce the average variance in half, 
though total cost of the experiments will then at least double. Also, half of all 
resources are allocated to this reference, thus accounting for half of all expenses. 
However, samples can easily be replaced or added without problems, making it a 
very flexible setup to use. 
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▲Figure 8: Experiment design. See accompanying text in section Experiment Design. 
Adapted from121.  
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Considerations On Data Mining 
During the last five years, the procedures to analyse gene-expression data derived 
from micro-array studies have evolved profoundly. The relative ease and large scale 
of data generation calls for standardized methods that guide unbiased data mining 
and interpretation. However, the collective contribution from many research fields, 
e.g., biology, statistics, bioinformatics and software engineering, have yet to result in 
a “one size fits all” consensus to handle and interpret genome-wide expression data. 
Nevertheless, some concepts appear to have emerged.  
 
Comparing Two Conditions 
Several approaches are available when comparing two conditions. Initially, studies 
used an arbitrary fold-change cut-off value between group averages as a criterion for 
differential expression. This, however, cannot be considered a statistical test, i.e., it 
does not take into account the gene-specific variances within or between groups. T-
tests do estimate group variances, but due to the low number of replicates that are 
usually available in expression array studies, the t-test may have low power. Also, 
this low number of samples may lead to small variance estimates by chance alone, 
which could lead to high t-statistic values, even when the fold change between the 
groups is small. Estimating the error variance by pooling variances from across all 
genes that were analysed is possible, however under the assumption that the 
individual gene variances are homogenous among the genes. The resulting statistic is 
essentially reduced to a fold-change test that does not estimate the individual gene 
variances. Other approaches using modifications to the normal t-test remove some of 
the problems of the original t-test and are therefore more reliable, e.g., significance 
analysis of microarrays (SAM) by adding a small constant to the denominator122 and 
the regularized t-test by combining a weighted average of the gene-specific and 
global average variance estimates123. 
 
Comparing More Than Two Conditions 
When comparing more than two groups, the F-tests contained within the analysis of 
variance (Anova) statistical framework may provide the necessary method124-126, in 
which the spot intensities are used instead of calculated ratios between the channels 
of the arrays. Of note is that the Anova tests can also be applied when comparing 
two groups. These F-tests are generalizations of the t-test that determine any 
pattern of differential expression between more than two groups by comparing the 
within- and between-group variance estimates. In parallel to the different variations 
in t-tests, several F-test are available to choose from124, 126. The classic F-test, i.e., 
generalization of the t-test, operates on a gene-by-gene basis for variance estimates 
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and is likely to result in low statistical power. F-tests that assume a common error 
variance across genes and use a pooled error variance (F3), or that are analogue to 
the regularized t-test (F2), are able to incorporate information from across genes to 
estimate the error variance. However, taking the simple average of variance 
estimates may lead to biased results and is hard to justify. The Fs test compiles 
estimators of variance depending on the variability of the individual gene variances, 
without making any prior assumptions about their distribution. If a homogenous 
distribution is present, i.e., individual variance estimates are similar, a pooled 
estimate is used. However, when the individual variances are dissimilar, indicating 
heterogeneity, more weight is attributed to the gene-specific variances.  
It is important to keep in mind that in principle micro-array data do not follow the 
standard Gaussian null-distribution and that non-parametric approaches have 
preference. Permutation analysis allows for empirical estimation of the null 
distribution of the data-set. It is widely applicable due to its flexibility, but a large 
number of permutations needs to be performed for reliable results. 
 
Gene-Ontology Analyses 
A typical micro-array experiment series may result in the identification of a few to 
several hundreds of differentially expressed genes. Although many tools are available 
to assist the researcher127-131, interpreting the biological significance of these findings 
remains the most challenging aspect of a micro-array experiment. In general, these 
tools assess whether predefined classes of genes are more present or enriched in the 
list of significantly regulated genes than is to be expected on the basis of chance 
alone. The gene-ontology project (www.geneontology.org) provides a classification 
for gene products into three categories, i.e., molecular function, cellular component 
and biological function. Other widely used classifications are the KEGG132 and 
GenMapp133 pathways. 
The power of these tools lies in the unbiased analysis of any large number of 
significantly regulated genes for common features, e.g., muscle development, MAPK 
signalling, cell-cycle activity. Also, compared to manual Pubmed literature searches, 
these automated tools may drastically cut down the total time needed for the 
interpretation of a large sets of data. The return output lists a series of categories 
with associated genes and p-values for over-representation. Several statistical 
methods are used to calculate the p-values, e.g., Fisher exact test134-137 and χ2 
test138, 139.  
Proteomics 
In parallel to the transcriptome, the proteome represents the total protein 
complement of a cell at a given time and condition. As a direct result of patho-
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physiological changes, the proteome may be subject to post-transcriptional 
modifications (PTM), e.g., conformation changes, proteolytic cleavage, acetylation, 
phoshorylation, oxidation, nitrosylation and glycosylation, which may affect both the 
intrinsic iso-electric point (pI) and mass (Mr) of a protein.  
The application of two dimensional gel electrophoresis (2DGE) in mammals was 
pioneered by J. Klose et al.140, 141. Although protein micro-arrays are available142, 143, 
2DGE remains the most used method for the separation of complex protein mixtures 
containing a large number of polypeptides in a single experiment. An advantage of 
the 2DGE approach is the ability to detect PTM alterations on both the pI and/or Mr 
levels. Proteins are separated in the first dimension on the basis of their pI in an 
isoelectric focussing (IEF) step and in the second dimension on the basis of their Mr 
in a SDS-PAGE step. Increased resolution in the first dimension can be gained by 
using several more focussed pH ranges in parallel IEF sessions of the same sample of 
interest, while the mass separation can be modulated by different gradations in 
acrylamide/duracryl composition of the SDS-PAGE gel. Further augmentation of the 
specificity of 2DGE may be achieved by using specific subcellular fractions, e.g, 
mitochondria, SR, nuclear envelope, myofilaments or the cytoplasm, though only the 
soluble fractions of these compartments can be separated using the 2DGE technique.  
After visualization by silver, coomassie or sypro ruby staining, individual PTM of 
proteins will appear as separate spots on the SDS-PAGE gel. Computer assisted 
matching of corresponding protein spots between individual gels is generally 
performed with specific software, e.g., PDQuest®, which can also determine the spot 
intensities for each spot on each SDS-PAGE gel and subsequently use these 
intensities to test for significant differences in protein-expression levels between 
groups. The identity of significantly regulated proteins needs to be determined with 
matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass 
spectrometry144. To do this, the spot is physically excised from the SDS-PAGE gel and 
subjected to trypsin digestion to yield polypeptide fragments from the native protein. 
After purification of these fragments they are embedded into a crystaline layer of 
MALDI-matrix on a solid support surface, i.e. the MALDI-chip. Documentation and 
data-base searches, cross-referencing the fragment-ion-mass fingerprints of the 
specific individual peptides fragments may lead to the identification of the protein in 
question. 
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Aim And Outline Of This Thesis 
 
The general aim of this thesis was to explore alterations on either the transcriptome 
or proteome level during RV remodelling due to pressure overload for events that are 
associated with the development of either an adaptive or maladaptive hypertrophic 
phenotype. Knowledge of the composition and timing of these critical events may 
lead to a more thorough understanding of the pathophysiological processes involved 
in the development of either hypertrophic phenotype. In addition, assessment of 
gene-expression that specifically correlate with either adaptive or maladaptive 
remodelling could potentially lead to bio-marker discovery and to improved diagnosis 
of the pathological phenotype in patients.  
The large-scale, high-throughput analyses techniques used to measure alterations on 
either the transcriptome or proteome level were expression micro-arrays and 2DGE, 
respectively. Both of these methods allow for the analysis of thousands of mRNA 
transcripts or proteins simultaneous. 
 
To achieve the goals described above, an animal model was needed that allows for 
the controlled induction of either the adaptive or maladaptive phenotype well before 
phenotypical differences become apparent. This model is introduced in Chapter 2. 
Gene-expression profiles from right-ventricular tissue were compared between 
animals developing adaptive or maladaptive hypertrophy and control animals at 14 
days after the imposition of pressure overload.  
In Chapter 3 a time-course experiment is presented describing gene-expression 
alterations during adaptive and maladaptive ventricular remodelling at 10, 19 and 25 
days after the imposition of pressure overload. 
In parallel to the gene-expression analyses, RV myocardial protein-expression 
profiles obtained from animals at 10 days after MCT injections were compared using 
2-dimensional gel-electrophoresis in Chapter 4.  
In Chapter 5 the experimental data presented in this thesis are placed in a broader 
perspective and discussed in relation to recent publications concerning adaptive and 
maladaptive hypertrophy. 
 
As in the case of left ventricular (LV) hypertrophy, the concept of compensated or 
adaptive hypertrophy in aortic stenosis (AS) has been questioned. Kupari et al. (Eur 
Heart J. 2005 Sep;26(17):1790-6), stated that: ”LV hypertrophy may be maladaptive 
rather than beneficial in AS in man”. The evidence provided by Kupari et al. are 
discussed in Chapter 6. 
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Abstract 
 
Myocardial right-ventricular (RV) hypertrophy due to pulmonary hypertension is 
aimed at normalizing ventricular wall stress. Depending on the degree of pressure 
overload, RV hypertrophy may progress to a state of impaired contractile function 
and heart failure, but this can not be discerned during the early stages of ventricular 
remodelling. We tested whether critical differences in gene-expression profiles exist 
between ventricles before the ultimate development of either a compensated or 
decompensated hypertrophic phenotype. Both phenotypes were selectively induced in 
Wistar rats by a single subcutaneous injection of either a low or a high dose of the 
pyrrolizidine alkaloid monocrotaline (MCT). Spotted oligonucleotide micro-arrays were 
used to investigate pressure-dependent cardiac gene-expression profiles at two 
weeks after the MCT injections, between control rats and rats that would ultimately 
develop either compensated or decompensated hypertrophy. Clustering of 
significantly regulated genes revealed specific expression profiles for each group, 
although the degree of hypertrophy was still similar in both. The ventricles destined 
to progress to failure showed activation of pro-apoptotic pathways, particularly 
related to mitochondria, while the group developing compensated hypertrophy 
showed blocked pro-death effector signalling via p38 MAPK, through upregulation of 
MKP1. 
In summary, we show that already at an early time point, pivotal differences in gene 
expression exist between ventricles that will ultimately develop either a compensated 
or a decompensated phenotype, depending on the degree of pressure overload. 
These data reveal genes that may provide markers for the early prediction of clinical 
outcome as well as potential targets for early intervention. 
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Introduction 
 
Myocardial ventricular hypertrophy is a major risk factor that is associated with a 
higher incidence of clinical events, morbidity and mortality from cardiovascular 
disease1, generally leading to heart failure. Right-ventricular (RV) hypertrophy is a 
general adaptive mechanism of the heart to increased workload, resulting from, i.e., 
chronic pulmonary hypertension, valvular disease or left-ventricular (LV) dysfunction. 
RV hypertrophy is aimed at normalizing ventricular wall stress and, as in the case of 
LV overload, depending on the degree or duration of the pressure overload, RV-
hypertrophy may progress from a compensated state into a pathological state with 
progressive myocyte apoptosis and compromised cardiac function, ultimately leading 
to congestive heart failure2. Multiple signal transduction pathways are known to be 
involved in the remodelling of the heart3, and hypertrophy and failure are 
characterized to varying degrees by changes in extracellular matrix composition, 
energy metabolism, contraction, adrenergic signalling and calcium handling4. Which 
of these changes is critical in the ultimate transition to heart failure is a matter of 
debate. More importantly, it remains unclear which signalling pathway or 
combination of signalling pathways mediate the development of pathological 
hypertrophy and whether the pathological phenotype is induced early during overload 
as a function of the degree of mechanical overload, or only as a secondary response 
when compensation is insufficient3, 5. 
To address this question we used the established monocrotaline (MCT) model of 
chronic pulmonary hypertension and subsequent RV hypertrophy to determine gene 
transcription profiles early in the development of compensated and decompensated 
hypertrophy6. MCT is a pyrrolizidine alkaloid and its bioactive metabolite, which has a 
short half-life, selectively injures the vascular endothelium of the lung and induces 
pulmonary vasculitis and an increase in vascular resistance and pulmonary arterial 
pressure7. With the MCT doses typically used in rats, the RV hypertrophy progresses 
to failure and death around day 28 in most animals, but up to 50% of the animals 
may develop compensated RV hypertrophy with no signs of failure8-13. Detailed 
analyses of the development of heart failure in this model have shown that critical 
changes in contractile function and expression of proteins involved in beta-adrenergic 
signalling and calcium handling, do not become apparent until after three weeks14, 15. 
Furthermore, pressure-dependent activation of pro-apoptotic pathways in the 
hypertrophied RV are suggested to underlie the transition to failure around this 
time16. However, comparative analyses of the compensated and heart failure groups 
are few, and limited to late stages when the separate groups can be identified8, 9, 11, 13. 
Following earlier work in our laboratory13, 17, 18 we now refined the MCT model to allow 
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the selective induction of either compensated or decompensated RV hypertrophy by 
using a low or a high dose of MCT, respectively. Animals developing the pathological, 
decompensated phenotype die of congestive heart failure (CHF) four weeks following 
MCT injection, while animals in the low-dose group developed a stable compensated 
hypertrophic phenotype (HYP) showing no signs of failure. Because the outcome of 
the hypertrophic process is known for both groups, early stages in the development 
of compensated and decompensated hypertrophy can be investigated with this model 
before phenotypical differences become apparent. 
In the present study we used spotted oligonucleotide micro-arrays representing 4803 
known genes to analyze ventricular gene expression of control, HYP and CHF animals 
early at the onset of myocardial ventricular hypertrophy, i.e., two weeks following 
MCT administration. Analysis of the expression profiles revealed quantitative but also 
qualitative differences in gene expression in the hypertrophying RV that may be 
crucial for the ultimate development of either the compensated or the 
decompensated state. 
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Methods 
 
Animals 
Animals were treated according to the national guidelines and with the permission of 
the Institutional Animal Care and Use Committee (IACUC) of the VU University 
Medical Center Amsterdam, the Netherlands. Male Wistar Rats, weighing 180-200 g 
(Harlan, Zeist, The Netherlands) were housed individually (250 cm2/animal) and 
received food and water ad libitum. 
A total of 58 animals were randomly assigned to three groups. All animals received a 
single subcutaneous injection with either saline (control group: CON, n=18), 30 mg 
MCT/kg body weight (hypertrophy group: HYP, n=20) or 80 mg MCT/kg body weight 
(congestive heart failure group: CHF, n=20). Two weeks after treatment 12 animals 
from each group were randomly picked and killed with a halothane overdose and 
heart and lungs were excised. A total of 2 mL of blood was taken and stored for 
subsequent measurement of plasma thyroid hormone level (T3) by specific RIA as 
previously described19. Hearts were rinsed by perfusion and the left and right 
ventricles and septum were separated. All tissues were weighed and snap frozen in 
liquid nitrogen and stored at –80 ºC. At four weeks after treatment the remaining 
animals were killed and blood samples, heart and lungs were collected. 
 
Total RNA Isolation 
Total RNA isolation from the left and right ventricles from each animal was performed 
using the TriZol (Invitrogen) method according to the manufacturer's protocol. Total 
RNA was quantified by A260 measurement and the A260/A280 ratio was used to 
check for possible contaminations. Sample integrity was also checked on a Agilent 
2100 bioanalyzer. A common reference pool was constructed by pooling equal 
amounts of RNA from all samples used in the micro-array experiments. Samples 
were dissolved in 100% formamide and stored at –80 ºC prior to use. RNA from six 
RVs and two LVs per group were used in the micro-array hybridizations for 
myocardial gene expression profiling. The remaining RV samples were used for the 
real time PCR confirmation of the micro-array results. 
 
Quantitative Real-Time PCR 
Gene-specific primers (Invitrogen) were designed using Primer Express v2.0 to 
generate amplicons with a length of 75-125 bp spanning exon-exon junctions. Primer 
pairs were checked for a linear response over a large cDNA input range and for non-
specific products with dissociation curves and 2% agarose gel electrophoresis. 
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Hypoxanthine-guanine phosporibosyltransferase (HPRT) was used as an internal 
control to normalize gene expression. 
A total of 5 µg total RNA was used to generate cDNA strands in a 20 µL reaction 
volume using the Cloned AMV First Strand Synthesis Kit (Invitrogen). An equivalent 
of 25 ng total RNA was subsequently used in the amplification with 50 nmol/L gene-
specific primers and 4 µL SYBR green master-mix (Applied Biosystems) in a total 
volume of 8 µL, using standard cycle parameters on an Applied Biosystems model 
7700. 
 
Western Blotting 
Right and left ventricular tissue was homogenized in modified 1D-buffer (15% 
glycerol, 1% SDS, 0.0625 mol/L TrisCl pH6.8, 500 µg/mL DTT (MP Biochemicals, 
Inc.), 500 µg/mL Pefabloc SC (Roche) and 5 µL/mL Phosphatase inhibitor cocktail 1 
(Sigma). Samples were then sonicated for 30 min, incubated at 80°C for 5 min and 
centrifuged for 20 min at 14.000 rpm. The protein samples were immunoblotted for 
phospho-p38 and MKP-1 (Santa Cruz). 
Western-blotting reagents were purchased from Amersham International 
(Amersham, UK). Equal amounts of protein (50 µg; BCA assay) were separated by 
electrophoresis (10% SDS-PAGE) and transferred to nitrocellulose membranes. 
Protein transfer was confirmed by Ponceau staining of the blot. Membranes were 
blocked with 5% non-fat milk in TBS-T for 1 h at room temperature. Phospho-specific 
p38 and MKP-1 antibodies were separately incubated in TBS-T containing 5% nonfat 
milk (Biorad) overnight at 4°C. After membranes were washed with TBS-T, they were 
incubated with the appropriate secondary antibodies conjugated to horseradish 
peroxidase for 1 h at room temperature. Bands were visualized by enhanced 
chemiluminescence and quantified using a FujiFilm LAS 3000 laser densitometer. 
 
Micro-Array Printing, Probe Generation, Hybridization And Washing 
The Compugen Rat OligoLibraryTM was purchased from Sigma-Aldrich. Oligos were 
resuspended to a concentration of 20 µmol/L in a 150 mmol/L sodium phosphate 
buffer, pH8.5 and printed on Motorola CodeLinkTM activated slides using an 
Amersham Pharmacia Biotech Spotter. Features were spotted as duplicates on the 
micro-array with pairs divided over two different regions. 
cDNA probes were generated from 100 µg total RNA, with an oligo-dT [(dT)20-VN] 
primer (Invitrogen) and SuperScript™ II Reverse Transcriptase (Invitrogen), with 
incorporation of aminoallyl-dUTP. Probes were indirectly labelled with Fluorolink Cy3 
(sample) or Cy5 (reference pool) mono-functional dyes. 
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Hybridization protocol was adapted from Snijders et al.20 with minor modifications. In 
brief, Cy3 and Cy5 labelled probes were combined and the hybridization mixture was 
prepared containing a final concentration of 2 µg/µL yeast tRNA, 0.4 µg/µL polyA and 
0.8 µg/µL human Cot-1 DNA in 91.2 µL H2O, 7.6 µL 10 % SDS, 30.4 µL glycerol and 
250.8 µL master mix (1 g dextran sulfate, 6 mL formamide, 1 mL, 20x SSC). Probe 
mix was denaturated at 70 ºC for 15 min and incubated at 30 ºC for 60 min Pre-
hybridization mixture was identical to the probe-mix but probe was substituted with 
salmon sperm DNA to a final concentration of 1 µg/µL.  
Several layers of rubber cement were applied closely around the array area to form a 
hydrophobic well to which the pre-hybridization mix was added. Pre-hybridization 
was maintained for 45 min at room temperature. Probe hybridization was initiated by 
gently removing as much of the pre-hybridization mix as possible without generating 
any dry areas on the array and applying the probe-hybridization mix. Hybridization 
was maintained for 16 h at 30 ºC on a rocking table (~1 rpm). To prevent liquid 
evaporation the arrays were kept at high humidity by placing them in separate 
containers situated in a larger, air tight, humid container.  
After hybridization excess hybridization mixture was rinsed off with PI buffer (0.1 
mol/L sodium phosphate, 0.1 % Igepal CA630, pH8), then washed once in 50% 
formamide, 2x SSC, pH7 at 35 ºC for 15 min followed by 15 min in PI buffer at RT. 
Excess salt was removed by subsequently rinsing in 0.2x SSC and 0.1x SSC for 1 min 
at RT. Slides were dried by centrifugation at 1000 rpm for 3 min For our most recent 
protocols see: http://www.vumc.nl/microarrays/onderzoek/protocols.html.  
 
Data Acquisition And Analysis 
Slides were scanned at a 10 µm resolution for Cy3 and Cy5 intensities using a Perkin-
Elmer Multi Laser Micro-Array Scanner operated by the ScanArray Express v1.0 
software. Array images were processed with Imagene v5.1. Flagged features were 
excluded from further analysis. Mean Cy3 and Cy5 intensities were background 
corrected. Because there was only a very small location effect, the duplicate signals 
for each gene were averaged. The mean Cy3 and Cy5 channel intensities were 
balanced, and the Cy3 to Cy5 log2-ratios were standardized to a Z-score with the 
fitted value as mean (μ) and the mean absolute distance as standard deviation (σ). 
Genes were considered to be suitable for further analysis if for all three RV groups, 
genes were present in at least three out of the six arrays per group. For the LV 
analysis, each gene had to be present in all six LV arrays to be accepted. These data 
have been deposited in the Gene Expression Omnibus21 as series GSE1652. 
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Significance Analysis 
Clustering of the significantly regulated genes was performed on the basis of their 
significant differences as determined in the three pair-wise comparisons. If there was 
a significant difference between the CON and HYP group, it was denoted with a “1”, 
or, if there was no difference observed, a “0”. This was also done for CON vs. CHF 
and HYP vs. CHF respectively. These “1” and “0” notations where then combined as x 
- x - x representing the CON vs. HYP, CON vs. CHF and HYP vs. CHF comparisons 
respectively. With three pair-wise comparisons, there are a total of seven 
combinations possible. A gene with no significant difference between CON vs. HYP 
[0], a significant difference between CON vs. CHF [1] as well as a difference between 
HYP vs. CHF [1], would then be assigned to cluster 0-1-1. In the remainder of this 
article, these clusters will be referred to as clusters I through VII (see Table 3 in the 
Results section). 
Note that this is a method that clusters only on the basis of significant differences 
between groups. It does not take the direction of change into account, i.e., up and 
downregulated genes can be assigned to the same cluster. 
 
Initially, differential expression between the CON, HYP and CHF groups was assessed 
with the significance analysis of microarrays program, SAM22. However, in contrast to 
33 upregulated genes, only four were found that were downregulated (data not 
shown). This imbalance in direction of regulation lead to search for alternative 
analysis methods for our data-set. 
According to the theorem of Stouffer-Hemelrijk23 the sum of n standardized log ratios 
has a normal distribution with mean of zero and standard deviation of √n. So its 
quotient Z = ∑zi / √n has a standard normal distribution with a mean of zero and a 
standard deviation of 1.  
 
If zi (z1, z2, .....zn)    ~ N (0,1) 
 
Then its sum 
 
∑ zi =  (z1+ z2 + ........ + zn)  ~ N (0,√ n)  
 
and  
  
 mean-Z(CON,HYP or CHF) = ∑zi / √n  ~ N (0,1) 
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The difference between two pair-wise conditions was tested on significance by Zscore 
in the following way. 
 
 Zscore = (Z2 – Z1) / √2   ~ N (0,1) 
 
For each group the mean-Z was calculated. Gene expression was considered to be 
significantly different if the absolute Z score value was greater than 2, which 
corresponds with a p-value < 0.025.  
 
Statistical Analysis For RT-PCR And Hypertrophic Parameters 
Relevant parameters were evaluated for significant differences between groups with 
a one-way ANOVA using the SPSS v9.0 statistical package with the Bonferroni 
correction for multiple testing. Differences with a p value smaller than 0.05 were 
considered significant. 
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Results 
 
Mct-Induced Development Of Compensated RV Hypertrophy Or Heart Failure 
In previous studies the use of a single dose of MCT of 40-60 mg/kg typically resulted 
in a mixed population of animals, developing either compensated hypertrophy or 
progressing to heart failure8-13. We found that administration of a high dose of MCT 
(80 mg/kg) induced RV hypertrophy which in all cases progressed to congestive heart 
failure (CHF). In contrast, 30 mg MCT/kg induced exclusively compensated RV 
hypertrophy (HYP). Figure 1 shows average growth curves of animals in both groups 
over a period of four weeks. MCT administration resulted in a slight reduction of the 
rate of growth, but animals in the HYP group did not cease to grow, while the CHF 
group started loosing weight around day 20. Apart from the progressive weight loss, 
all animals in this group showed secondary signs of right-sided CHF, including pleural 
effusion and ascites at the time of sacrifice at four weeks. No such signs were 
present in any of the animals in the HYP group. In a parallel study four HYP animals 
were sacrificed at twelve weeks and non of these animals showed signs of heart 
failure (not shown). 
Table 1 summarizes organ and body weights of animals sacrificed at four weeks or at 
two weeks. The latter group was used in the micro-array analysis described in the 
next section. The significantly greater increase in lung weight in the CHF versus the 
HYP group is indicative of the more extensive proliferative pulmonary vasculitis 
induced by the high dose of MCT24. The increase is not related to edema, since dry-
to-wet weight ratios of lung tissue did not differ between the groups at any time (not 
shown). Both groups developed a significant degree of RV hypertrophy in response to 
the increased pulmonary resistance, as evidenced by a 20% increase in the RV/LV+S 
weight ratio already at two weeks. The degree of hypertrophy was significantly 
greater in the CHF group (135%), compared to the HYP group (95%) after four 
weeks. In line with the development of severe heart failure, plasma thyroid hormone  
◄Figure 1: Body weight (g) was 
measured throughout the four week 
period after MCT treatment. Black, 
blue and red lines represent control, 
hypertrophic and heart failure rats 
respectively. Plotted is the mean 
body weight per group ± SEM 
confidence interval. 
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levels (T3) were significantly reduced at four weeks in the CHF group only.  
In an initial analysis of RV gene expression in this model we determined mRNA levels 
of sarcoplasmic-endoplasmic reticulum Ca2+-ATPase (SERCA2a) and atrial natriuretic 
factor (ANF) as representative hallmark genes regulated in hypertrophy (Table 2). As 
expected, changes in the levels of SERCA2a and ANF message correlated with the 
severity of the hypertrophy. The data showed a progressive increase in ANF mRNA at 
two and four weeks, which reached significance only in the CHF group. The levels of 
SERCA2a mRNA were reduced at four weeks, and significantly more so in CHF 
compared to HYP animals. At two weeks, however, no change was detectable in 
either group relative to controls. 
Taken together, these data indicate that the low and high dose of MCT induce 
different degrees of pulmonary hypertension and ensuing RV hypertrophy, which in 
the latter case progresses to failure. A large scale analysis of ventricular gene 
expression was next performed in the control, HYP and CHF groups at two weeks to 
assess early differences in gene expression. 
▲Table 1: Animals were sacrificed two or four weeks after receiving either saline (CON), 30 mg 
MCT/kg (HYP) or 80 mg MCT/kg (CHF). Mean values ± SEM of body weight (BW), plasma T3 
level, tissue wet weights of whole heart, right ventricle (RV) and lung are given, as well as tissue 
to body weigth ratios. RV/LV+S denotes the wet weight ratio of RV over the combined weight of 
left ventricle (LV) and septum (S). Data were analysed as described in the Materials and Methods 
section and * indicates P<0.05 relative to CON and † indicates P<0.05 relative to HYP, n=12 for 
all parameters at two weeks, except for lung weight (n=6); n=8 for all parameters at four weeks, 
except for the CON group (n=6). 
 2 weeks 4 weeks 
 CON HYP CHF CON HYP CHF 
BW (g) 284 ± 4 
 
258 ± 5 
* 
244 ± 4 
* 
352 ± 14 
 
332 ± 10 
 
250 ± 6 
*† 
Heart (mg) 
924 ± 28 
 
835 ± 31 
 
812 ± 28 
* 
980 ± 27 
 
1090 ± 30 
 
1007 ± 38 
 
Heart/BW  
(mg/g) 
3.25 ± 0.08 
 
3.23 ± 0.08 
 
3.32 ± 0.07 
 
2.80 ± 0.09 
 
3.29 ± 0.11 
* 
4.03 ± 0.09 
*† 
RV (mg) 
162 ± 8 
 
170 ± 9 
 
167 ± 9 
 
167 ± 11 
 
304 ± 23 
* 
334 ± 11  
*† 
RV/BW 
(mg/g) 
0.57 ± 0.02 
 
0.65 ± 0.03 
 
0.68 ± 0.03 
* 
0.47 ± 0.02 
 
0.93 ± 0.09 
* 
1.33 ± 0.02 
*† 
RV / LV + S 
(mg/mg) 
0.21 ± 0.01 
 
0.25 ± 0.01 
* 
0.26 ± 0.01 
* 
0.20 ± 0.01 
 
0.40 ± 0.04 
* 
0.50 ± 0.02 
* 
Lung(g) 
1.48 ± 0.03 
 
1.54 ± 0.03 
 
1.75 ± 0.05 
*† 
1.33 ± 0.11 
 
1.65 ±0.042 
* 
2.24 ± 0.09 
*† 
Lung/BW 
(mg/g) 
5.12 ± 0.05 
 
5.74 ± 0.08 
* 
6.99 ± 0.10 
*† 
3.72 ± 0.15 
 
4.96 ± 0.19 
* 
9.00 ± 0.42 
*† 
Plasma T3 
(nmol/L) 
1.10 ± 0.05 
 
1.20 ± 0.05 
 
1.03 ± 0.05 
 
0.98 ± 0.06 
 
1.00 ± 0.05 
 
0.33 ± 0.06 
*† 
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Micro-Array Analysis 
For the RV micro-arrays, 3010 unique genes of the total 4803 (62%) passed the 
required criteria for further analysis. All three RV groups were pair-wise analyzed by 
a Z-test. All Z-test scores with an absolute value higher than 2 ( |Z-score| > 2.0) 
were considered to be significant, which resulted in a total of 179 unique genes. 
Overall there were more genes upregulated than downregulated in the RV, as can be 
seen in Table 3. 
An analysis of the left ventricular myocardium resulted in ten differentially expressed 
genes, four of which were also regulated in the RV, although with different 
expression profiles between the three groups. We considered these left ventricular 
changes of minor importance in our model. 
Cluster CON 
vs. HYP 
CON 
vs. CHF 
HYP 
vs. CHF 
Genes Up / Down 
I [1-1-1] 1 1 1 6 6 / 0 
II [0-1-0] 0 1 0 69 52 / 17 
III [1-1-0] 1 1 0 22 17 / 5 
IV [0-1-1] 0 1 1 31 25 / 6 
V [1-0-1] 1 0 1 6 2 / 4 
VI [0-0-1] 0 0 1 20 11 / 9 
VII [1-0-0] 1 0 0 25 11 / 14 
    Total 
179 
124 up, 
55 down 
◄Table 3: Classification of 
genes into 7 separate clusters 
based on the significant 
differences between the three 
RV groups for all significantly 
regulated genes. Cluster [1-0-
1] indicates: a significant 
difference between CON vs. 
HYP [first digit], no significant 
difference between CON vs. 
CHF [second digit] and a 
difference between HYP vs. 
CHF [third digit]. In the last 
two columns, for each cluster 
the total number of genes and 
the number of up or 
downregulated are specified. 
 
 
2 weeks 4 weeks 
 CON (6) HYP (8) CHF (8) CON (6) HYP (8) CHF (8) 
ANF mRNA 
(%) 
100 ± 22 244 ± 33 317± 57 
* 
100 ± 33 450 ± 85 905 ± 145 
* 
SERCA2a 
mRNA (%) 100 ± 4 100 ± 6 93 ± 3 100 ± 11 64 ± 6 * 
37 ± 3 
* † 
 
▲Table 2: Right ventricles and plasma of 6-8 animals sacrificed two or four weeks after 
receiving either saline (CON), 30 mg MCT/kg (HYP) or 80 mg MCT/kg (CHF), were analyzed for 
tissue mRNA levels using slot-blot hybridization, as previously described13. All RNA samples were 
analyzed on the same blot and normalized to the mRNA level of glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH). Levels of ANF and SERCA2a mRNA are expressed relative to their 
average control level (100%). All data are the means ± SEM of (n) samples. Data were analyzed 
as described in the Materials and Methods section and * indicates P<0.05 relative to CON and † 
indicates P<0.05 relative to HYP. 
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A: Cluster I [1-1-1] ; 6 up / 0 down
R-CON R-HYP R-CHF
0
3
6
9
12 †*
*
lo
g 2
 ra
tio
B: Cluster II [0-1-0] ; 52 up / 17 down
R-CON R-HYP R-CHF
-6
-3
0
3
6 *
lo
g 2
 ra
tio
C: Cluster III [1-1-0] ; 17 up / 5 down
R-CON R-HYP R-CHF
-6
0
6
12
*
*
lo
g 2
 ra
tio
D: Cluster IV [0-1-1] ; 25 up / 6 down
R-CON R-HYP R-CHF
-9
-6
-3
0
3
6
9 †*
lo
g 2
 ra
tio
E: Cluster V [1-0-1] ; 2 up / 4 down
R-CON R-HYP R-CHF
-6
-3
0
3
6 *
†
lo
g 2
 ra
tio
F: Cluster VI [0-0-1] ; 11 up / 9 down
R-CON R-HYP R-CHF
-4
-2
0
2
4
†
lo
g 2
 ra
tio
G: Cluster VII [1-0-0] ; 11 up / 14 down
R-CON R-HYP R-CHF
-6
-3
0
3
6
*
lo
g 2
 ra
tio
▲Figure 2: On the X-axis are depicted the 
separate groups and on the y-axis the log2 
gene expression ratio of the three groups two 
weeks after MCT administration. Expression 
ratio of the CON group is set to zero for all 
cases for easy reference. Expression values 
for individual genes are connected with lines 
between the three group comparisons. 
Standard error bars per gene per group were 
omitted for clarity. Significant differences 
between the groups are indicated by * for vs 
RV CON and † for vs RV HYP. 
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All further analysis were performed on the 179 right ventricular genes only. A list of 
all differentially regulated left and right ventricular genes is available at 
http://physiolgenomics.physiology.org/cgi/content/full/00185.2004/DC1. 
 
Gene Cluster Classification 
To classify the identified genes, they were clustered on the basis of their significant 
differences in expression between the three RV groups. This lead to 7 clusters (Table 
3), of which four contain genes with a significant difference in expression between 
the RV HYP and RV CHF groups, i.e., clusters I, IV, V and VI. Expression plots of all 
seven clusters are shown in Figure 2A through G. Genes in these separate clusters 
may be involved in hypertrophic processes that determine the specific development 
of the compensated and decompensated phenotypes. 
Cluster I (Fig 2A) contains genes with an expression profile that correlates with the 
degree of pressure overload, i.e., there is a significantly higher expression in CHF 
than the HYP groups, both of which are also significantly different from CON levels. 
Genes like these are likely to be associated with general hypertrophic remodelling 
processes that appear to be load-dependent. Two of these genes, alpha-skeletal 
actin25 and myosin binding protein C26, have both been shown to be involved in 
myocardial hypertrophy. Genes in cluster II (Fig 2B) show an expression profile that 
is highly similar to cluster I, even though they only display significant differences in 
the CON vs. CHF comparisons. However these genes still appear to display a load-
dependent gene expression profile. Some downregulated genes in this cluster are 
cytosolic phospholipase A2, Selenoprotein W and dihydropryridine-sensitive calcium 
channel alpha-1, while beta-catenin (Catnb), cyclin D1 and alpha tubulin were 
upregulated in CHF relative to CON. Similar to cluster I, cluster III (Fig 2C) is 
comprised of genes which appear to be associated with a general hypertrophy 
transcription program, however their expression level is not sensitive to the 
difference in load between the HYP and CHF groups. Carnitine palmitoyltransferase 1 
beta (Cpt1b) was downregulated, while alpha-smooth muscle actin was upregulated 
in this cluster. Cluster IV (Fig 2D) contains genes that are regulated only in the CHF 
group. These genes may ultimately be associated with the development of a 
decompensated phenotype, since they are not differentially expressed in the HYP 
group at this point in time. In this cluster several mitochondria-related genes were 
significantly regulated, i.e., the mitochondrial transcription factor A (mtTFA) was 
downregulated in contrast to the upregulation of the mitochondrial voltage-
dependent anion channel (VDAC1) and mitochondrial adenine nucleotide translocator 
(ANT1) genes. 
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In contrast to cluster IV, cluster V (Fig 2E) represents those genes which are either 
up or downregulated in the HYP group when compared to both the CON and CHF 
groups. These genes may ultimately be associated with the development of 
compensated hypertrophy since they are not differentially expressed in CHF. This 
cluster showed the upregulation of a protein tyrosine phosphatase (Genbank 
U02553). A locuslink query on this gene showed it encodes a dual specificity 
phosphatase known as mitogen-activated protein kinase (MAPK) phosphatase-1 
(MKP-1). MKP-1 is a predominantly nuclear protein which recognizes and de-activates 
MAPKs, such as p38-MAPK, by dephosphorylating the threonine and tyrosine residues 
with the T-X-Y sequence. MAPK signalling and in particular the activation of p38-
MAPK has been implicated in the development of decompensated hypertrophy and 
heart failure. Consequently, the upregulation of MKP-1 HYP could be critical in 
adaptive remodelling in the HYP group (see next section and Discussion). 
Assigning a patho-physiological role to the last two clusters is more difficult. Cluster 
VI (Fig 2F) contains genes that are either up or downregulated in the CHF group 
relative to the HYP group only, with no significant differences relative to CON. Some 
of these genes show comparable expression profiles to cluster IV, while others show 
resemblance to genes in cluster V. However, since these genes do show a significant 
difference between the HYP and CHF group, they may still contribute to the distinct 
process leading to either compensated hypertrophy or heart failure. 
A nuclear receptor co activator, transcriptional intermediary factor 2, was found to be 
significantly downregulated in CHF relative to HYP, while the endothelin receptor-B 
and the calcitonin receptor-like receptor were upregulated in the CHF group. 
Finally, cluster VII (Fig 2G) contains genes that are only regulated in the HYP relative 
to the CON group, but not significantly different from CHF. This cluster showed a 
decrease in expression of gamma-butyrobetaine hydroxylase (BBH) and platelet-
derived growth factor B chain precursor. Thrombospondin 4 and the plasma protein 
alpha1-fetoprotein were upregulated in this cluster. 
These data indicate that early in the development of either compensated or 
decompensated right ventricular hypertrophy, qualitative differences in addition to 
quantitative differences in mRNA expression already exist between both hypertrophic 
phenotypes. 
 
p38-MAPK Phosphorylation In HYP And CHF 
As mentioned in the previous section, MKP-1 mediated deactivation of p38-MAPK 
might play a role in the differentiation between compensated and decompensated 
hypertrophy.  
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▲Figure 4: Real-time PCR confirmations for beta-catenin, mitochondrial ATP synthase beta 
subunit (ATP5b) atrial natriuretic factor (ANF), ceruloplasmin, cyclinD1, inositol 1,4,5-
triphosphate 3-kinase (lp3k), cyclinB1, oncomodulin and vascular endothelial growth factor A 
(vegfA). Control expression values for both the array and RT-PCR data have been set to 1. In 
each graph the expression levels are displayed for array-CON, HYP, CHF and PCR-CON, HYP, CHF 
from left to right respectively. Significant differences relative to the CON or HYP group are 
indicated by * or † respectively. 
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◄Figure 3: Western blot 
analysis of phospho-p38 
MAPK levels and MKP1 in 
right and left ventricular 
samples. From top to 
bottom: A: RV phospho-
p38, B: LV phospho-p38, 
C: RV MKP1. 
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Therefore, we first assessed p38-MAPK activation in RV samples from CON, HYP and 
CHF animals. Western blot analysis of phospho p38-MAPK levels showed marked 
activation in the CHF group only (Fig 3a). This activation was restricted to the RV, 
since an analysis of the LV showed no difference in phospho p38-MAPK levels 
between the three groups (Fig 3b). Next, we examined whether the absence of p38-
MAPK activation in the HYP group was associated with increased MKP-1 expression as 
suggested by the micro-array expression data. Indeed, MKP1 protein levels in the RV 
of the HYP group were clearly increased relative to control levels, with considerably 
less expression in the CHF group (Fig 3c). 
 
Real-Time PCR Gene Confirmations 
From the significantly regulated genes, twelve were selected to be confirmed by real-
time PCR. Nine of these showed expression profiles in agreement with the micro-
array data, although with occasional differences in the fold changes that were 
observed (Fig 4). Three of the twelve genes showed no change in expression 
(monoamine oxidase A and calpain 3), or a decrease in expression where an increase 
was expected (SUP) (data not shown). 
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Discussion 
 
In this study, we used 65-mer spotted oligonucleotide micro-arrays representing 
4803 known rat genes, to probe the ventricular myocardial transcriptome for 
differential expression of genes at an early stage of development of either 
compensated or decompensated RV hypertrophy. Although the degree of RV 
hypertrophy was similar in both MCT-treated groups two weeks following injections, 
their gene-expression profiles were strikingly different. Clustering revealed 
expression profiles that were uniquely associated with the development of either the 
compensated or decompensated hypertrophic phenotype. As we will discuss later, we 
found genes which were not previously associated with hypertrophy and heart failure, 
as well as genes which are well known to be involved. Some of these may prove to 
be pivotal in the ultimate development of either compensated hypertrophy or failure, 
such as the genes involved in MAPK signalling and apoptosis pathways. 
These divergent transcription profiles, caused by different degrees of pressure 
overload, were generated by using a novel adaptation of the monocrotaline model for 
RV hypertrophy. 
 
Model 
The rat MCT model is widely used to study right-ventricular hypertrophy in response 
to a chronically elevated hemodynamic load, with most studies reporting progression 
of RV hypertrophy to failure and death in the majority of animals around day 28 
following a single injection of 40-60 mg of MCT/kg. However, using these doses of 
MCT, up to 50% of the animals may develop stable compensated RV hypertrophy 
with no signs of failure8-13. The animals that do progress to failure show a 
significantly greater degree of RV hypertrophy and more pronounced changes in RV 
gene expression, reflecting the development of higher pulmonary arterial 
pressures13,27,28. A single dose of MCT may thus induce a graded response, which is 
most likely related to differences between individual animals in rate of MCT 
metabolism, or susceptibility to its bioactive metabolite. The MCT model could 
therefore provide a valuable tool to study the development of compensated 
hypertrophy or failure in response to pressure-overload, but a comparison of early 
stages has not been possible, because both groups cannot be reliably distinguished 
until after three weeks, when differences become apparent14, 15.  
In the present study we show that a dose of 80 mg MCT/kg consistently induced RV 
hypertrophy progressing to congestive heart failure (CHF), whereas 30 mg MCT/kg 
induced only compensated RV hypertrophy (HYP). The values for body weight, 
plasma T3 levels and index of RV hypertrophy, i.e., RV/LV+S weight, for the CHF 
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group at four weeks (Table 1), are identical to those reported earlier for the sub-
group of animals that developed CHF following a dose of 40 mg MCT/kg13. 
Furthermore, the parameters of the animals that developed compensated 
hypertrophy in that study, are identical to those in the present HYP group (Table 1), 
with a significantly smaller degree of RV hypertrophy in the HYP relative to the CHF 
group13. The reduced levels of plasma T3 at four weeks in the CHF group only, may 
serve as an indicator of the severity of heart failure. In our earlier study we showed 
that the ultimate 60% drop in plasma T3 is characteristic of severe non-thyroidal 
illness and, although in part related to a diminished caloric intake, it is primarily the 
effect of the condition of heart failure29. The more pronounced reduction of RV mRNA 
levels of SERCA2a in CHF versus HYP at four weeks (Table 2), also confirms our 
earlier observation and those made by others15. At two weeks we already find 
significant RV hypertrophy, in line with previous findings27, but the degree of 
hypertrophy is the same for both groups. Nevertheless, lung weight was already 
significantly more increased in the CHF compared to the HYP group (Table 1), 
indicating more extensive vascular injury and proliferative vasculitis in this group 
(the weight increase was not associated with edema)27, 28. A consequently higher 
hemodynamic load and RV wall stress in this group is indicated by the greater 
increase in ANF mRNA expression in RV from the CHF group (Table 2), which is in 
agreement with earlier studies16, 30, 31. Furthermore, the absence of an effect on 
SERCA2a expression in either group at two weeks supports the notion that essential 
changes in gene expression occur after this time14, 15.  
It cannot be ruled out that the dose of 80 mg/kg has additional effects compared to 
the low dose of MCT, that are not related to the degree of pulmonary vasculitis and 
subsequent RV hypertrophy. However, with respect to ventricular gene expression 
such additional systemic effects of MCT appear to be marginal, given that only ten LV 
genes were differentially regulated in the analysis of all groups. Taken together, the 
data indicate that our current MCT-protocol predictably induces different degrees of 
pulmonary hypertension, leading to either compensated or decompensated RV 
hypertrophy and failure. 
 
Expression Profile Clusters 
Clustering the regulated RV genes on the basis of their significant differences 
between the three groups classified them to the seven distinct groups of genes (Fig 
2A - 2G). For the majority of the genes, when either up or downregulated in the HYP 
relative to the CON group, the expression in the CHF group showed a greater change 
in the same direction, i.e., clusters I, II and III. Genes in these clusters appear to be 
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load sensitive and are associated with general hypertrophic remodelling in both 
compensated and decompensated hypertrophy. 
There were two clusters of genes that were uniquely associated with either the 
compensated hypertrophic phenotype (cluster V) or decompensated phenotype 
(cluster IV). This indicates that heart failure is not merely a result of quantitative 
gene expression differences, but that there is a certain group of genes whose 
expression is associated with the development of either maladaptive ventricular 
remodelling or adaptive hypertrophy (see discussion below). Our data indicate that, 
although the compensated and decompensated myocardium do have a lot of 
regulated genes in common, their expression profiles are in fact strikingly different. 
  
Altered Gene Expression In HYP And CHF 
In addition to several well known genes involved in hypertrophic remodelling, e.g., 
alpha-smooth muscle actin , alpha skeletal actin, and alpha-tubulin4, several other 
genes emerged as well. 
In pressure overload induced cardiac hypertrophy and heart failure, myocardial 
energy utilization is switched from fatty acids to glucose as a substrate. In line with 
this, Cpt1b and BBH were downregulated in clusters III and VII. Cpt1b is situated in 
the outer mitochondrial membrane, where it is involved in the transport of long-chain 
fatty acyl-CoAs from the cytoplasm into the mitochondria, thereby regulating 
mitochondrial beta-oxidation rates32. BBH catalyzes the formation of L-carnitine from 
gamma-butyrobetaine and is essential for the transport of activated fatty acids 
across the mitochondrial membrane33. 
Although HIF1 alpha was not significantly regulated in our analysis, a more hypoxia-
responsive gene, hypoxia inducible factor 3 alpha (HIF3a)34, was found to be 
upregulated in cluster III. This indicates some degree of cellular hypoxia in both HYP 
and CHF. We did not find a change in HIF3a gene expression in the left ventricular 
myocardium, thereby excluding systemic hypoxia as a cause for the expression of 
this gene in the RV. 
In cluster IV we found the metabotropic glutamate receptor 1 (mGLUR1) to be 
specifically downregulated in the CHF group. mGLUR1 has been shown to be 
expressed in the central nervous system, where it is involved in preventing neuronal 
apoptosis via HOMER - PIKE-L complex interaction, leading to PI3K activation35. A 
patho-physiological role for mGLUR1 in the heart has not been described, although 
cardiac mGLUR1 expression has been reported36. Downregulation of this gene in the 
heart in CHF could impair anti-apoptotic effects, which might be crucial in the 
development of the decompensated phenotype. However, more research will be 
needed to confirm a role for mGLUR1 in heart failure. 
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Interestingly, the growth hormone (GH) receptor was upregulated in HYP (cluster 
VII). Although no other groups showed a significant difference in expression, the HYP 
vs. CHF comparison, with a |Z-score| of 1.95, was almost significantly different. The 
expression profile of this gene shows a striking similarity to cluster V, the HYP 
specific cluster. Recently, González-Juanatey et al. showed that GH attenuated 
apoptosis in cardiac myocytes via calcineurin signalling. In addition to this, they 
showed a decrease in p38-MAPK phosphorylation level after GH treatment37. As will 
be discussed in the next section, p38-MAPK signalling in relation to apoptosis may 
play a pivotal role in the development of the HYP and CHF phenotypes. 
 
Putative Mediators In Compensated Hypertrophy Or Heart Failure 
It is impossible within the limits of this paper to present a full description of the 
possible functional significance of regulated genes. However, we did find several 
genes that may play a crucial role in the development of either compensated or 
decompensated ventricular hypertrophy.  
Our data show the HYP-specific upregulation of Mitogen-activated protein kinase 
(MAPK) phosphatase-1 (MKP-1), in cluster V. MKP-1 recognizes and de-activates 
MAPKs with higher preference for p38-MAPK and c-Jun N-terminal kinases (JNK1/2) 
than for extracellular signal-related kinases (ERK1/2). Evidence is accumulating that 
MKP-1 is involved in a negative feedback loop mechanism suppressing MAPK 
signalling activity. MAPK pathway activation ultimately leads to the phosphorylation 
and activation of one of three end effectors, i.e., p38-MAPK, JNK1/2 or ERK1/2, all of 
which can activate a wide array of transcription factors, thereby contributing to 
altered gene expression. MAPK signalling has repeatedly been shown to be of major 
importance in ventricular remodelling due to pressure overload38. Recently, it has 
been shown that p38-MAPK acts as a pro-death effector, and that attenuation of p38-
MAPK phosphorylation was associated with the upregulation of anti-apoptotic bcl-2, 
both in vitro and in vivo39. In a study of MCT-induced RV hypertrophy, an increase in 
bcl-2 expression was observed in an early stage of hypertrophy, while it was 
markedly downregulated in the transition to heart failure, where it was associated 
with severe apoptosis16. Transient MKP-1 over-expression reduced myocardial 
hypertrophy associated gene expression as evidenced by attenuated ANF, beta-
myosin heavy chain and alpha skeletal muscle actin promotor activity after 
phenyleprine (PE) stimulation of isolated rat neonatal ventricular cardiomyocytes40. 
MKP-1 transgenic mice also showed in addition to blocked activation of p38-MAPK, 
JNK1/2 and ERK1/2 following acute catecholamine stimulation, that expression of 
MKP-1 attenuated hypertrophy both in response to pressure-overload and prolonged 
isoproterenol infusion41. 
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Our observation that MKP-1 is specifically upregulated in the HYP group suggests 
blocked pro-death signalling mediated via p38-MAPK de-phosphorylation which is not 
present in the CHF group. Western analysis indeed confirmed the upregulation of 
MKP-1 in the RVs of the HYP group which consequently showed no p38-MAPK 
activation, in contrast to the RVs of the CHF group.  
Subsequent increases in bcl-2 levels in the HYP group will then exert their anti-
apoptotic effects in the compensated hypertrophic myocardium only. High levels of 
bcl-2 were indeed found at an early stage of hypertrophy by Ecarnot et al.16, while it 
was markedly downregulated in the subsequent transition to heart failure. This 
decrease in bcl-2 levels coincided with a stimulation of cyclin D1 expression, a pro-
apoptotic mediator, leading to extensive myocardial apoptosis. Indeed, our array 
data show a significant increase in cyclin D1 expression in the CHF group relative to 
CON (cluster II), which was confirmed by realtime-PCR. 
In addition to the above mentioned alterations in the expression of key pro-apoptotic 
and pro-survival signalling molecules, we found that the genes encoding the two 
major components of the mitochondrial permeability transition pore complex (PTPC), 
i.e., the mitochondrial adenine nucleotide translocator 1 (ANT1) and the 
mitochondrial voltage dependent anion channel 1 (VDAC1), were significantly 
overexpressed in CHF, but not in HYP. This is particularly relevant in light of the 
potential role of p38 and JNK in the mitochondrial death pathway42, 43. However, 
western blot analysis did not yet indicate altered expression of either VDAC1 or ANT1 
at this point in ventricular remodelling (data not shown). This could be explained by a 
time lag between mRNA and actual protein expression, which is supported by the 
observation that apoptosis is not yet detected at day 14 in the MCT model16. 
Mitochondrial involvement was also suggested by the significantly reduced expression 
of the mitochondrial transcription factor A (mtTFA) in CHF, but not in HYP. mtTFA 
controls mitochondrial replication and transcription44, 45. Mitochondrial synthesis and 
function require an estimated 1000 polypeptides, 37 of which are encoded by 
mitochondrial (mt)DNA, the rest by nuclear (n)DNA46. This suggests that reduced 
mitochondrial biogenesis via mtTFA downregulation and associated mitochondrial 
dysfunction may play a role in development of pathological hypertrophy. Reduced 
mtTFA levels were also found at end point heart failure in a study of aortic stenosis-
induced LV hypertrophy six months after surgery47. In fact, mitochondrial dysfunction 
enhances oxidative stress, which may directly trigger mitochondrial membrane 
permeabilization and subsequent apoptosis by opening of the PTPC48, 49. 
The changes described above, see also Figure 5 for a schematic summary, indicate 
that there is a fundamental shift in the balance of pro-apoptotic vs anti-apoptotic 
signalling in the two different hypertrophic phenotypes studied. Already early in 
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myocardial remodelling, hearts that will eventually develop heart failure appear to be 
sensitized to apoptosis, in contrast to compensated hearts which seem to have 
become more resistant. Similar changes have recently been described by Kang et 
al.50, both in vivo and in vitro. 
The concept that there are signalling pathways specifically linked to either 
compensated or decompensated hypertrophy, has been gaining more acceptance 
over the last couple of years, for a recent review see5. However, the time point at 
which these discriminating signals are activated, i.e., the suggested transition of 
hypertrophy to heart failure, is unknown. Our observation that discriminating 
pathways have already been invoked very early in myocardial remodelling, and not 
after compensation has failed, challenges the paradigm that there is in fact such a 
transition. 
 
Clinical Relevance 
Primary pulmonary hypertension is a disease which usually has a rapid course. 
Patients become symptomatic with non-specific complaints in about two years. Upon 
presentation, patients may show rapid development of right failure (NYHA Class III - 
IV), some with only moderately increased pressures, whereas a sub-group of patients 
show pressures up to systemic levels who remain NYHA Class I, indicating successful 
◄Figure 5: Schematic representation of 
pivotal signalling pathways early in the 
development of compensated or 
decompensated hypertrophy. As discussed in 
the accompanying text, increased MKP-1 
expression in the HYP group dephosphorylates 
p38-MAPK, blocking this pro-death effector. 
This is associated with increased anti-
apoptotic bcl-2 expression and unchanged 
levels of both VDAC1 and ANT1, resulting in 
blocked apoptotic signalling. In contrast, due 
to unchanged MKP-1 levels in the CHF group, 
p38-MAPK signalling is maintained, which is 
associated with a decrease in anti-apoptotic 
bcl-2, an increase in cyclin D1 expression, and 
ultimately increased levels of VDAC1 and 
ANT1 leading to PTPC opening and subsequent 
apoptosis.  
↑: upregulation  
↓: downregulation  
=: unregulated  
p38-MAPK~p: phosphorylated p38-MAPK 
p38-MAPK~p
Bcl-2
Cyclin D1
VDAC1
ANT1
PTPC opening
→ apoptosis
MKP-1 = MKP-1 ↑
Pressure overload
MCT80 MCT30
↓
↑
↑
=
↑
↑
=
=
PTPC closed
pro apoptotic anti apoptotic
CHF HYP
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compensatory RV hypertrophy. The ability to make a reliable early prognosis 
concerning the progression of the disease state will be invaluable to clinicians. The 
use of diagnostic expression micro-arrays may therefore be ideal to distinguish 
patients at risk early after clinical presentation. However much work remains to be 
done before such diagnostic arrays are proven to be reliable and highly 
reproducible51. Our data indicate that such early differences can be detected, in an 
animal model for right ventricular hypertrophy secondary to pulmonary hypertension. 
These data may provide target genes for phenotypical screening early in the 
development of heart failure, and suggest potential targets for early clinical 
intervention.  
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Abstract 
 
Background-In pressure overload, maladaptive myocardial hypertrophy is presumed 
to evolve from an adaptive precursor state. This presumption was tested in a rat 
model of monocrotaline (MCT)-induced pulmonary hypertension(PH) using two doses 
of MCT. Methods and Results-After administration of 30 mg/kg (HYP-group), adaptive 
right ventricular(RV) hypertrophy was observed over a 25 day period whereas after 
80 mg/kg (CHF-group), adaptive RV hypertrophy evolved from day 19 into 
maladaptive RV hypertrophy. RV myocardium of HYP and CHF was compared by 
micro-array analysis at day 10, when RV phenotypes were identical, at day 19, when 
RV phenotypes started to diverge and at day 25, when RV phenotypes differed. 
Differential gene expression between HYP and CHF was already present at day 10. 
The number of genes with differential expression between HYP and CHF remained 
almost constant (day 10: 13; day 19: 13; day 25: 16). Self-organizing-maps(SOM)-
clustering revealed for several gene-clusters earlier up- or downregulation in CHF 
than in HYP. Gene-Ontology-analyses and real-time PCR showed genes promoting 
cell-cycling such as cyclin-B1 to be among the early (day 10) upregulated genes in 
CHF. In HYP, the rise in cyclin-B1 occurred later (day 19) and was accompanied by 
higher expression of the G2/M-transition inhibitor Gadd45a. Conclusions-The early 
presence of differentially expressed genes and the constancy of their number over 
time indicates RV myocardium of HYP and CHF to differ already shortly after 
imposition of the overload without a shared adaptive precursor state. Premature 
upregulation of genes promoting cell-cycling without suppressed G2/M-transition 
characterized future development of a maladaptive phenotype. 
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Introduction 
 
Cardiac hypertrophy is often perceived as an initial and beneficial adaptive response 
to pressure overload1. Many patients with arterial hypertension, aortic stenosis or 
primary PH indeed remain asymptomatic for a prolonged period of time before heart 
failure develops. Prior to heart-failure development, a transition from adaptive to 
maladaptive ventricular hypertrophy is presumed to have occurred. Numerous 
processes in the cardiac myocyte, such as signal transduction2, 3, use of energy 
substrates4 and calcium handling5 have been implicated in this transition but there is 
no agreement on the process or combination of processes that is ultimately 
responsible for the transition from adaptive to maladaptive left ventricular (LV) 
hypertrophy. Furthermore, the paradigm of such a transition is challenged both by 
epidemiological studies, which showed LV hypertrophy to be associated with higher 
morbidity and mortality6, 7 and by clinical studies, which observed a higher prevalence 
of LV hypertrophy in aortic stenosis patients presenting with heart failure8, 9. These 
studies suggest that pressure overload-induced ventricular hypertrophy becomes 
maladaptive immediately following imposition of the overload stimulus. Usually the 
adaptive and maladaptive outcomes are presumed to emerge from an identical 
adaptive precursor state that occurs subsequent to imposition of the overload 
stimulus and prior to the emergence of the final hypertrophic phenotype. The 
transition to maladaptive hypertrophy is hereby presumed to result from the inability 
of the compensatory mechanisms to cope with the magnitude of the overload2, 10, 
while adaptive hypertrophy remains a mere continuation of the precursor state. 
 
We recently introduced a modification of the established rat monocrotaline (MCT) 
model for PH and right ventricular (RV) hypertrophy, which by using two different 
doses of MCT (30 or 80 mg/kg bw) allows for the controlled induction within 25 days 
of either an adaptive (30 mg/kg bw) or maladaptive (80 mg/kg bw) RV hypertrophic 
phenotype11. For both doses of MCT, the RV response proceeds through an initial 
phase of RV hypertrophy (day 14-19). From day 19 on, the animals that received 80 
mg/kg progress towards decompensation and premature death around day 25-28. In 
these rats, decompensation is evident from progressive weight loss and signs of 
right-sided failure such as ascites and pleural effusion. In contrast, compensated RV 
hypertrophy develops in the animals that received 30 mg/kg since these animals 
show no signs of failure up to 84 days after MCT injections11. This model of controlled 
phenotypical outcome provides the unique opportunity to characterize the myocardial 
response to pressure overload during the initial stages after imposition of the 
overload stimulus before phenotypical differences become apparent. Using micro-
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array analyses in this model, we observed significant differences in gene-expression 
levels between the two MCT doses at day 14 after the MCT injections when the 
hypertrophic response in both groups was identical11. Similar results were reported 
by Sharma et al. during development of LV hypertrophy in homozygous transgenic 
TGRmRen2-27 rats that progressed either towards adaptive hypertrophy or 
maladaptive hypertrophy with failure12. This early detection of differential gene 
expression in both studies challenges the presence of a common adaptive precursor 
state for the two phenotypical outcomes. In the present study, gene-expression 
profiles were obtained in the MCT-induced PH model at an earlier stage, namely 10 
days following administration of either 30 or 80 mg/kg MCT and subsequently 
compared to gene-expression profiles 19 and 25 days following administration of 
MCT. The following questions were addressed: 1) Do RV myocardial gene-expression 
profiles differ 10 days after MCT administration between rats receiving 30 or 80 
mg/kg MCT? 2) How does a difference in gene-expression profile evolve over time, 
i.e., does the number of differentially expressed genes rise over time as one would 
expect if both phenotypical outcomes progressively diverge from a common 
precursor, or does the number of differentially expressed genes fall over time as a 
result of the HYP group catching up in gene expression after a smaller initial 
stimulus? 3) What is the identity of the genes that are differentially expressed, are 
these genes associated with specific pathways and can these pathways be related to 
phenotypical outcome? 
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Methods 
 
Animals 
Animals were treated according to the national guidelines and with the permission of 
the Institutional Animal Care and Use Committee (IACUC) of the VU University 
Medical Center Amsterdam, the Netherlands. Male Wistar Rats, weighing 180-200 g 
(Harlan, Zeist, The Netherlands) were housed individually (250 cm2/animal) and 
received food and water ad libitum. 
A total of 36 animals were randomly assigned to three groups. All animals received a 
single subcutaneous injection with either saline (control group: CON, n=12), 30 mg 
MCT/kg body weight (stable adaptive hypertrophy group: HYP, n=12) or 80 mg 
MCT/kg body weight (maladaptive hypertrophy, congestive heart failure group: CHF, 
n=12). At day 10, 19 and 25 after treatment, four animals from each group were 
randomly picked and sacrificed with a halothane overdose. Lungs were excised, 
hearts were rinsed by perfusion and the left ventricle (LV) and right ventricle (RV) 
and interventricular septum (IVS) were separated. All tissues were weighed and snap 
frozen in liquid nitrogen and stored at -80 ºC. Three animals per group per time point 
were used for the micro-arrays analysis.  
 
Force Measurements 
A parallel group of CON (n=4), HYP (n=5) and CHF animals (n=4) was used for 
assessing RV contractile properties by analysis of isolated trabeculae at 25 days after 
imposition of pressure overload. The heart was rapidly excised and a trabecula was 
isolated from the RV as described in detail before13. Trabeculae were stretched to 
87% of the length (Lmax)at which maximum force (Fmax) was developed, yielding a 
passive force of ~8% of Fmax. Trabeculae were equilibrated for 45 min at a 
stimulation frequency of 0.5 Hz. The force-frequency relationship (FFR) was 
determined by measuring the developed active force relative to baseline (0.2 Hz) in 
response to a stepwise increase in the stimulation frequency up to 8 Hz. Length and 
dry-weight of the trabeculae were determined to calculate the cross-sectional area, 
assuming a cylindrical preparation.  
 
Micro-Array Experimental Procedures, Data Handling, Statistical Analysis And Real-
Time PCR 
The Compugen Rat OligoLibraryTM representing 4803 genes was used. Protocols 
concerning all procedures can be found in the additional methods section. This 
section also contains information regarding data handling and statistical ANOVA 
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analysis. Figure 1 schematically depicts the micro-array data handling and analysis 
steps as performed. 
 
Self Organizing Maps Clustering 
Significantly-regulated genes were clustered using a self-organizing-map (SOM) with 
the Tigr Multiple-experiment-viewer (MeV) software package14. Control values per 
time point were set to zero. Prior to clustering, average expression values per group 
were mean centered and normalized for genes and arrays. The HYP and CHF 
expression profiles were entered as a single profile per gene. Expression plots were 
generated by superimposing the HYP and CHF expression profiles for each cluster. 
This ensured that the HYP and CHF expression profiles for each single gene were 
present in the same cluster. A 4-by-4 SOM cluster was generated using Pearson 
correlation as metric with 600K iterations and cluster p<0.05.  
 
Gene-Ontology Classifications 
Genes in each of the 16 resulting SOM-clusters were analysed for over-represented 
themes using the Expression Analysis Systematic Explorer (EASE)15 tool. Clustered 
genes were tested for over-representation of specific transcription factor bindings 
N=3N=3N=3CHF
N=3N=3N=3HYP
N=3N=3N=3CON
Day 25Day 19Day10
27 arrays x 4854 genes
Data pre-processing:
3148 accepted genes
Average of 52x GAPDH
NO flagged features allowed
Average Intensity 54 channels ≥ 256
No more than 3 channel Intensities ≤ 100
Fixed model ANOVA: time, mct and time:mct interaction
Fs statistic using 2000 permutations on residuals
Benjamini-Hochberg linear step-up FDR on F-tests (≤1%) 
Per time-point: CON vs. HYP, CON vs. CHF, HYP vs. CHF
Fs statistic using 2000 permutations on residuals
Bonferroni correction (P≤0.025)
Minimal 1.5 fold change584 regulated genes
F-test analysis
Post-hoc tests
+
GSEA: processes associated with development
of either the HYP or CHF phenotype
Define significant regulation between CON, HYP and CHF
for the three time points
4x4 SOM cluster
EASE: over-represented processes per cluster
◄Figure 1: Schematic 
representation of data 
handling and analysis steps. 
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sites (TFBS), GenMapp and KEGG pathways and the gene ontology classifications for 
molecular function, cellular component and biological processes, with the enhanced 
annotation option enabled (same official gene symbol, Homologene COGs, 
Homologenes and same gene symbol for human, mouse and rat). The background 
population used were the 3148 genes that were analyzed in the ANOVA analysis. 
Gene classifications needed to represented at least three genes and have a EASE-test 
p-value below 0.05 to be considered over-represented.  
The HYP vs. CHF group comparisons for each time point were explored using the 
Gene set enrichment analysis (GSEA)16 java-package. Only GenMapp pathways were 
included in this analysis. Due to the low number of replicates, 1000 permutations on 
genes were used. In consideration with the known issues of possible overestimation 
of significance levels when using this type of permutation, the FDR q-val cutoff was 
set at 0.05 instead of the 0.25 value used in the methodological manuscript16. 
 
Statistical Analysis For Real-Time-PCR And Hypertrophic Parameters 
MCT parameters, real-time PCR and FFR measurements were evaluated for 
significant differences with a two-factor ANOVA with Bonferroni corrected post-hoc 
tests. Significant and positive correlation between the array and real-time PCR was 
determined with a Pearson correlation test (p<0.05). Data in Tables and Figures are 
presented as means ± standard error unless stated otherwise. * : p<0.05 rel to CON 
same time point, † : p<0.05 rel to HYP same time point. 
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Additional Methods Section 
 
Total RNA Isolation 
Total RNA isolation and real-time PCR were performed as previously described11. A 
common reference RNA pool for the micro-array procedures was constructed by 
pooling the RNA from IVS samples of animals sacrificed at 19 and 25 days.  
 
Micro-Array Procedures  
Array printing: The Compugen Rat OligoLibraryTM was purchased from Sigma-
Aldrich. Oligonucleotides were printed on Motorola CodeLinkTM activated slides 
(Amersham Biosciences) using an Perkin Elmer Piezorray non-contact micro 
dispensing printer. Features were spotted in duplicates divided into two separate 
regions on the array surface. 
Preparation of labelled cDNA probe: Three animals per time point per group 
were selected for micro-array analysis. cDNA strands were generated from 30 µg 
total RNA taken from the RV as previously described11, 17. In short, cDNA was 
synthesis was performed using an oligo-dT [(dT)20-VN] primer (Invitrogen) and 
SuperScriptTM II Reverse Transcriptase (Invitrogen) with incorporation of aminoallyl-
dUTP. Probes were indirectly labelled with Fluorolink Cy3 and Cy5 mono-functional 
dyes for the Reference pool and RV samples, respectively.  
Micro-array hybridization: Prior to use, the slides were processed following 
guidelines provided in the manufacturers protocol. Pairs of labelled reference pool 
(Cy3) and RV sample (Cy5) were combined in a hybridization mix containing 50% 
formamide and 2x SSC. Hybridization time was set to 14 hours at 37 ºC with 
agitation, using a Perkin Elmer HybArray 12TM hybridization station. Detailed 
information on the probe generation and hybridization procedures can be found at 
http://www.vumc.nl/microarrays/onderzoek/index.html?protocols.html~hoofd.  
 
Data Acquisition And Processing 
Slides were scanned at a 10 µm resolution for Cy3 and Cy5 intensities using a Perkin-
Elmer Multi Laser Micro-Array Scanner operated by the ScanArray Express v1.0 
software. Array images were processed with Imagene v5.1. Spot signal intensities 
had to be at least three times higher than the local background to allow further 
processing. Mean Cy3 and Cy5 intensities were background corrected and duplicate 
signals for each feature on the array were averaged. The number of GAPDH 
replicates (52x) were averaged. To ensure a balanced design for a robust analysis of 
variance framework, only genes without flags in any of the 27 arrays were selected 
for analysis. In addition, genes with a average spot intensity over all 54 channels of 
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the 27 arrays below 256, were excluded from further processing, as were genes with 
more than three of the 54 channel intensities below 100. For the remaining genes, 
Cy3 and Cy5 mean channel intensities were log2 transformed, mean centered and 
standardized.  
 
Micro-Array Data Analysis 
We performed a modified analysis of variance (ANOVA) method to test for differential 
expression in our dataset18. This F-statistic estimates the error variance by borrowing 
cross-gene information using the James-Stein shrinkage concept as described by Cui 
et al.19. This approach is appropriate for datasets with a small number of biological 
replicates, as in our case, n=3 per group and is supposed to result in a more stable 
estimate of the error variance. 
To evaluate the 3148 genes for differential expression, a fixed model ANOVA was 
used. Factors included in the ANOVA analysis were array, MCT treatment, time point 
and the interaction between MCT treatment and time point. Significance of the 
interaction factor would indicate that the effect of MCT treatment is not constant over 
time. P-values were calculated using 2000 permutations on residuals, using the Fs 
statistic. Benjamini-Hochberg linear step-up false discovery rate (FDR) corrections20 
were performed separately on the F-tests for MCT treatment, Time point and 
interaction factor (FDR<1%). Bonferroni corrected post-hoc tests (p<0.025) were 
performed for all three time points separately for the CON vs. HYP, CON vs. CHF and 
HYP vs. CHF comparisons. Per gene this lead to three post-hoc t-tests per time point. 
Additionally, a minimal 1.5 fold change for post-hoc comparisons was included. All 
calculations were performed in R-statistics v2.0.1 using the Maanova package 
v0.98.3. 
Adaptive vs. Maladaptive Remodelling 
 83 
Results 
 
MCT-Induced RV Hypertrophy 
Subcutaneous injection of MCT resulted in a progressive increase in lung weight for 
both the HYP and CHF groups. This increase was already significant at day ten, while 
a significant difference between the HYP and CHF group was observed at day 25. The 
increase in lung weight is indicative of increased pulmonary vascular resistance21, 22 
resulting in RV hypertrophy as evidenced by the increase in RV to LV + IVS weight 
ratio at day 19 and 25 for both the HYP and CHF groups. These parameters are 
shown in Table 1 with the body weights of these animals at the time of sacrifice. 
Growth curves are depicted in Figure 2, indicating the drastic fall in body weight in 
the CHF group after day 19. In agreement with our earlier data, these animals 
showed secondary signs of heart failure, including pleural effusion and ascites. 
Contractile properties of RV trabeculae at day 25 were subsequently analyzed to 
assess myocyte function in both hypertrophy groups relative to controls.  
 
Contractile Characteristics Of RV Trabeculae And FFR  
Maximal active force of trabeculae expressed per unit cross-sectional area did not 
differ between the experimental groups (CON: 22 ± 3, HYP: 40 ± 9 and CHF: 25 ± 6 
mN/mm2). Control trabeculae exhibited a positive FFR between 0.2 and 8 Hz, in 
agreement with earlier reports23, while those from the CHF group showed no 
potentiation (Figure 2). In contrast, trabeculae of the HYP group displayed a 
potentiation of force similar to control trabeculae. The difference in FFR between the 
HYP and the CHF group is indicative of the presence of maladaptive hypertrophy in 
the CHF group and adaptive hypertrophy  in the HYP group.  
 
Inter-Group Differences In Gene Expression 
RV gene-expression profiles were determined for the three groups at day 10, 19 and 
25. The total number of genes analyzed after pre-processing equalled 3148. When 
comparing CON to HYP, 8, 123 and 386 genes were differentially expressed at day 
10, 19 and 25, respectively. When comparing CON to CHF, 42, 125 and 454 genes 
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were differentially expressed at day 10, 19 and 25, respectively. The increase over 
time in the number of differentially expressed genes observed in both the HYP and 
CHF groups is consistent with the progression of RV hypertrophy. In contrast, when 
comparing HYP to CHF the number of differentially expressed genes is almost 
constant with 13 genes differentially expressed on day 10, 13 genes on day 19 and 
16 genes on day 25. Even more remarkable, when expressed relative to the total 
number of differentially expressed genes, the number of genes that are differentially 
expressed between the HYP and CHF groups fell progressively (day 10: 23.6%; day 
19: 7.5%; day 25: 3.1%). Furthermore, as evident from Figure 3A, the genes with 
differential expression between the HYP and CHF groups varied at each time point, 
whereas genes with differential expression between the CON and HYP or CON and 
CHF groups showed considerable overlap at successive time points (Figures 3B and 
3C). 
The total number of differentially expressed genes equalled 584. A complete listing of 
these 584 genes is given in Online Results supplement A. The array data set has 
been deposited in the Gene-expression Omnibus24 as series GSE3675.  
 
Time-Dependent Changes In Gene Expression 
To evaluate the time-dependent expression alterations of individual genes in the HYP 
and CHF groups, a 4-by-4 Self Organizing Map (SOM) clustering was performed on all 
584 differentially expressed genes (Figure 4 A through P). At each time point, the 
expression of an individual gene in HYP (green lines) or CHF (red-lines) was 
  
Lung 
 (g) 
RV  
(mg) 
RV / LV+IVS 
(mg/mg) 
Body weight 
 (g) 
CON 1.07 ± 0.04 151 ± 8 0.22 ± 0.02 248 ± 4 
HYP 1.39 ± 0.02 * 149 ± 7 0.24 ± 0.01 226 ± 4 * 
Day 
10 
CHF 1.39 ± 0.05 * 130 ± 11 0.24 ± 0.01 229 ± 4 
CON 1.29 ± 0.03 159 ± 5 0.20 ± 0.01 333 ± 8 
HYP 1.57 ± 0.10 * 185 ± 17 0.25 ± 0.01 * 302 ± 4 * 
Day 
19 
CHF 1.80 ± 0.03 * 188 ± 13 0.28 ± 0.02 * 285 ± 4 * 
CON 1.31 ± 0.02 147 ± 11 0.18 ± 0.01 351 ± 8 
HYP 1.72 ± 0.06 * 329 ± 24 * 0.40 ± 0.02 * 320 ± 5 * 
Day 
25 
 CHF 2.22 ± 0.14 *† 295 ± 13 * 0.42 ± 0.01 * 262 ± 9 *† 
 
▲Table 1: Measured parameters for the CON, HYP and CHF groups at 10, 19 and 25 days after 
MCT injections. 
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expressed relative to control levels, which was set to zero. Opposite expression 
profiles ended up at opposing sides of the cluster grid, with continuously 
downregulated genes predominantly located in the top row, and continuously 
upregulated genes in the bottom row. The middle two rows contain genes whose 
expression shifts over time. 
In clusters J and K and to a lesser extent in clusters A, C and O, upregulated or 
downregulated individual genes occurred earlier in CHF (red lines) than in HYP (green 
lines) as evident from the red lines rising or falling on day 10 and the green lines 
displaying a similar pattern only at day 19. At day 25, up- or downregulation of gene 
expression had become similar in CHF and HYP as evident from the overlap of red 
and green lines. This finding implies that development of CHF phenotype is related 
more to the timing of gene expression than to changes in expression of specific 
genes. Earlier upregulation of expression of genes in the CHF group could be 
explained by faster elevation of RV wall stress because of more rapid development of 
PH after administration of 80 mg/kg MCT. 
An ontology analysis for each of these 16 clusters, indicated significant over-
representation of several biological themes. Genes with protein products located in 
the mitochondria showed a significant call in clusters A through D and G. All these 
clusters had progressively downregulated expression levels. The same clusters also 
contained genes encoding protein products associated with cell metabolism, e.g., 
lipid metabolism, mitochondrial fatty-acid beta-oxidation and amino acid metabolism. 
Another over-represented theme was cell-cycling in cluster J. Genes encoding for 
protein products of the extracellular space were over-represented in cluster D, which 
corresponded with continuous downregulation over time, as well as in cluster P which 
corresponded with continuous upregulation over time. A complete overview of over-
represented classes is given for each cluster in Online Results supplement B. 
◄Figure 3: Overlap of significantly 
regulated genes at the three time 
points for each of the three pair-
wise group comparisons, i.e., HYP 
vs. CHF (A), CON vs. HYP (B) and 
CON vs. CHF (C), respectively. 
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Inter-Group Differences In Gene Expression Using Gene Set Enrichment Analysis 
Gene-expression differences on day 10, 19 and 25 between HYP and CHF were 
further analysed using the GSEA program to assess differential activation of specific 
GenMapp pathways (Table 2). GenMapp pathways showing significant enrichment 
scores for the HYP vs. CHF comparisons again included cell cycle and electron 
transport chain (ETC). For the cell-cycle pathway 7 genes were upregulated at day 
10. The position of the upregulated genes in the cell-cycle pathway is indicated in 
Figure 1 of online Results supplement C. For the ETC, 15 genes were upregulated at 
day 10 and 12 genes downregulated at day 25, predominantly affecting complexes I, 
IV and V. These observations suggest that relative to the HYP group, oxidative 
phosphorylation activity in the CHF group is upregulated early and downregulated 
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▲Figure 4: Expression profiles for all genes in the 16 clusters were corrected for control values 
per time point. HYP (green lines) and CHF (red lines) expression patterns were superimposed. 
The total number of genes per cluster is indicated in brackets next to the cluster designation. 
Note the expression differences at day 10 for clusters J and K while profiles overlap at day 19 
and 25. 
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late during development of maladaptive hypertrophy. The position of the up- or 
downregulated genes in the ETC is indicated in Figure 2 of online Results supplement 
C. Other GenMapp pathways showing significant enrichment scores were related to 
G-protein signalling, ribosomal proteins and proteasome degradation.  
 
Real-Time PCR Confirmation 
As a reliability check, the micro-array data were tested for a significant correlation 
with SYBR-green based real-time PCR. Figure 5 shows bar graphs with the micro-
array and real-time PCR data with a correlation plot between both methods for a 
selection of genes. Figure 3 in Online Results Supplement 3 shows the correlation 
plots for several other confirmed genes. Overall, over 80% of checked genes showed 
significant positive Pearson correlation p-values.  
 
 
 
 Pathway Gene number - Regulated Normalized Enrichment 
score (| NES| ) 
FDR 
q-val 
G protein signalling 10 - Down in CHF 1.81 0.034 
Electron transport chain 15 - Up in CHF 1.71 0.038 
Cell cycle 7 - Up in CHF 2.01 0.005 
day 10 
Ribosomal proteins 20 - Up in CHF 1.67 0.035 
day 19 Ribosomal proteins 19 - Up in CHF 2.26 0.001 
Electron transport chain 12 - Down in CHF 1.92 0.010 
day 25 
Proteasome degradation 11 - Down in CHF 1.80 0.019 
 
▲Table 2: Summary of pathways implicated by a GSEA of CHF relative to the HYP group, at all 
three time points. Indicated for each GenMapp pathway are the number of genes supporting the 
pathway, expression level in the CHF group relative to the time-matched HYP group, the absolute 
value of the normalized enrichment score and the FDR q-value. 
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▲Figure 5: Log2 expression values for array and real-time PCR data and an array-PCR 
correlation-plot for heme-oxygenase1 (HO1) and the cell cycle related genes cell division cycle 
control protein 2 (Cdc2a / Cdk1), growth arrest and DNA-damage-inducible-alpha (Gadd45a), 
cyclin B1 and cell division cycle 20 homolog (p55cdc / cdc20). For each time point the CON 
values were set to zero.  
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Discussion 
 
The present study observed the following findings: 1) A comparison of gene-
expression profiles between HYP and CHF groups revealed the number of 
differentially expressed genes to be small and to remain almost constant at the 
different time points (day 10: 13; day 19: 13 and day 25: 16). 2) SOM-clustering of 
all differentially expressed genes detected important differences in the time-course of 
up- or downregulation of gene expression. For several clusters of genes, up- or 
downregulation of gene expression occurred earlier in CHF (day 10) than in HYP (day 
19) but later (day 25) gene-expression profiles of these two groups were largely 
overlapping. This implies development of the CHF phenotype to result from 
differences in timing of up- or downregulation of gene expression and not from up- or 
downregulation of specific genes. The varying identity of the differentially expressed 
genes between the HYP and CHF groups over time (Figure 3A) also fits the 
observation of a phase shift of gene expression between the HYP and CHF groups 
whereby the HYP group progressively catches-up in terms of its gene-expression 
profile with the CHF group (Figure 4). 3) In the CHF group, both ontology analysis of 
the SOM clusters and GSEA showed initial (day 10) upregulation of genes involved in 
cell-cycling and electron transport chain. Premature upregulation of these genes 
seems to predispose RV myocardium to a maladaptive hypertrophic phenotype in 
experimental MCT-induced PH. 
 
Controlled Induction Of RV Hypertrophy Or Failure 
The present study used a previously described11 modification of the rat MCT model of 
PH-induced RV hypertrophy which allows for controlled induction of either adaptive or 
maladaptive RV hypertrophy. The impaired FFR of isolated trabeculae in the CHF 
group, but not in the HYP group, illustrate the critical difference in contractile 
function between the adaptive and maladaptive forms of RV hypertrophy (Figure 2). 
The observed difference in FFR may be related to the previously reported lower RV 
expression level of SERCA2a in CHF relative to HYP at 25 days after MCT injections11, 
since SERCA2a activity is a determinant of the frequency-dependent increase in Ca2+-
transient amplitude which underlies the positive FFR in rat trabeculae23. 
Since the outcome for both groups was known in advance, RV myocardial gene-
expression profiles could be characterized at early stages of development of either 
adaptive or maladaptive RV hypertrophy well before functional or morphological 
differences between groups became apparent. Moreover, the stimulus for 
hypertrophy was similar in both groups, namely pressure overload, and differed only 
in severity. This avoided comparison of gene-expression profiles of adaptive and 
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maladaptive hypertrophy induced by different stimuli such as pressure overload and 
exercise training. 
 
Differences In Gene-Expression Profiles Between HYP And CHF Groups  
The number of differentially expressed genes between HYP and CHF groups was small 
and remained almost constant throughout the entire observation period. Small 
differences in myocardial gene expression were also observed in a mouse model of 
graded LV pressure overload when animals developing adaptive LV hypertrophy were 
compared to maladaptive LV hypertrophy25. Relative to the number of differentially 
expressed genes observed in the comparison between CON and HYP groups or CON 
and CHF groups, differential gene expression between HYP and CHF groups actually 
fell over time despite progressive phenotypic divergence. Absence of an initial 
identical gene-expression profile in HYP and CHF groups and absence of a progressive 
rise in the number of differentially expressed genes between HYP and CHF groups 
argue against a common adaptive hypertrophic phenotype from which both HYP and 
CHF phenotypes evolved. 
 
Variation In Gene-Expression Profiles Over Time 
The 16 clusters that were generated with the SOM analysis can be separated into two 
main categories, i.e., those clusters that do not show a difference in expression levels 
between the HYP and CHF groups at any of the three time points (B, D-I, L-N, and P) 
and those that show a difference in expression between the two hypertrophic 
phenotypes at day 10, with later disappearance of the observed difference (clusters J 
and K and to a smaller degree clusters A, C and O). Genes assigned to the first set of 
clusters can be regarded as genes involved in general hypertrophic remodelling. 
Many genes that were previously thought to be involved in the progression from 
adaptive to maladaptive hypertrophy can be found in these clusters. These genes 
showed altered expression levels relative to the control group, but no difference 
between the HYP and CHF groups. These genes included genes encoding for proteins 
involved in fatty-acid beta-oxidation (FAbOx)4, genes encoding for mitochondrial 
proteins26 and genes encoding for components of the extracellular matrix27. For the 
second set of SOM clusters, genes in the CHF group appear to be regulated prior to 
those in the HYP group. This catch-up of gene expression observed in the HYP group 
can be explained by the lower intensity of the hypertrophic stimulus to which the HYP 
group was subjected. These findings suggest the magnitude of the hemodynamic 
stimulus to be of critical importance for eventual development of a maladaptive 
hypertrophy phenotype. These findings are also in line with previous experiments in 
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dogs which developed maladaptive hypertrophy during LV pressure overload when 
baseline wall-stress prior to imposition of the aortic band was already elevated28, 29. 
 
Identity Of Differentially Expressed Genes 
Identification of the genes significantly different between the HYP and CHF groups 
reveals information on the processes associated with development of either adaptive 
or maladaptive hypertrophy. Caution needs to be exerted when drawing conclusions 
based on over-representation of biological themes from a relatively small number of 
differentially regulated genes. In this study the number of differentially expressed 
genes between the HYP and CHF groups was relatively small and using the EASE-
program this could render interpretation of over-representation of biological themes 
unreliable. Therefore, a GSEA approach was used to evaluate the differences in 
expression levels between the HYP and CHF groups in terms of over-representation of 
biological themes. The GSEA analysis indicated several GenMapp pathways such as 
cell-cycling and electron transport with differential expression between the HYP and 
CHF groups (Table 2).  
In the cell-cycle pathway at day 10, three of seven genes showed a significant 
increase in expression levels in the CHF group relative to both the CON and HYP 
group, i.e., cell division cycle control protein 2 (Cdc2a / cdk1), cyclin B1 (Ccnb1) as 
well as cell division cycle 20 homolog (Cdc20), all three of which were confirmed by 
real-time PCR (Figure 5). The other four genes, i.e., pituitary tumor-transforming 
gene 1 (PTTG1), proliferating cell nuclear antigen (PCNA), Cyclin D1 (Ccnd1) and cell 
division cycle 25 homolog A (Cdc25a), had increased expression in CHF relative to 
HYP.  
As a result of downregulation of cell-cycle related genes during postnatal 
development30 cardiac myocytes are considered to remain in the G1 phase of the 
cell-cycle during their entire life-span. Increased levels of cell-cycle related genes 
have however been reported during hypertrophic ventricular remodelling11, 12, 31, 32. In 
the present study, increased mRNA levels of both cyclinB1 and cdk1 were observed 
10 days after MCT administration in the CHF group and 19 days after MCT 
administration in both HYP and CHF groups. Upregulation of cyclinB1 and cdk1 
indicates a progression from the G1 phase of the cell-cycle to the S and G2 phases. 
Subsequent nuclear translocation of the cyclinB1-Cdk1 complex (M-phase promoting 
factor; MPF), is a requisite for the G2/M transition. The activity of the MPF complex is 
inhibited by GADD45a which binds to the MPF complex and dissociates it. The present 
study observed significantly higher expression levels of GADD45a in the HYP groups 
relative to both the CON and CHF groups at days 19 and 25 following MCT 
administration. Hence, 10 days after MCT administration the upregulation of cyclinB1 
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and cdk1 in the CHF group occurs in the absence of GADD45a upregulation. This 
situation favours G2/M transition which can be deleterious in terminally differentially 
cells as it leads to mitotic catastrophe or apoptosis33, 34. The latter could relate to the 
maladaptive hypertrophic phenotype observed in the CHF group. In contrast, in the 
HYP group upregulation of cyclinB1 and cdk1 occurs later, at a time when expression 
of GADD45a is already increased. This prevents the deleterious effects of G2/M 
transition and could thereby preclude the development of maladaptive hypertrophy in 
this group.  
 
Conclusion 
In the present model of controlled induction of HYP and CHF phenotypes, genes that 
are differentially expressed between HYP and CHF groups are already observed early 
after imposition of the hypertrophy stimulus, which argues against the existence of 
an adaptive precursor state during development of adaptive or maladaptive 
hypertrophy. Furthermore, the number of differentially expressed genes remains 
constant over time. For several clusters of genes, up- or downregulation of gene 
expression occurred earlier in CHF (day 10) than in HYP (day 19) but later (day 25) 
gene-expression profiles of these two groups were largely overlapping. Gene-
ontology analyses of these early regulated genes in the CHF group revealed 
involvement of cell-cycling genes. Premature upregulation of cell-cycling genes 
therefore predisposes RV myocardium to a maladaptive hypertrophic phenotype. 
Adaptive vs. Maladaptive Remodelling 
 93 
Reference List 
 
 (1)  Grossman W, Jones D, McLaurin LP. Wall stress and patterns of hypertrophy in the human left 
ventricle. J Clin Invest 1975 July;56(1):56-64. 
 (2)  Frey N, Olson EN. Cardiac Hypertrophy: The Good, the Bad, and the Ugly. Annu Rev Physiol 
2003 January 1;65(1):45. 
 (3)  Chien K. Molecular biology of cardiac hypertrophy and heart failure. Grace A, Hunter J, editors. 
In Molecular Basis of Cardiovascular Disease, Chapter 9 , 211-250. 1999. 
 (4)  Lehman JJ, Kelly DP. Gene regulatory mechanisms governing energy metabolism during cardiac 
hypertrophic growth. Heart Fail Rev 2002 April;7(2):175-85. 
 (5)  Wolkart G, Stromer H, Brunner F. Calcium Handling and Role of Endothelin-1 in Monocrotaline 
Right Ventricular Hypertrophy of the Rat. Journal of Molecular and Cellular Cardiology 2000 
November;32(11):1995-2005. 
 (6)  Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of 
echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J 
Med 1990 May 31;322(22):1561-6. 
 (7)  Manyari DE. Prognostic implications of echocardiographically determined left ventricular mass in 
the Framingham Heart Study. N Engl J Med 1990 December 13;323(24):1706-7. 
 (8)  Buermans HPJ, Paulus WJ. Iconoclasts topple adaptive myocardial hypertrophy in aortic 
stenosis. Eur Heart J 2005 September 1;26(17):1697-9. 
 (9)  Kupari M, Turto H, Lommi J. Left ventricular hypertrophy in aortic valve stenosis: preventive or 
promotive of systolic dysfunction and heart failure? Eur Heart J 2005 April 28;ehi290. 
 (10)  Morisco C, Sadoshima J, Trimarco B, Arora R, Vatner DE, Vatner SF. Is treating cardiac 
hypertrophy salutary or detrimental: the two faces of Janus. Am J Physiol Heart Circ Physiol 
2003 April 1;284(4): H1043. 
 (11)  Buermans HPJ, Redout EM, Schiel AE, Musters RJP, Zuidwijk M, Eijk PP, van Hardeveld C, 
Kasanmoentalib S, Visser FC, Ylstra B, Simonides WS. Microarray analysis reveals pivotal 
divergent mRNA expression profiles early in the development of either compensated ventricular 
hypertrophy or heart failure. Physiol Genomics 2005 May 11;21(3):314-23. 
 (12)  Sharma UC, Pokharel S, van Brakel TJ, van Berlo JH, Cleutjens JPM, Schroen B, Andre S, Crijns 
HJGM, Gabius H, Maessen J, Pinto YM. Galectin-3 Marks Activated Macrophages in Failure-Prone 
Hypertrophied Hearts and Contributes to Cardiac Dysfunction. Circulation 2004 November 
9;110(19):3121-8. 
 (13)  Musters RJP, van der Meulen ET, van der Laarse WJ,  van Hardeveld C. Differential Effects of 
Norepinephrine on Contractile Recovery of Rat Trabeculae Following Metabolic Inhibition. 
Journal of Molecular and Cellular Cardiology 1998 February;30(2):435-40. 
 (14)  Saeed AI, Sharov V, White J, Li J, Liang W, Bhagabati N, Braisted J, Klapa M, Currier T, 
Thiagarajan M, Sturn A, Snuffin M, Rezantsev A, Popov D, Ryltsov A, Kostukovich E, Borisovsky 
I, Liu Z, Vinsavich A, Trush V, Quackenbush J. TM4: a free, open-source system for microarray 
data management and analysis. Biotechniques 2003 February;34(2):374-8. 
 (15)  Hosack D, Dennis G, Sherman B, Lane H, Lempicki R. Identifying biological themes within lists 
of genes with EASE. Genome Biology 2003;4(10):R70. 
 (16)  Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA , Paulovich A, 
Pomeroy SL, Golub TR, Lander ES, Mesirov JP. Gene set enrichment analysis: A knowledge-
based approach for interpreting genome-wide expression profiles. PNAS 2005 September 
30;0506580102. 
 (17)  Bergman AM, Eijk PP, Ruiz van Haperen VWT, Smid K, Veerman G, Hubeek I, van den IJssel P, 
Ylstra B, Peters GJ. In vivo Induction of Resistance to Gemcitabine Results in Increased 
Expression of Ribonucleotide Reductase Subunit M1 as the Major Determinant. Cancer Res 2005 
October 15;65(20):9510-6. 
 (18)  Kerr MK, Martin M, Churchill GA. Analysis of variance for gene expression microarray data. J 
Comput Biol 2000;7(6):819-37. 
 (19)  Cui X, Hwang JTG, Qiu J, Blades NJ, Churchill GA. Improved statistical tests for differential gene 
expression by shrinking variance components estimates. Biostat 2005 January 1;6(1):59-75. 
 (20)  Reiner A, Yekutieli D, Benjamini Y. Identifying differentially expressed genes using false 
discovery rate controlling procedures. Bioinformatics 2003 February 12;19(3):368-75. 
Chapter 3 
 94 
 (21)  Wilson DW, Segall HJ, Pan LC, Lame MW, Estep JE, Morin D. Mechanisms and pathology of 
monocrotaline pulmonary toxicity. Crit Rev Toxicol 1992;22( 5-6):307-25. 
 (22)  Jones JE, Mendes L, Rudd MA, Russo G, Loscalzo J, Zhang YY. Serial noninvasive assessment of 
progressive pulmonary hypertension in a rat model. Am J Physiol Heart Circ Physiol 2002 July 
1;283(1):H364-H371. 
 (23)  Janssen PML, Stull LB, Marban E. Myofilament properties comprise the rate-limiting step for 
cardiac relaxation at body temperature in the rat. Am J Physiol Heart Circ Physiol 2002 February 
1;282(2):H499-H507. 
 (24)  Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and 
hybridization array data repository. Nucl Acids Res 2002 January 1;30(1):207-10. 
 (25)  Rothermel BA, Berenji K, Tannous P, Kutschke W, Dey A, Nolan B, Yoo KD, Demetroulis E,  
Gimbel M, Cabuay B, Karimi M, Hill JA. Differential Activation of Stress-Response Signaling in 
Load-Induced Cardiac Hypertrophy and Failure. Physiol Genomics 2005 July 20;00061. 
 (26)  Rosenberg P. Mitochondrial dysfunction and heart disease. Mitochondrion 2004 September;4(5-
6):621-8. 
 (27)  Wong K, Boheler KR, Petrou M, Yacoub MH . Pharmacological Modulation of Pressure-Overload 
Cardiac Hypertrophy : Changes in Ventricular Function, Extracellular Matrix, and Gene 
Expression. Circulation 1997 October 7;96(7):2239-46. 
 (28)  Koide M, Nagatsu M, Zile MR, Hamawaki M , Swindle MM, Keech G, DeFreyte G, Tagawa H, 
Cooper G, IV, Carabello BA. Premorbid Determinants of Left Ventricular Dysfunction in a Novel 
Model of Gradually Induced Pressure Overload in the Adult Canine. Circulation 1997 March 
18;95(6):1601-10. 
 (29)  Ross J, Jr. On Variations in the Cardiac Hypertrophic Response to Pressure Overload. Circulation 
1997 March 18;95(6):1349-51. 
 (30)  Chen HW, Yu SL, Chen WJ, Yang PC, Chien CT, Chou HY, Li HN, Peck K, Huang CH, Lin FY, Chen 
JJW, Lee YT. Dynamic changes of gene expression profiles during postnatal development of the 
heart in mice. Heart 2004 August 1;90(8):927-34. 
 (31)  Setoguchi M, Leri A, Wang S, Liu Y, De Luca A, Giordano A,  Hintze TH, Kajstura J, Anversa P. 
Activation of cyclins and cyclin-dependent kinases, DNA synthesis, and myocyte mitotic division 
in pacing-induced heart failure in dogs. Lab Invest 1999 December;79(12):1545-58. 
 (32)  Ecarnot-Laubriet A, Assem M, Poirson-Bichat F,  Moisant M, Bernard C, Lecour S, Solary E, 
Rochette L , Teyssier J-R. Stage-dependent activation of cell cycle and apoptosis mechanisms in 
the right ventricle by pressure overload. Biochimica et Biophysica Acta (BBA) - Molecular Basis 
of Disease 2002 April 24;1586(3):233-42. 
 (33)  Castedo M, Perfettini JL, Roumier T, Kroemer G. Cyclin-dependent kinase-1: linking apoptosis to 
cell cycle and mitotic catastrophe. Cell Death Differ 2002 December;9(12):1287-93. 
 (34)  Datwyler DA, Magyar JP, Weikert C, Wightman L, Wagner E, Eppenberger HM. Reactivation of 
the mitosis-promoting factor in postmitotic cardiomyocytes. Cells Tissues Organs 
2003;175(2):61-71. 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Early Adaptive And Maladaptive Hypertrophic 
Myocardial Proteome Responses During 
 Pressure Overload 
 
Henk P.J. Buermans1, Marian Zuidwijk1, René J.P. Musters1  
Cornelis van Hardeveld1, Connie R. Jiménez2, Frans C. Visser3  
Walter J. Paulus1, Warner S. Simonides1 
 
 
1. Laboratory for Physiology, Institute for Cardiovascular Research (ICaR-VU), 
VU University Medical Center, Van der Boechorststraat 7, 1081 BT 
Amsterdam, The Netherlands. 
 
2. Department of Molecular and Cellular Neurobiology, Research Institute 
Neurosciences, Faculty of Earth and Life Sciences 
Vrije Universiteit, De Boelelaan 1085, 1081 HV Amsterdam, The Netherlands. 
 
3. Department of Cardiology, Institute for Cardiovascular Research (ICaR-VU), 
VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The 
Netherlands. 
Submitted for publication
Chapter 4 
Chapter 4 
 96 
Table of contents 
 
Abstract 97 
Introduction 98 
Methods 100 
Animals 100 
Protein Sample Preparation For 2DGE 100 
Isoelectric Focusing, SDS-Page, And MALDI-TOF Mass Spectrometry 100 
Quantification And Statistical Analysis Of 2DGE Gels 101 
Quantitative Real-Time PCR 101 
Statistical Analysis Of PCR And Hypertrophy Parameters 102 
Results 103 
MCT-Induced RV Hypertrophy 103 
Between-Group Differences In Protein Expression 103 
Identity Of Differentially Expressed Proteins 105 
Quantitative Real-Time PCR 106 
Discussion 107 
Induction Of Adaptive Or Maladaptive Hypertrophy 107 
Alterations In Fatty Acid Transport And Mitochondrial Beta-Oxidation 108 
Alterations In Peroxide Handling 109 
Heat Shock Protein Survival Signalling 110 
Conclusion 110 
Reference List 111 
Proteome Profiling 
 97 
Abstract 
Ventricular hypertrophy is a general response of the heart to overload and depending 
on the degree and the duration of the overload, either and an adaptive or 
maladaptive hypertrophic phenotype may evolve. We recently observed myocardial 
gene-expression differences between adaptive and maladaptive hypertrophy early 
after the imposition of pressure overload, challenging the existence of a common 
hypertrophy precursor state preceding the development of either of these 
phenotypes. In the present study, myocardial protein-expression levels were 
evaluated for significant differential expression early after the imposition of pressure 
overload between control rats and rats developing either adaptive or maladaptive 
hypertrophy. 
Adaptive or maladaptive hypertrophy phenotypes were induced by subcutaneous 
injections of either 30 (HYP-group) or 80 (CHF-group) mg monocrotaline(MCT)/kg 
body weight, respectively. At 10 days after MCT injections when RV phenotypes were 
identical, right ventricular (RV) cytosolic-protein fractions from HYP, CHF and time 
matched control (CON) animals were separated and compared using 2-dimensional 
gel electrophoresis. When comparing CON to HYP, CON to CHF and HYP to CHF, 5, 15 
and 23 protein-spots showed significant differential expression, respectively. MALDI-
TOF mass spectrometry identification of a subset of proteins indicated fatty acid 
metabolism, reactive oxygen species handling and apoptosis signalling to be already 
altered at 10 days after the imposition of pressure overload between the HYP and 
CHF groups. 
In conclusion, the observed differences at the myocardial protein-expression level 
between the HYP and CHF groups at 10 days after the imposition of pressure 
overload, further argues against the existence of a common hypertrophic precursor 
state. 
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Introduction 
 
Ventricular hypertrophy is a general adaptive mechanism of the heart to increased 
workload and is aimed at normalizing ventricular wall stress. Depending on the 
duration and the degree of the overload, either an adaptive or maladaptive 
hypertrophy phenotype will evolve over time. Numerous processes have been 
associated with hypertrophic ventricular remodelling, e.g., re-expression of the fetal-
gene programme1, 2, alterations in calcium handling3, altered energy metabolism 
substrate4, 5, extracellular matrix composition6 and signal transduction cascades7. 
Still, it remains uncertain which of these changes or combination of changes are 
critical for the development of either an adaptive of maladaptive hypertrophy 
phenotype. Moreover, the time point at which these crucial alterations are initiated 
during remodelling remains largely unknown. 
It is generally presumed that both the adaptive and maladaptive phenotypes evolve 
from a common hypertrophy precursor state and that maladaptive remodelling 
becomes evident after compensation mechanisms have failed to maintain normal 
pump function. However, this concept has recently been challenged by clinical8, 9 and 
epidemiological10, 11 studies, which suggest that ventricular hypertrophy is already 
maladaptive immediately after the imposition of pressure overload. 
 
The monocrotaline(MCT)-dose controlled model of either an adaptive or maladaptive 
ventricular hypertrophy phenotype due to graded pulmonary hypertension provides 
the unique opportunity to study the right-ventricular(RV) responses at early time 
points after the imposition of pressure overload12, 13. At 10 days after MCT injections, 
micro-array analyses revealed RV myocardial gene-expression profiles that were 
already specifically associated with either the adaptive or maladaptive phenotypical 
outcome, though no RV hypertrophy had yet developed. These observations also 
argue against a hypertrophy precursor state common for both the adaptive and 
maladaptive phenotypes13. However, it is unknown whether in parallel to the 
differences observed at the transcription level, differences in protein expression occur 
between adaptive and maladaptive remodelling at day 10. More specifically, changes 
at the transcription level do not necessarily lead to altered protein-expression levels, 
and, changes at the protein level may be observed in the absence of differential 
transcription regulation. 
 
In this study, using the MCT-dose controlled model, we compared the adaptive and 
maladaptive hypertrophy phenotypes at day 10 after the imposition of pressure 
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overload to test for significant differential protein-expression levels using 2-
dimensional gel electrophoresis (2DGE). The aim of this study was threefold:  
1) Is there evidence that supports the presence of differential protein expression at 
10 days after the imposition of pressure overload. 2) What is the identity of 
differentially expressed proteins and do these proteins provide clues to critical 
alterations that could mediate either adaptive or maladaptive remodelling. 3) How 
does differential protein expression relate to alterations at the transcription level of 
their corresponding genes.  
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Methods 
 
Animals 
Animals were treated according to the national guidelines and with the permission of 
the Institutional Animal Care and Use Committee (IACUC) of the VU University 
Medical Center Amsterdam, the Netherlands.  
Monocrotaline(MCT)-dose controlled induction of adaptive hypertrophy (HYP; 30 mg 
MCT/kg body weight (bw), n=4) and maladaptive hypertrophy (CHF; 80 mg MCT/kg 
bw, n=4) was performed as previously described12, 13. Animals were sacrificed 10 
days after subcutaneous MCT injections. Lungs were excised, hearts were rinsed by 
perfusion and the left ventricle (LV), right ventricle (RV) and interventricular septum 
(IVS) were separated. All tissues were snap frozen in liquid nitrogen and stored at -
80 ºC.  
 
Protein Sample Preparation For 2DGE 
The RV from three animals per group were used in the 2DGE experiments. All 
chemicals were electrophoresis-grade from Sigma unless stated otherwise. 
Approximately 15 mg RV tissue was homogenized in 400 µL lysis buffer (8 mol/L 
urea, 4% w/v CHAPS, 50 mmol/L DTT) using a glass-glass homogenizer, for a total of 
10 strokes per sample. The homogenate was left on ice for 45 min. and centrifuged 
for 15 min. at 14.000 g at 4 ºC. A total of 150 µg protein (Bradford method) from the 
supernatant fraction was prepared in 450 µL lysis buffer with 0.5% v/v IPG buffer 
pH3-10-non-linear (NL) (Amersham biosciences). A pool of equal amounts of protein 
of each of the nine samples was run in parallel to the nine individual samples and 
served as the preparative gel for MALDI-TOF protein identification. 
 
Isoelectric Focusing, SDS-Page, And MALDI-TOF Mass Spectrometry 
The protein pool for the preparative gel and the three individual samples per 
experimental condition were processed in parallel. Protein samples were applied to 
IPG gels (Immobiline DryStrip 24 cm, pH 3-10 non-linear (NL), Amersham 
biosciences). Gel rehydration and isoelectric focusing were performed over night 
(o/n) on an Ettan™ IPGphor™ II IEF System (Amersham biosciences) at 50 µA per 
strip (65 kVh: 30 V, 12 h; 500 V, 1 h; 100 V, 1 h and 8000 V, 8h [step-n-hold 
gradient type]) at 20 ºC, in strip holders covered with Immobiline DryStrip Cover 
Fluid. After focusing, the IPG strips were wrapped in plastic foil and stored at -80 °C. 
Second dimension SDS-PAGE separations was performed as described14 with minor 
modifications. Individual IPG strips were applied to simultaneously cast [1-1.5 mm] 
12% dyracryl gels (12% dyracryl, 0.365 mol/L Tris pH8.8, 0.1% SDS, 0.1% APS and 
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0.5 μl TEMED). The gels were run in 1x Tris-glycin-SDS buffer at 15 ºC for 24h at 12 
W followed by 4h at 15 W using the Isodalt System (Amersham Biosciences). 
After second dimension separation the nine sample gels were silver stained as 
described by Shevchenko et al.15, with minor modifications. Three parallel staining 
batches were performed, each containing one gel from each experimental condition. 
After staining the gels were stored in 0,2 % HAc/10% MeOH at 4°C. The preparative 
gel was fixed in 10% Methanol/7% acetic acid o/n and subsequently washed 3 times 
for 10 min. with distilled water. This gel was stained with Sypro-Ruby fluorescent 
staining solution for 3 h, directly followed by a Coomassie staining (34% Methanol, 
3% phosphoric acid, 15% w/v ammoniumsulphate, 0.1% Coomassie brilliant blue 
G250).  
Protein spots of interest were manually excised from the Sypro-Ruby/Coomassie 
stained gel. In-gel trypsin digestion, MALDI-TOF procedures and database searches 
were performed as described15, 16 with minor modifications. 
 
Quantification And Statistical Analysis Of 2DGE Gels 
The silver-stained 2D gels were scanned using a densitometer (Bio-Rad). Computer 
assisted matching and quantifications of corresponding protein spots across multiple 
gels was done using PDQuest image analysis software (v7.0; Bio-Rad). Only spots 
matched to all nine gels were selected for processing and statistical analysis. Spot 
intensities per gel were normalized to the total quantity of valid spots. Spots with 
average intensities outside the 5-95th percentile interval were excluded from further 
analysis. To test for significant differential expression, a modified analysis of variance 
(ANOVA) method was performed which uses an F-statistic to estimate the error 
variance by borrowing cross-gene information using the James-Stein shrinkage 
concept17, 18. Bonferroni corrected post-hoc tests (p<0.05) were performed for the 
three pair-wise comparisons. A minimal 1.5-fold change between groups was 
included. P-values were calculated using 1000 permutations on residuals.  
  
Quantitative Real-Time PCR 
Realtime-PCR experiments were performed as previously described12. Gene 
expression was normalized to HPRT levels. The gene-specific primer sequences used 
were (5’ to 3’): Echs1 (NM_078623, F: GCC-ACT-GAT-GAC-CGG-AGA-GA, R: GGT-
GGA-GAA-AGG-TAT-GGC-TGC); Fabp3 (NM_024162, F: TCG-TGA-CAC-TGG-ACG-
GAG-G, R: GCC-ATG-GGT-GAG-AGT-CAG-GAT); Hspb1 (NM_031970, F: AAT-ACA-
CGC-TCC-CTC-CAG-GTG, R: GAT-TGT-GTG-ACT-GCT-TTG-GGC); Prdx2 (NM_017169, 
F: CCC-TCT-GCT-TGC-TGA-TGT-GAC, R: GAG-GCC-CCT-GTA-AGC-GAT-G); Hprt 
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(M63983, F: ATG-GGA-GGC-CAT-CAC-ATT-GT, R: ATG-TAA-TCC-AGC-AGG-TCA-GCA-
A).  
 
Statistical Analysis Of PCR And Hypertrophy Parameters 
Significant differences were evaluated using a one-way ANOVA with the Bonferroni 
multiple testing correction. Differences with a p-value smaller than 0.05 were 
considered significant. 
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Results 
 
MCT-Induced RV Hypertrophy 
At 10 days after subcutaneous injection of either 30 or 80 mg MCT/kg bw, a 
significant increase in lung weight for both the HYP and CHF groups relative to CON 
was observed. This is indicative of increased pulmonary vascular resistance19, 20. In 
agreement with previous observations, this increase in pulmonary pressure did not 
yet result in RV hypertrophy at day 10, i.e., both RV weight and the RV to LV + IVS 
weight ratio did not show a significant increase13. Body weight of both MCT injected 
groups showed a small, yet significant difference relative to the CON group. These 
parameters are shown in Table 1. 
 
Between-Group Differences In Protein Expression  
The SDS-PAGE gels showed a high level of reproducibility. Representative images of 
corresponding sections from all nine individual gels are shown in Figure 1. A total of 
396 protein spots were matched across all gels. Spots with average intensities 
 
 CON (n=4) HYP (n=4) CHF (n=4) 
BW (g) 251 ± 5 230 ± 7 * 222 ± 3 * 
RV (mg) 162 ± 9 147 ± 7 144 ± 10 
RV to LV+S (mg / mg) 0.243 ± 0.006 0.234 ± 0.002 0.229 ± 0.007 
Lung (g) 1.13 ± 0.01 1.42 ± 0.02 * 1.49 ± 0.07 * 
 
▲Table 1: Measured parameters for the CON, HYP and CHF groups at 10 days after MCT 
injections. Data represent Mean ± SE and significant differences are indicated with * : p<0.05 
relative to CON. 
Name + symbol 
Protein 
accession 
Pred 
pI 
Pred 
mass 
Protein 
score CI(%) 
Nr of  
Fragments 
Fatty acid-binding protein-3, 
heart (Fabp3) 
P07483 5.92 16.4 99.70 1 
Peroxiredoxin 2 (Prdx2) P35704 5.34 21.7 99.43 3 
Enoyl-CoA hydratase, 
mitochondrial (Echs1) P14604 8.40 31.5 99.99 8 
Heat-shock protein beta-1 
(Hspb1) 
P42930 6.12 22.9 99.43 4 
 
▲Table 2: Name and protein accession number of the four identified proteins. Indicated are the 
predicted pI and mass, protein identity confidence interval (CI) and the number of protein 
fragments on which the identification was based. 
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0
1up
3dn
1up
0
6up
1dn
CON vs. HYP CON vs. CHF
HYP vs. CHF
4up
3dn
14up
2dn
outside the 5-95th percentile range were excluded from further analysis. The 
remaining 353 spots were tested for significant differential expression between the 
three replicate groups. When comparing CON to HYP, CON to CHF and HYP to CHF, 5, 
15 and 23 spots were differentially expressed, respectively. Some proteins were 
significantly regulated in more than one of the pair-wise comparisons. The total 
number of unique protein spots with significant differential expression was 35 (Figure 
2). 
 
►Figure 2: The number of significantly differentially-
expressed proteins for each pair-wise comparison as 
indicated by the ANOVA analysis. Also indicated are the 
number of upregulated (up) and downregulated (dn) 
proteins.  
▲Figure 1: SDS-PAGE images from corresponding segments from the gels. Crosses mark 
matched spots in all nine gels. Sections represent a mass range of ~20 to 25 kDa and isoelectric-
point range of ~5 to 7. 
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Identity Of Differentially Expressed Proteins 
Of the 35 differentially expressed protein spots, 20 were excised from the preparative 
gel to be identified using MALDI-TOF mass spectrometry. Four proteins were 
positively identified. Table 2 list the names, protein accession number, predicted 
mass and pI as well as the protein score for positive identification for these spots. 
The position of these four protein spots with corresponding mass and pI on the SDS-
PAGE gel is indicated in Figure 3. An example of the protein fragments from the 
trypsin digest that identified the Echs1 protein is shown in Figure 4.  
pH 3 pH 10 200 150 
100 
75 
50 
37 
25 
20 
15 
Hspb1 
22.9kDa – pI 6.12 
Echs1 
31.5kDa – pI 8.40 
Prdx2 
21.7kDa – pI 5.34 
Fabp3 
16.4kDa – pI 5.92 
▲Figure 3: Representative image of a silver-stained SDS-PAGE gel. Mass and pI markers are 
indicated at the right and top of the image, respectively. Significantly differentially regulated and 
identified protein spots are marked in the image.  
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Quantitative Real-Time PCR 
Realtime PCR was used to assess whether the altered protein expression observed for 
the four identified proteins were a result of changes at the transcription level of their 
corresponding genes. Only Echs1 mRNA-expression levels showed a similar 
downregulation in the CHF group relative to both HYP and CON as was found for the 
protein-expression levels. Expression levels for both the protein and their matching 
mRNA transcripts are shown in Figure 5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
◄Figure 5: Expression 
profiles of the identified 
significantly differentially 
expressed proteins from 
both 2DGE and real-time 
PCR experiments. Control 
expression levels were set to 
1. Data represent Mean ± 
SE and significant 
differences are indicated 
with * : p<0.05 rel to CON; 
†: p<0.05 rel to HYP. 
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▲Figure 4: Protein fragments from the Echs1-trypsin digest identified by MALDI-TOF mass 
spectrometry. Top: schematic representation of the Echs1 protein spanning 290 amino-acid 
residues from N- to C-terminus. Protein fragments 1 through 8 (horizontal bars) are aligned 
relative to their position on the Echs1 protein. Bottom: Protein fragments in ascending order of 
observed mass. Indicated are start and end amino-acid position on the Echs1 protein strand, 
fragment length and amino-acid sequence per fragment. 
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Discussion 
 
In the present study, global proteome profiling using 2-dimensional gel 
electrophoresis at the early stages during the development of either adaptive or 
maladaptive RV hypertrophy in a MCT-dose controlled rat model for pulmonary 
hypertension, yielded the following results: 
1) When comparing RV myocardial protein-expression levels at 10 days after the 
imposition of pressure overload, 5 proteins displayed significant differential 
expression between the CON and HYP groups, 15 proteins between the CON and CHF 
groups and 23 proteins between the HYP and CHF groups. 2) Evaluation of function 
of identified proteins with significant differential expression levels indicated 
alterations at the level of fatty acid metabolism, reactive oxygen species handling 
and apoptosis-related signalling to be present already early during myocardial 
remodelling. 3) Only for specific proteins could altered protein-expression levels be 
related to changes at the transcription level of their corresponding genes.  
 
Induction Of Adaptive Or Maladaptive Hypertrophy 
The model used in this study allows for the controlled induction of either an adaptive 
or maladaptive hypertrophic RV phenotype by a subcutaneous injection of either 30 
or 80 mg MCT/kg body weight, respectively12, 13. Early stages during the development 
of either an adaptive or maladaptive phenotype can therefore be reliably 
characterized during the period just after the imposition of pressure overload and 
before functional or morphological differences between groups become apparent. 
In previous studies using this model, significant differences in mRNA-expression 
levels between RV myocardial tissue from HYP and CHF animals were determined by 
micro-array expression profiling at 10, 14, 19 and 25 days after MCT injections12, 13. 
When considering day 10 after the imposition of pressure overload, of the total of 55 
genes with significant differential expression levels, 13 displayed a significance call in 
the HYP vs. CHF comparison (23.6%). The present study suggests that these 
differences are more distinct at the proteome level, i.e., 23 of 35 protein spots 
(67%). This indicates that the divergence of adaptive and maladaptive remodelling at 
the early stages after the imposition of pressure overload results in more pronounced 
responses at the proteome level than can be observed at the mRNA-transcript level. 
This is substantiated by the observation that alterations at the protein level could 
only be related to changes at the transcription level for the Echs1 protein.  
However, it cannot be excluded that the differences in observations between both 
studies may partially be explained by differences in the statistical procedures used to 
determine significant differential expression. In addition, the micro-arrays assayed a 
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defined set of 4803 genes, while in the 2DGE experiments an unknown number of 
cytosolic proteins were assayed.  
 
Alterations In Fatty Acid Transport And Mitochondrial Beta-Oxidation 
Of the identified proteins which show significant differential expression, Fabp3 and 
Echs1 could be related to alterations in energy metabolism substrate. Under 
physiological conditions, mitochondrial fatty-acid (FA) β-oxidation generates 
approximately 70% of the total ATP production in the heart. However, severe 
downregulation of FA oxidation, accompanied by increased glycolysis and glucose 
oxidation are observed at the advanced stages of ventricular hypertrophy due to 
pressure overload4, 5. Long chain-FA (LCFA) are broken down in four steps during β-
oxidation, generating reduced flavin adenine dinucleotide (FADH2), reduced 
nicotinamide adenine dinucleotide (NADH) and acetyl-CoA. The second step of this 
cycle is provided by Echs1, which catalyzes the hydration of 2-trans-enoyl-coenzyme-
A (CoA) intermediates to L-3-hydroxyacyl-CoAs.  
Significantly reduced Echs1 mRNA and protein levels in the maladaptive hypertrophy 
group at day 10 after the imposition of pressure overload indicate that the switch 
towards glucose as the predominant metabolic substrate may already have been 
initiated. The adaptive hypertrophy group did not show these changes at day 10, 
indicating that the shift towards glucose metabolism is indeed associated with 
maladaptive hypertrophic remodelling. Micro-array Echs1-expression profiles from 
previous experiments are in agreement with these findings13. Mitochondrial beta-
oxidation shutdown may lead to intracellular lipid accumulation21. Lipid accumulation 
has been shown to occur in human non-ischemic heart failure22 and has been 
associated with lipotoxicity leading to apoptosis in multiple cell types, including 
cardiac myocytes23, 24 and with cardiac contractile dysfunction in Zucker diabetic fatty 
rats22 and obese (ob/ob) mice25. 
In response to increased intracellular lipids, levels of fatty-acid binding proteins 
(Fabps) are increased23. In line with this, our data show significantly higher 
expression levels of the heart-specific Fabp (Fabp3) form in the maladaptive relative 
to the adaptive-hypertrophy group. Fabps are a group of ~15kDa cytoplasmic 
proteins which are highly expressed in tissues dependent on FA metabolism. Fabps 
are involved in gene-expression regulation via peroxisome proliferator activated 
receptor alpha (PPARα), protection against detergent-like properties of local high 
long-chain FA (LCFA) concentrations and intracellular transport of hydrophobic 
compounds, such as LCFA26.  
The increase in Fabp3 may affect cardiac-myocyte function on multiple levels. It 
could serve as a protective mechanism in response to the toxic effects of increased 
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cellular lipid accumulation. Also, LCFA-Fabp3 complexes may participate with PPARα 
in upregulation of FA metabolism-related genes in order to increase FA metabolism 
and counteract intracellular lipid accumulation4, 21. Indeed, the upstream promotor 
sequence of the Echs1 gene contains functional PPARα response elements27, 28 and 
Echs1 expression in the CHF group at day 19 appeared to be normalized, i.e., no 
longer significantly different from CON and HYP levels13.  
 
Alterations In Peroxide Handling 
Peroxiredoxins (Prdxs) are involved in cellular proliferation, protection against 
oxidative stress through degradation of H2O2, organic hydroperoxides and 
peroxynitrite, as well as modulation of intracellular signalling routes that use H2O2 as 
the 2nd messenger. Prdxs contain conserved redox-active cysteine residues in their 
catalytic center which are involved in the enzymatic peroxidase activity. Peroxide 
substrates oxidize these cysteine-residues to sulfenic acids, leading to a reversible 
inactivation of the peroxidase activity29. Although Prdxs have relatively low catalytic 
efficiencies (~105 M−1 s−1)30 compared to glutathione peroxidases (~108 M−1 s−1)30 
and catalases (~106 M−1 s−1)31, Prdxs contribute significantly to intracellular-peroxide 
clearance due to their abundant expression levels. The detected increase in Prdx2-
protein levels in both the adaptive and maladaptive phenotypes indicates Prdx2 to be 
involved in general hypertrophic remodelling. These increased Prdx2 levels could 
provide additional tolerance to peroxide stress.  
We recently observed early activation of the cdc2-cyclinB complex during 
maladaptive- but not adaptive-hypertrophic remodelling13. Activation of the cdc2-
cyclinB complex causes untimely progression through the G2/M transition of the cell 
cycle. Chang et al. showed that the active cdc2-cyclinB complex is able to 
phosphorylate Prdx2 and subsequently deactivate this Prdx2 in vitro32. Loss of Prdx2-
peroxidase activity would lead to intracellular H2O2 accumulation which is needed for 
progression through the cell cycle32. It is tempting to speculate that via this 
mechanism, H2O2 levels will be higher in CHF relative to HYP. Mitogen-activated 
protein kinases have been shown to be activated by H2O2 in a dose dependent 
manner, in which Erk1/2 appeared to be activated at lower doses than Jnk and 
p3833,34. Early stages of adaptive remodelling would then be associated with pro-
hypertrophic Erk1/2 activation while during maladaptive remodelling, pro-apoptotic 
Jnk and p38 signalling would be present in addition to Erk. Previous observations at 
14 days after MCT injections, indeed found increased p38-phosphorylation levels to 
be associated with maladaptive remodelling12. 
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Heat Shock Protein Survival Signalling 
In this study we observed a significantly higher expression of the Hspb1/Hsp27 
protein in the HYP group relative to the CHF group, with no significant differences 
relative to CON levels. Hsp27 expression has been associated with increased survival 
after cytotoxic stimuli. Different mechanisms have been proposed to mediate the 
survival properties of Hsp27 overexpression, many of which interfere with pro-
apoptotic signalling35.  
The lower Hsp27-expression levels observed in the maladaptive hypertrophy group, 
relative to the adaptive hypertrophy group, could indicate a more apoptosis-prone 
myocardium at the early stages during maladaptive remodelling. This is in line with 
previous observation using this model12, 36. 
 
Conclusion 
In this study using the MCT-dose controlled induction of either an adaptive or 
maladaptive hypertrophic phenotype, significant differences in protein expression 
were observed between the HYP and CHF groups at 10 days after the induction of 
pressure overload. This, in conjunction with our previous observations of mRNA-
expression differences between HYP and CHF at 10 days after the imposition of 
pressure overload, further argues against the existence of a common adaptive 
precursor state during the development of either an adaptive or maladaptive 
hypertrophy phenotype. Moreover, our data indicate that early during the 
development of either an adaptive or maladaptive hypertrophic response, differences 
in pro-survival signalling as well as in fatty acid metabolism may already be present. 
Differences in the rise of pressure overload over time between the HYP and CHF 
groups are likely to be responsible for the observed differences between these two 
groups through differential activation of signal transduction pathways that mediate 
the protein and mRNA expression levels. 
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Adaptive vs. Maladaptive Myocardial Hypertrophy 
 
This thesis is focused on gene-expression alteration during the development of right-
ventricular hypertrophy in a rat model for pulmonary hypertension. The aim of this 
research was to determine putative hypertrophic signalling events that drive general 
hypertrophy and to distinguish between processes at the transcriptome level that are 
specifically associated with the development of either an adaptive or maladaptive 
hypertrophic phenotype, due to pressure overload. The adaptations of the heart, 
e.g., alterations in signal transduction cascades, energy metabolism and calcium 
handling, are a result of changes in the expression level of specific genes. A better 
understanding of the gene-expression alterations during the development of 
ventricular hypertrophy may therefore allow for the identification of key processes 
involved in myocardial remodelling.  
Cardiac hypertrophy has long been thought to represent an adaptive or beneficial 
response mechanism of the heart to increased workload, in which elevated wall 
stress is normalized by thickening of the ventricular wall1 and adequate blood flow is 
maintained. However, depending on the degree and level of the overload, the 
adaptive response may progress to a state of impaired contractile capability, leading 
to heart failure. In the MCT-dose-controlled model of graded pulmonary hypertension 
and defined phenotypical outcome described in this thesis, the term maladaptive 
hypertrophy does not exclude the existence of a compensatory phase during 
ventricular remodelling. In fact, for both MCT doses, the RV response is first thought 
to proceed through an initial phase of RV hypertrophy, i.e., days 14-19. At the end of 
this phase, the balance between beneficial and detrimental signals shifts towards 
maladaptive remodelling, causing the adaptive or maladaptive characters of the 
response to become discernable. This implies that prior to the shift in balance from 
beneficial towards detrimental signalling, the hypertrophy observed in both these 
phenotypes is likely to be identical. However, this paradigm of ventricular 
hypertrophy does not take into account the possibility that adaptive and maladaptive 
myocardial remodelling may already have diverged at an early stage during the 
overload. 
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1: Myocardial Hypertrophy 
 
The observed decreases in plasma T3 and body weight between days 19 and 25, are 
indicative of the development of the maladaptive phenotype. However, these two 
parameters do not provide any direct information regarding the contractile function 
of the RV of the heart. Therefore, it is essential for the unambiguous interpretation of 
the data presented in this thesis to have a clear set of definitions of what 
characterizes the adaptive and maladaptive hypertrophic phenotypes.  
 
Defining Hypertrophy Phenotypes 
Dorn II et al. devised a simple scheme with criteria to differentiate between these 
two phenotypes (Figure 1)2. First of all, hypertrophy at the individual cardiac 
myocyte level has to be evident, i.e., increased cell size, and not just an increase of 
the heart or ventricle itself. In the MCT model, RV myocyte cross-sectional area 
(CSA) for the HYP and CHF groups at day 19 after MCT injections showed a similar 
increase in size for both MCT-injected groups relative to control levels (CON vs. HYP 
vs. CHF; 258 ± 54 vs. 462 ± 5* vs. 473 ± 26* μm2). Interestingly, myocyte CSA at 
day 25 for the three groups showed comparable levels to those observed at day 19 
(232 ± 19 vs. 467 ± 50* vs. 476 ± 51* μm2) (unpublished observations; Figure 2). 
This indicates that the parallel addition of sarcomeres, i.e., concentric remodelling, 
had already reached a maximum level at day 19. The additional increase in RV 
weight observed between day 19 and 25 may be explained both by excessive 
extracellular matrix deposition and/or increased myocyte length through the addition 
of sarcomeres in series to existing ones, i.e., eccentric remodelling.  
As a second differentiating criterion between either an adaptive or maladaptive 
hypertrophy phenotype, a measure of cardiac myocyte contractility should be 
provided. SERCA2a is an important contributor to cardiac myocyte contractility since 
SERCA2a activity is a determinant of the frequency-dependent increase in Ca2+-
transient amplitude which governs the positive FFR in rat trabeculae3. SERCA2a-
mRNA expression was shown to be significantly downregulated at day 25 in the CHF 
group relative to both CON and HYP animals. In line with these observations, positive 
force-frequency relationships were observed for both the CON and HYP animals at 
day 25, whereas CHF animals did not show this potentiation.  
The increases in cardiac myocyte CSA in both hypertrophy groups and the differences 
in FFR responses between the two groups, indicate the adaptive and maladaptive 
nature of the HYP and CHF hypertrophy phenotypes, respectively. However, more 
data may be added to further characterize the adaptive and maladaptive hypertrophy 
phenotypes in the MCT-dose-controlled hypertrophy model. In addition to cardiac 
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myocyte CSA, myocyte volume determinations could better characterize the eccentric 
remodelling response between day 19 and 25. Also, the increases in RV mass for 
both the HYP and CHF groups could partially be related to immune-related cell types, 
i.e., macrophage4 and mast cells5, which have been shown to infiltrate hypertrophic 
myocardium during conditions of pressure overload. Additional parameters that could 
be used to determine the functional characteristics underlying the adaptive or 
maladaptive phenotypes include calcium sensitivity, end-diastolic and systolic 
pressures, fractional shortening, ejection fraction and wall stress, as a classical 
parameter. In fact, a recent publication by Hessel et al. characterized the RV 
hemodynamics in the MCT-dose controlled RV hypertrophy model6. At four weeks 
after MCT injections, RV end-systolic pressure (PES) and relaxation time constant 
(tau) were maintained in the adaptive hypertrophy group. However, in the 
maladaptive group, these parameters were significantly altered relative to both 
controls and MCT30 animals, i.e., increased PES and decreased tau. The RV ejection 
fraction was significantly reduced in the MCT30 group (rel. to CON), as well as in the 
MCT80 group (rel. to CON and HYP). Moreover, this paper also suggests that the 
eccentric remodelling observed in the MCT model may, in part, be due to myocyte 
slippage6. 
 
Natriuretic Peptive Levels 
Plasma brain natriuretic peptide levels have recently been proposed as a diagnostic 
and prognostic marker in heart failure7, 8. Surprisingly, plasma BNP-32 levels did not 
allow differentiation between the adaptive and maladaptive hypertrophy phenotypes. 
BNP mRNA expression on the arrays showed a similar profile. Nevertheless, plasma 
BNP levels at day 25 showed a significant correlation with RV to LV+IVS ratio 
◄Figure 1 - Simple 
criteria for classifying 
cardiac hypertrophy 
phenotypes. See 
accompanying text. Adapted 
from Dorn II2 et al. 
 
Is the heart enlarged?
Cardiomegaly Normal heart size
Are the cardiomyocytes enlarged? Are the cardiomyocytes enlarged?
Hyperplasia or infiltration Hypertrophy Eutrophy
Is cardiomyocyte contractility normal?
Adaptive Maladaptive
What is the proteome, transcriptome, metabolome profile?
yes no
yesno no
yes no
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(p=0.0028, R2=0.69) and lung weight (p=0.0012, R2=0.75) (Figure 2). These data 
suggest that elevations of plasma BNP levels are a late event during RV hypertrophy 
development and not to be a reliable predictor of outcome in this model. Similar 
findings have been reported when BNP mRNA transcript levels of hearts from 
hypertensive homozygous renin-overexpressing (Ren-2) rats that progressed to early 
HF were compared with those of Ren-2 rats that remained compensated9. 
 
Left Ventricular Alterations Due To RV Hypertrophy 
Evidence is emerging that RV hypertrophy in the MCT model also affects the LV of 
these hearts. A likely mechanism for these alterations is through increased plasma 
noradrenalin levels, leading to reduced total β-adrenergic receptor density in both the 
LV and RV through downregulation of the β1 receptor isoform10. As a result of 
diminished β1-adrenergic receptor densities, ventricular protein and mRNA 
expression may be altered. Proteome analysis comparing both RV and LV to their 
corresponding time-matched control ventricles at 20-24 days after injection of 50 mg 
MCT/kg bw, indicated protein expression changes unique to either ventricle, i.e., no 
overlap was observed between proteins that were significantly regulated in the RV 
and LV11. 
However, the time point at which these additional alterations emerge, as well as to 
how these factors contribute to the overall phenotype are poorly understood. 
Therefore, physiological as well as molecular parameters should be determined not 
only in RV, but also in LV and IVS. Nonetheless, it is without question that the 
primary trigger for these additional events is the hypertrophic response of the RV to 
pressure overload. 
RVtoLV+S ~ BNP correlation
0.0 0.1 0.2 0.3 0.4 0.5
0
100
200
300
0.0028P=
R2= 0.6921
RV to LV+S
pl
as
m
a 
B
N
P
Lung weight ~ BNP correlation
1.00 1.25 1.50 1.75 2.00 2.25 2.50
0
100
200
300
0.0012P=
CON
HYP
CHF
R2= 0.7507
Lung
pl
as
m
a 
B
N
P
▲Figure 2: Cardiac 
myocyte cross sectional 
area and BNP 
correlations. Data 
represent Mean ± SE. 
significant differences are 
indicated with * : p<0.05 
rel to CON; †: p<0.05 rel to 
HYP. 
Myocyte CSA (µm2)
19d 25d
0
200
400
600
****
plasma BNP (pg/ml)
19d 25d
0
100
200
300 **
RV BNP mRNA
d19 d25
0
1
2
3 ** CON
HYP
CHF
Ex
pr
es
si
on
 (A
U
)
M
yo
cy
te
 C
S
A
 (µ
m
2 )
 
Ex
pr
es
si
on
 (A
U
) 
Pl
as
m
a 
BN
P
 (p
g/
m
L)
 
General Discussion 
 119 
Alternative Models For Adaptive vs. Maladaptive Remodelling 
In the literature, several studies have been described that used animal models to 
study adaptive and maladaptive myocardial hypertrophy. Most of these studies 
focussed on end-stage phenotypes to investigate molecular processes associated with 
the development of either adaptive or maladaptive hypertrophy, making it difficult to 
discern between primary and secondary hypertrophic responses to pressure overload. 
The primary molecular hypertrophic responses that drive either adaptive or 
maladaptive remodelling can only be visualized at time points prior to the divergence 
of these two phenotypes. However, the time point at which this divergence of the two 
phenotypes actually occurs, is not known, and is likely to differ between models and 
different species. Visualizing the primary events leading to either of the hypertrophic 
phenotypes can only be achieved in animal models for which phenotypical outcome is 
known in advance, e.g., exercise induced hypertrophy12-14 and the MCT-dose 
controlled model15, or, when a reliable assessment of phenotypical outcome can be 
obtained at early time points during ventricular remodelling, without affecting the 
normal remodelling processes, e.g., through plasma profiling or procuring biopsies.  
The hypertensive homozygous renin transgenic TGR (mRen-2) (Ren-2) rats16 have 
recently been used to study early events during myocardial remodelling9, 17. All Ren-2 
rats develop cardiac hypertrophy, although only a subset of these animals rapidly 
progress towards a maladaptive phenotype (12-14 weeks of age), while the 
remaining rats develop an adaptive hypertrophy state (sacrificed at 17 weeks of 
age). Micro-array analyses performed on LV tissue from both the adaptive and 
maladaptive rats indicated 48 genes with higher expression and 14 genes with lower 
expression in the Ren-2 rats that developed heart failure compared to those that 
developed compensated hypertrophy. In a parallel series of experiments, LV 
myocardial biopsy material was obtained from these Ren2 rats at a time point prior 
to phenotypical divergence, i.e., 10 weeks of age. End-point phenotype of the 
individual rats was determined by longitudinal follow-up observations up to 17 weeks 
of age. Analysis performed on the 10 week biopsy samples using qPCR indicated that 
from the set of regulated genes both thrombospondin-29 and Galectin-317 were 
already upregulated in the rats that would later progress to heart failure, while for 
those that remained in a compensated hypertrophy state, the expression of these 
two genes was comparable to that in time-matched Sprague-Dawley control rats.  
Similar to the emergence of two groups for the Ren-2 rats in 17 weeks, a single dose 
of 40 mg MCT / kg body weight leads to subsets of animal phenotypes, either with or 
without characteristic signs of heart failure within 4 weeks after MCT injections18. 
However, an analogous approach to the one described above is not feasible for this 
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model due to the thin RV wall which does not allow for the procurement of tissue 
biopsy samples. 
Another frequently used approach to investigate differences in gene-expression 
between adaptive and maladaptive ventricular remodelling is to compare exercise-
induced left-ventricular hypertrophy with maladaptive remodelling. Strøm et al. first 
evaluated gene-expression differences between LV myocardium of male Wistar rats 
after 7.5 weeks of intermittent treadmill exercise with age matched sedentary rats13. 
Next, they focussed, using qPCR, on metabolism related genes, and confirmed the 
differential expression of both upregulated genes, i.e., fatty acid translocase 
(FAT/CD36), fatty acid binding protein 4 (FABP4), fatty acid transport protein 
(Slc27a1) and glucokinase regulatory protein (GCKR), as well as downregulated 
genes, i.e., uncoupling protein 2 (UCP2) in the exercise group. An additional set of 
qPCR experiments focussed on UCP2 and CD36 expression in the non-infarcted 
ventricular regions of the LV three weeks after myocardial infarction (MI). This 
revealed that CD36 was only upregulated in the exercise hypertrophy group, i.e., the 
MI animals did not show a significant difference in expression relative to control 
animals. UCP2 expression was downregulated in adaptive exercise-induced 
hypertrophy, while expression of this gene was upregulated after MI relative to 
control animals. In general, downregulation of fatty acid metabolism-related genes is 
observed during hypertrophic remodelling19, 20. Interestingly, upregulation of such 
genes was observed in the exercise-induced hypertrophy group. From these studies 
the authors concluded that the exercise-induced adaptive hypertrophy group showed 
signs of a successful switch in metabolism13. However, this study did not provide a 
large scale comprehensive gene-expression comparison between adaptive and 
maladaptive hypertrophy responses, as was presented in a study by Kong et al12. 
Exercise-induced cardiac hypertrophy was compared to hypertrophy and heart failure 
in Dahl salt-sensitive rats12. A similar degree of hypertrophy was achieved in both 
groups when compared to time-matched control animals. However, several distinct 
clusters of genes could be discerned, i.e., genes with expression alterations that were 
specific for either the adaptive or maladaptive group and genes that showed similar 
gene-expression changes in both hypertrophy groups relative to controls. These 
results are comparable to those described in Chapter 2 of this thesis, i.e., clusters V, 
IV and III, respectively. However, the identity of the genes within these clusters 
varied substantially between these studies. The authors concluded from these model-
specific gene-expression responses that activation of different signalling cascades is 
associated with either model, e.g., inflammation, oxidative stress, apoptosis and 
acute stress responses. 
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A more drastic view of model-specific responses was presented by Aronow et al.. 
They initially hypothesized that the hypertrophic response of the myocardium which 
is observed in human cardiomyopathies and in a wide variety of animal models, is 
the result of a conserved hypertrophic gene-expression program21. When they 
compared LV myocardium obtained from three transgenic mouse models for cardiac 
hypertrophy to their non-transgenic control animals, the number of differentially 
expressed genes did appear to be correlated with the observed phenotypic severity. 
However, when the gene-expression alterations of the three transgenic mouse 
models were compared, no common conserved transcription program could be 
observed for these models. Rather, unique transcriptional responses to each 
individual genetic cause of hypertrophy were found21. 
 
The studies described above provide valuable information on processes that discern 
between adaptive and maladaptive ventricular hypertrophy. However, the 
remodelling response observed for the MI model is a complex mixture of pressure 
and volume overload, making extrapolation to isolated pressure overloaded 
concentric hypertrophy difficult.  
Also, one must keep in mind that during exercise-induced cardiac hypertrophy, 
neither an increase in resting left ventricular systolic pressure14 nor in mean arterial 
pressure13 is observed. Moreover, exercise training has an on/off nature. In contrast 
to a chronic pathological stimulus, the profile of intermittent stimuli in time may allow 
the ventricle to adapt successfully.  
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2: Time Dependent Remodelling Processes 
 
The myocardial gene-expression alterations in the RV during the development of 
pressure overload, were determined in two separate micro-array experiment series, 
i.e., day 14 (Chapter 2; set 1) and days 10, 19 and 25 (Chapter 3; set 2). To obtain 
a complete picture of the time-dependency of gene-expression alterations, these two 
datasets may be combined. This may appear to be straightforward, however there 
are some fundamental differences between these two data sets that need to be taken 
into account.  
 
Differences Between Expression Array Data sets 
When comparing the experimental setup of both array series, several common as 
well as different features become apparent. An identical oligonucleotide-library set 
representing 4803 features was spotted in duplicate on different areas of the arrays, 
albeit with an overall different spatial distribution due to the different array printing 
techniques used. Also, both experiment series used the common reference design 
setup, but different RNA pools were used for each of these series to hybridize the 
CON, HYP and CHF samples. In addition, the amount of total RNA used per channel 
was reduced from 100 to 30 µg in the second set, yet the generation of labelled 
cDNA strands was identical. Also, the hybridization techniques differed from the 
custom setup, including a pre-hybridization for set 1, whereas for experiment set 2, 
automated hybridization, without pre-hybridization, was used. These methodological 
differences between micro-array experiment series, as well as different data pre-
selection criteria, lead to different sets of genes to be analysed after pre-processing 
the raw data, i.e., 3060 and 3148 genes analysed in Chapters 2 and 3, respectively. 
In total, 3335 unique features were analysed, of which 2823 were overlapping 
between datasets (Table 1).  
 
Statistical (re)Considerations 
A more important difference between the array series is that the statistics used to 
test for significant differential gene expression between experimental groups was 
different between the two array experiment series. The relatively simple Z-test used 
for statistical inference for array set 1 could not be used for the second, more 
complex data set. The structure of the second set, i.e., containing the experimental 
factors time and MCT, as well as the interaction between these two factors, called for 
a more suitable statistical framework which would be able to cover the structure of 
this dataset.  
General Discussion 
 123 
Linear models22, e.g., Maanova23, 24 and Limma25, can be used for the analysis of two-
colour micro-array expression data and allow for the incorporation and analysis of 
multiple experimental factors at once in one dataset. Re-analyzing the day 14 
dataset using a similar approach to the one described in Chapter 3 is possible, as is 
integration of the day 14 dataset into the day 10-19-25 dataset and analysing all four 
time points in a multifactorial design. In retrospect however, a mixed-model Anova 
using the fixed factors MCT (CON, HYP, CHF), Time (d10, d14, d19, d25), the 
interaction between the Time and MCT factor, and the random factors Array (45 in 
total), Spot (two duplicates per array) and the hybridization sessions (d14 vs 
d10+d19+d25), would be able to efficiently cover all expression data. However, a 
thorough re-analysis of the entire dataset containing all four time points, including 
GSEA and/or EASE over-representation analyses on individual Self-organizing-Map 
clusters, falls outside the scope of this discussion. However, at some points in the 
discussion, a few relatively simple data manipulations will be presented, although the 
remainder will focus on processes as discussed in Chapters 2, 3 and 4. 
 
Increase In Pulmonary Arterial Pressure In Time 
MCT leads to dose-dependent damage and remodelling of the pulmonary arterioles. A 
higher MCT dose does not only lead to more extensive vascular damage and 
remodelling, but is also likely to give rise to an accelerated increase in pulmonary 
arterial pressure (PAP) compared to lower doses, as is depicted in the left panel of 
 Chapter 2 (set1) Chapter 3 (set2) 
Days after MCT injection 14 10, 19, 25 
Arrays 6 per group 3 per group per time point 
Reference pool 
Equal amounts of RNA from all 
three groups from RV and LV 
IVS from all three groups at 
days 19 and 25 
totalRNA per sample 100µg 30µg 
Hybridization 
Custom setup 
With pre-hybridization 
Perkin Elmer HybArray 12™ 
No pre-hybridization 
Gene selection 
Max three flagged datapoints of 
six arrays per group per gene 
No flagged datapoints allowed in 
entire dataset 
Genes analysed 3060 3148 
Statistical test Z-score R/Maanova 
 
▲Table 1 - Methodological differences between micro-array experiments. 
See accompanying text. 
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Figure 3. The rise in PAP is related to the increase in lung weight26, 27 (Figure 3 – right 
panel). Possibly, this delayed and dampened, increase in pressure-overload in the 
MCT30 group allows the ventricle to adapt gradually, in contrast to the MCT80 group, 
where pressure increases shortly and sharply after MCT administration, which may 
tip the delicate balance between detrimental and beneficial processes already early 
during remodelling.  
The expression patterns of the cell-cycle related genes cyclin B1, cell division cycle 
control protein 2 (Cdc2a), cell division cycle control protein 20 (cdc20/p55cdc), as 
well as aurora kinase-B (AurkB), fit the above described profile, i.e., an earlier 
upregulation in the CHF than in HYP. This response may represent a futile response 
of the myocardium to increase the number of cardiac myocytes, i.e., adult cardiac 
myocytes are unable to proceed through the cell cycle, and in fact, may be 
detrimental, ultimately leading to decompensation. However, it may just as well be 
that these changes represent cell division responses originating from other 
ventricular cell types, e.g., endothelial cells, vascular smooth muscle cells or cardiac 
fibroblasts. The heterogeneous cell population of the heart makes unambiguous 
interpretation of the mRNA-expression data difficult. To cope with this problem, 
Wang et al. recently proposed a method that allows for computational deconvolution 
of the mixed cell-type tissue expression profiles, by incorporating expression profiles 
of the individual cell types present in that mixed tissue28. Alternatively, 
immunofluorescence may be used to detect changes in protein levels, or, in situ 
hybridizations may be used to measure mRNA levels to determine the cellular origin 
of the observed changes. 
Correlation to lung weight may identify unknown pressure-overload-responsive genes 
although actual pressure measurements would be preferable. In parallel, significant 
correlation with the RV to LV+IVS weight ratio, or RV weights alone, would implicate 
hypertrophy-associated gene-expression processes. Table 2, summarizes the number 
of significant positively and negatively correlated genes for several parameters. 
Interestingly, though only a few genes were correlated to body-weight alterations in 
the experiment series and none to liver weight, in total 138 genes displayed 
significant correlations to lung weight. This indicates an obvious link between lung 
weight changes and RV hypertrophy. The largest number of genes was found to be 
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significantly correlated to the RV weight. An EASE30 gene-ontology over-
representation analysis indicated cell adhesion and extracellular space to be 
represented in the top ranking processes for the positively correlated genes, while 
fatty acid metabolism and mitochondrion were top ranking in the negatively 
correlated genes (data not shown). In Chapter 3 - Figure 4, these same gene 
categories were shown to be present in clusters displaying either predominantly up- 
or downregulated genes. Also, in a model of transverse aortic constriction, these 
same classifications emerged when correlating gene-expression alterations to LV 
parameters31, indicating that LV and RV myocardial remodelling show a substantial 
number of parallel cellular responses to pressure overload. 
 
Dynamic Processes Associated With Maladaptive Remodelling 
Highly dynamic gene-expression alterations were observed during the development 
of both adaptive and maladaptive ventricular hypertrophy, with simultaneous 
alterations of many related and unrelated processes over time. These highly variable 
expression profiles illustrate the importance of proper timing when comparing mRNA 
and protein-expression levels between different experimental models, or even within 
one model.  
At different time points during ventricular remodelling, changes at the metabolism 
substrate level could be inferred. The switch from fatty acids towards glucose as the 
predominant substrate for energy metabolism in the established hypertrophied heart 
is a well known fact19, 20. Chapter 2 provided the first evidence of altered 
mitochondrial biogenesis between the HYP and CHF groups at day 14 during 
myocardial remodelling in the form of CHF-specific downregulation of the 
mitochondrial transcription factor A (mtTFA). Chapter 3 showed a more extensive 
picture of altered substrate metabolism, predominantly at days 19 and 25 after MCT 
 Liver Body weight Lung RV RV / LV+S 
POS 0 10 63 134 130 
NEG 0 4 75 205 187 
total 0 14 138 339 317 
 
▲Table 2 - Significant correlation with physical parameters. Significant positive or 
negative correlation between the expression data derived from the array and physical 
parameters was determined with a Pearson correlation test. Genes having a Benjamini-Hochberg 
false discovery rate(FDR)29 corrected p-value below 0.01, i.e., a maximum of 1% FDR genes in 
the list or significantly regulated genes, and with a Pearson correlation coefficient greater than 
0.7 or below -0.7, were considered to be significantly correlated.  
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injections, though with little differences between the two hypertrophy groups. The 
late events in the shift in metabolism were paralleled by a decrease in the expression 
of the transcription cofactor peroxisome proliferative activated receptor-α (PPARα) 
coactivator-1a (PGC-1a) (Chapter 3, online results supplement), with an overall 
decrease in expression of genes with corresponding mitochondrial proteins, as 
described in the previous paragraph and Chapter 3.  
Unexpected was the observed CHF-specific downregulation of mitochondrial enoyl-
CoA hydratase (Echs1) at both the mRNA and protein levels already at day 10 after 
MCT injections in Chapter 4, as determined by qPCR and 2-dimensional gel 
electrophoresis, respectively. However, the micro-array data indicated that this 
downregulation was abolished at day 19, while it was again downregulated at day 25, 
both in the HYP and CHF groups relative to control levels. Moreover, a gene set 
enrichment analysis (GSEA) that specifically focussed on the differences between the 
HYP and CHF groups, indicated elevated gene-expression levels in CHF compared to 
HYP at day 10 for genes implicated in the mitochondrial electron transport chain 
(mETC). However, at day 25 these elevated expression levels in CHF had decreased 
to a level below that of the HYP group, suggesting reduced mETC activity in the CHF 
group at day 25. This argues for a possible biphasic regulation for at least a part of 
the metabolism-related genes during ventricular remodelling.  
The GSEA analysis mentioned in the previous paragraph also indicated cell-cycle 
regulation to be associated with phenotypical outcome. The delayed increase in 
cyclinB1 and Cdk1 levels in HYP relative CHF, as well as increased Gadd45a 
expression levels in the HYP group at later time points, could prevent potentially 
detrimental G2/M checkpoint transition in adaptive remodelling. The gene-expression 
data obtained at day 14 after MCT injections, pointed to detrimental p38-MAPK 
related processes triggering apoptosis, and subsequent maladaptive remodelling. 
However, at the other time points examined, p38-related processes and apoptosis 
related gene-expression alterations could not be detected.  
Overall, these observations attest to phases, or, successive waves of detrimental 
processes over time that ultimately culminate into maladaptive remodelling. 
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3: Clinical Implications 
 
Patients with PAH display right atrial (RA) and RV enlargement, reduced RV function, 
displacement of the interventricular septum and tricuspid regurgitation. A 
subpopulation of patients who have been diagnosed with having pulmonary arterial 
hypertension (PAH), may die within months after diagnosis, while others survive for 
decades, reflecting the CHF and HYP groups as characterized using the MCT model in 
this thesis. A hemodynamic predictor of survival for patients with idiopathic PAH 
(IPAH), is mean PAP. The detection of pericardial effusion by echocardiography has 
negative prognostic implications, as does indexed RA area. Also a reduced 
performance in the 6 minute walking test (6MWT) for PAH patients has been 
observed. A detailed overview of clinical parameters for prognosis determination was 
recently described by McLaughlin et al.32. However, the sum of clinical parameters is 
insufficiently able to reliably determine prognosis, pressing the need for additional 
parameters. 
Halting, or even reversing progression of detrimental myocardial remodelling, is 
essential for proper patient care. The data presented within this thesis may provide 
information for the further research and development of new biomarkers that allow 
for accurate patient prognosis. Though many of the genes that were assayed display 
similar regulation for both the HYP and CHF groups relative to the control animals 
and display highly variable expression patterns in time, a small set of genes did show 
commitment differential expression between the adaptive and maladaptive 
hypertrophy groups. 
From this subset of genes it may be possible to device a method that allows for 
prediction of phenotypical outcome, at least for MCT rats. A combination of gene-
expression profiles for growth arrest and DNA-damage-inducible alpha (Gadd45a), 
which has significantly higher expression levels in the HYP groups at days 19 and 25 
rel. to CHF and CON, and heme-oxygenase 1 (HO1), which has higher expression 
levels in the CHF group rel. to both HYP and CON at days 10, 19 and 25 (Figure 4), 
may be able to predict the emergence of either an adaptive or maladaptive 
hypertrophic phenotype.  
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The micro-array data from all four time points may also provide a more solid basis, 
or at least a starting point, for the development of a set of prognostic arrays for 
phenotypical outcome. Figure 5 shows the results of a simple approach taken to 
determine if there indeed is a subset of genes at each of the time points that may 
differentiate between the CON, HYP and CHF groups. For each of the four time 
points, the three experimental groups show complete or near complete separation. 
Still, one must keep in mind that only three to six arrays per group were used, which 
is a too small sample population for such predictor analyses. Thus, more research 
has to be done to confirm these claims, not only in MCT rats but also in other models 
for either adaptive or maladaptive ventricular remodelling, and a human patient 
population. The development of a diagnostic array which could classify patients on 
the basis of many differentiating genes may appear to be ideal, however, the major 
disadvantage is that one needs to obtain cardiac muscle tissue to perform the tests, 
which may not be easily accessible. 
 
▲Figure 5 - Hierarchical clustering separates the three experimental groups per time 
point. Classical One way ANOVA (p≤0.01) between groups for each separate time point. 
Significantly regulated genes were mean centered and normalized for genes followed by mean 
center and normalize per sample. Data were hierarchically clustered using average linkage and 
euclidean distance. Clustering was based on 37, 47, 122 and 381 significantly regulated genes 
for time points 10, 14, 19 and 25 days post MCT injections, respectively. Anova analyses and 
clustering were performed in the Tigr multiple experiment viewer which is part of the TM4 
software package33. From left to right, sample tree dendrograms are shown for days 10, 14, 19 
and 25, respectively. Note that the CON, HYP and CHF samples form separate clusters at each 
time point, except at day 14, where almost complete separation is seen. 
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4: Perspectives For Further Studies 
 
At several points in the previous paragraphs, proposals for further research have 
already been mentioned, and some additional options will be presented here. 
 
Extension Of The Expression Arrays Analyses 
The total genome of the taxus Rattus norvegicus, comprising 20 autosomes, one sex 
chromosome and a mitochondrial chromosome, contains an estimated 33.991 gene 
transcripts, ~20.000 of which may represent protein-coding genes 
(www.ensembl.org). The arrays used in the studies described in this thesis 
represented only ~24% of the whole protein-coding genome. New series of 
experiments covering a larger extent of the rat genome is likely to identify more 
genes with expression alterations that are associated with myocardial remodelling. 
Particularly, more genes may be identified that drive the differentiation between the 
adaptive and maladaptive hypertrophy groups. The new generation of arrays that are 
now available contain enough unique probe sequences to effectively cover the entire 
rat genome, e.g., Affymetrix and Agilent-technologies. 
The expression profiles obtained in this thesis were mainly focussed on the RV 
myocardium, with only a small representation of LV profiles (n=2 per group, Chapter 
2). Still, a small number of genes was indicated to be regulated in the LV. Extending 
the array analyses to other (extra)myocardial tissue components at different time 
points could further characterize this response and potentially reveal the origin of 
these additional effects. 
 
Proteome Analyses 
The 2-dimensional gel electrophoresis experiments displayed a high reproducibility, 
which is essential if one would like to extend the current day 10 analyses to span 
multiple time points, several tissue components and/or subcellular organelle 
fractions. Over 10% of the total number of regulated genes coded for genes with 
corresponding proteins that localized to the mitochondria, identifying it as an 
important affected subcellular compartment in heart failure.  
One shortcoming of the proteome analysis described in Chapter 4 is the relatively low 
number of positively identified significantly regulated proteins. A higher success-rate 
percentage will profoundly increase the value of the data presented. Moreover, in 
general, proteins may be subject to multiple forms of post-translational modifications 
like phosphorylation, acetylation, glycosilation. The study as it was performed was 
unable to detect such modification.  
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Unexplored here, but related to proteome analyses, is serum or plasma protein 
profiling. Blood is more conveniently collected than a small piece of ventricular 
tissue. Also urinary biomarkers may be explored as a potential means to classify 
patients to either a good or bad prognosis.  
  
General Extrapolation 
To assess whether the findings assembled in Chapters 2, 3 and 4, represent more 
generally applicable mechanisms, it will be essential to specifically explore these 
alterations in other animal models representing human cardiomyopathies as well as 
in the human patient population at risk.  
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5: Conclusions 
 
Does maladaptive right-ventricular hypertrophy evolve from an adaptive precursor 
state? The evidence presented in this thesis, accumulated by different techniques 
ranging from fundamental protein and mRNA measurements to physiological cardiac 
function determinations, states that it does not.  
Already early after the imposition of pressure overload in the MCT model for 
controlled phenotypical outcome, the adaptive and maladaptive hypertrophy groups 
differ at both the proteome and transcriptome levels. Maladaptive remodelling was 
associated with signs of aberrant cell-cycle progression, decreased mitochondrial 
beta-oxidation of fatty acids and increased mitochondrial electron transport chain 
activity at 10 days after MCT injections. At 14 days, decreased mitochondrial 
biogenesis paired with pro-death effector signalling via p38 MAPK were observed for 
maladaptive remodelling, while at day 25, decreased mitochondrial electron transport 
chain activity could be inferred from the micro-array expression data. These 
successive waves of detrimental processes over time ultimately culminate into 
maladaptive remodelling. 
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Introduction 
 
For more than thirty years, the development of concentric left ventricular (LV) 
hypertrophy in pressure overload was considered adaptive because the parallel 
deposition of new sarcomeres and the corresponding LV wall thickening succeeded to 
normalize LV systolic wall stress despite the high intracavitary systolic pressure1. In 
aortic stenosis, the validity of this paradigm was demonstrated by hemodynamic 
studies, which established an inverse relationship between LV systolic wall stress and 
LV ejection fraction (EF) and by clinical outcome studies, which demonstrated worse 
postoperative prognosis if LV performance fell below this inverse LV wall stress-LVEF 
relationship2, 3. This clinical paradigm of adaptive myocardial hypertrophy developing 
during progression of aortic stenosis clearly withstood the test of time despite the 
mounting epidemiological evidence of LV hypertrophy being associated with excess 
cardiac mortality and despite the ominous significance of LV hypertrophy in 
congenital aortic stenosis.  
In this issue of the European Heart Journal, Kupari et al. are the first to challenge the 
time-honored concept of adaptive LV hypertrophy in aortic stenosis4. In a carefully 
designed prospective study of patients with isolated aortic stenosis, they observed an 
inverse relation between LV mass index and LVEF and a higher prevalence of LV 
hypertrophy in patients suffering of heart failure. They therefore concluded that 
development of LV hypertrophy was actually promoting heart failure instead of 
preventing it. 
 
 
Basic Inspiration 
 
When Kupari et al. started their prospective study 5 years ago, they were well ahead 
of the crowd in appreciating emerging basic evidence on pressure overload-induced 
myocardial hypertrophy and in translating it to clinical cardiology5. During LV 
pressure overload, the raised biomechanical stress on the cardiac myocytes 
stimulates various signal transduction pathways to the nucleus6 and induces 
autocrine production and secretion of angiotensin II and endothelin, whose receptors 
are coupled to Gq proteins. It was precisely in a mouse model with cardiorestricted 
deficiency in Gq signalling that the paradigm of adaptive LV hypertrophy during 
pressure overload received a first serious blow7. After one week of aortic constriction, 
control mice showed complete normalization of LV systolic wall stress in contrast to 
the cardiac gene-targeted mice, who had a blunted hypertrophic response and were 
unable to reduce LV systolic wall stress. After 8 weeks of aortic constriction, despite 
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initial normalization of wall stress, control mice developed an increase in chamber 
dimensions and progressive deterioration of LV function with echocardiographic 
fractional shortening falling from 59 to 35%. In contrast, cardiac gene targeted mice 
with blunted LV hypertrophy and persistent elevation of LV systolic wall stress 
showed after 8 weeks only limited LV dilatation and preserved LV function with an 
echocardiographic fractional shortening of 52%. From these experiments it was 
concluded that in pressure overload the left ventricle is better off being “stressed 
out” than being hypertrophied.  
In other models of experimental pressure-overload, investigators however clearly 
succeeded in creating adaptive or physiological hypertrophy. One of these models 
was a rat model of right ventricular (RV) hypertrophy caused by 
monocrotaline(MCT)-induced pulmonary hypertension8. When rats were given 30 
mg/kg of MCT subcutaneously, they developed slow onset pulmonary hypertension 
and adaptive RV hypertrophy but when rats were given 80 mg/kg of MCT, there was 
rapid development of pulmonary hypertension, which was accompanied by RV failure 
and by premature death. Fourteen days after MCT injection, RV hypertrophy was still 
identical in rats having received 30 or 80 mg/kg of MCT. However, when RV 
myocardium was subjected to a micro-array analysis 14 days after MCT injection, 63 
genes out of the 3010 cardiac genes screened were already differentially expressed 
between rats that had received 30 mg/kg of MCT and were going to develop adaptive 
RV hypertrophy and rats that had received 80 mg/kg of MCT and were going to 
develop RV failure. This study implies that adaptive hypertrophy does not precede 
maladaptive hypertrophy in pressure-overload and that the magnitude of the initial 
pressure-overload stimulus predestines the myocardium to development of an 
adaptive or maladaptive phenotype. In accordance to these results, development of 
heart failure in the mice-aortic constriction model and in clinical aortic stenosis is 
related respectively to the tightness of the aortic band and to the progression of 
valvular stenosis. Clinical trials, which try to slow the progression of valvular stenosis 
with statins or angiotensin converting enzyme inhibitors could test the validity of this 
assumption by demonstrating slower progression of valvular stenosis to be 
accompanied by reduced incidence of heart failure.  
 
 
Clinical Translation 
 
Before converting to the iconoclastic view that in aortic stenosis LV hypertrophy is 
maladaptive, a critical appraisal of the evidence provided by Kupari et al. seems 
justified. The following issues are of concern: 1) failure to identify and to characterize 
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aortic stenosis patients with LV hypertrophy and no heart failure, i.e. with adaptive 
LV hypertrophy; 2) no demonstration of a persistent elevation of LV wall stress in the 
aortic stenosis patients without LV hypertrophy and 3) presence of discordant LVEF-
LV hypertrophy relationships when LV hypertrophy is assessed either by LV mass 
index or by relative wall thickness.  
Sixty three aortic stenosis patients were free of heart failure and had evidence of LV 
hypertrophy defined by a LV mass index > 110 g/m2 in women and by a LV mass 
index > 134 g/m2 in men. This group was larger than the group of aortic stenosis 
patients presenting with heart failure and similar evidence of LV hypertrophy (n=39). 
Aortic stenosis patients with adaptive LV hypertrophy therefore outnumbered aortic 
stenosis patients with maladaptive LV hypertrophy in this prospective study 
population. The investigators failed to look for clinical features discriminating patients 
with adaptive LV hypertrophy from patients with maladaptive LV hypertrophy. Such 
discriminating clinical features could have identified an hormonal or environmental 
background, which predisposes pressure-overload hypertrophy to evolve into a 
maladaptive phenotype. In this respect, body mass index and arterial blood pressure 
were significantly higher in the patients who developed heart failure. Obesity and 
hypertension are established risk factors for LV diastolic dysfunction9 and as aortic 
stenosis progresses, these co-morbidities can direct LV hypertrophy towards a 
maladaptive phenotype with diastolic heart failure. Obesity and hypertension are 
both associated with insulin resistance, which lowers myocardial nitric oxide (NO) 
content by reducing protein kinase B-mediated endothelial NO synthase (NOS3) 
phosphorylation. Myocardial NO content is a potent modulator of the hypertrophy 
process as recently demonstrated in transgenic mice with cardiac-myocyte restricted 
NOS3 overexpression10. Hence, development of maladaptive LV hypertrophy should 
not necessarily be ascribed to the hypertrophy gene programme but could also result 
from deleterious modification of its expression by hormonal and environmental 
factors.  
Normalization of LV wall stress is a key feature of the adaptive hypertrophy paradigm 
in pressure overload. In the original studies that applied this paradigm to aortic 
stenosis, failure to normalize LV wall stress was kept responsible both for contractile 
dysfunction2 and for poor postoperative outcome3. The study by Kupari et al. comes 
to the opposite conclusion as they observe better contractile function in the absence 
of LV hypertrophy. Absence of LV hypertrophy in their study does however not imply 
persistent elevation of LV wall stress, which they unfortunately failed to measure. As 
mentioned before, LV hypertrophy was diagnosed when LV mass index exceeded 
preset values. Since LV mass index also depends on LV end-diastolic volume index, 
its use to categorize patients for LV hypertrophy can cause patients with small LV 
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volumes and moderate increase in LV wall thickness to end up in the group “without 
LV hypertrophy”. This indeed happened as evident from Table 3, which shows 
patients “without LV hypertrophy” to have elevated septal (13±0.3 mm) and 
posterior (12±0.4 mm) wall thickness and a LV end-diastolic diameter smaller than 
the patients “with LV hypertrophy”. Patients labeled as having no LV hypertrophy 
could well have developed sufficient LV hypertrophy to normalize LV wall stress for a 
small LV cavity and their superior contractile performance was therefore no surprise. 
To clarify this issue, the study needs to be implemented with an invasive assessment 
of LV wall stress. 
Finally, since LV mass index depends on LV end-diastolic volume index and since LV 
end-diastolic volume index was significantly larger in the heart failure group, the 
inverse relation between LV mass index and LVEF can also be explained by an 
inadequacy of LV hypertrophy to normalize LV wall stress for a large LV cavity. In 
fact, when LV mass index was replaced by relative wall thickness (i.e. septal and 
posterior wall thickness divided by end-diastolic diameter), this inadequacy of LV 
hypertrophy got accounted for and the relation between LVEF and LV hypertrophy 
actually reversed with a higher LVEF now being observed at a higher relative wall 
thickness. 
 
 
Conclusion 
 
Avoidance or modification of maladaptive LV hypertrophy remains a major clinical 
challenge. The study by Kupari et al. deserves credit for being the first to translate 
recent basic evidence on maladaptive myocardial hypertrophy to the clinical setting 
of valvular heart disease. At present, their iconoclastic idea on LV hypertrophy in 
aortic stenosis awaits further confirmation by invasive studies. As with all iconoclastic 
acts, history will tell if it cleared perspectives or spoiled the view. 
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Adaptive and maladaptive myocardial remodelling due to pressure 
overload do not evolve from a common hypertrophy precursor stage 
Characterization of ventricular proteome and transcriptome profiles 
 
Summary 
 
Heart failure contributed to approximately 287.200 deaths in the year 1999 in the 
United States and on average, 5 million cases of heart failure exist in the U.S alone. 
Two recent epidemiological studies, based on two separate populations, indicated an 
overall higher incidence of heart failure in men, with no decreased incidence over 
time. For women however, one study showed decreased incidence while the other 
indicated no change during the last two decades. Both studies indicated an overall 
increase in the survival rate, in particular for men and young persons. However, this 
increase in survival rate was less prominent in women and the elderly. With an 
overall 5 year survival rate of 52% and an increasing elderly population, heart failure 
remains a major health problem. 
Heart failure is a clinical end-point of a syndrome characterized by a progressive loss 
of pump function, manifested by respiratory distress, pedal edema and ascites, and 
profound exercise intolerance. Myocardial ventricular hypertrophy is a major risk 
factor that is associated with a higher incidence of clinical events, morbidity and 
mortality from cardiovascular disease, generally leading to heart failure. Although 
myocardial hypertrophy due to pressure overload is aimed at normalizing wall stress, 
depending on the degree and duration of the overload, the hypertrophic response 
may progress into a state of compromised cardiac function, ultimately leading to 
congestive heart failure. Ventricular hypertrophy is both associated with, and 
characterized by, many known alterations at the transcriptome and proteome 
expression levels. Well known examples of which are changes in extracellular matrix 
composition, a switch in energy metabolism substrate, altered signal transduction 
pathway activity and impaired calcium handling. However, which of the alterations 
are critical to the development of either an adaptive or maladaptive hypertrophy 
phenotype is under debate. Moreover, the time point at which the divergence 
between the phenotypes occurs during pressure overload remains unknown.  
 
The work presented in this thesis was focussed on investigating alterations on the 
transcriptome and proteome level that occur during myocardial hypertrophic 
remodelling which are associated with the divergence towards either an adaptive or 
maladaptive phenotype. Micro-array analysis and 2-dimensional gel electrophoresis 
were the techniques of choice to determine these pivotal molecular events on both 
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the transcriptome and proteome level, respectively. To this end, protein- and mRNA-
expression levels were compared between adaptive and maladaptive hypertrophy 
responses to pressure overload over time.  
 
Chapter 2 first describes the animal model representing human pulmonary 
hypertension (PH) that allowed for the controlled induction of either an adaptive or 
maladaptive phenotype. Right ventricular (RV) hypertrophy secondary to PH was 
induced by a single injection of monocrotaline (MCT). A subcutaneous MCT injection 
of 30 mg/kg leads to stable adaptive RV hypertrophy (HYP) while 80 mg/kg leads to 
a transient phase of adaptive RV hypertrophy (day 14-19) followed by maladaptive 
hypertrophy and RV failure (CHF) around day 25-28. This MCT-dose-controlled model 
for RV hypertrophy provided the unique opportunity to characterize the molecular 
myocardial changes during the initial stages of pressure overload and was therefore 
used to investigate ventricular mRNA and protein expression levels well before overt 
phenotypical differences became apparent.  
RV gene-expression profiles generated by a rat oligonucleotide micro-array 
representing 4803 unique features, were compared between animals developing 
adaptive hypertrophy, maladaptive hypertrophy and control (CON) animals at 14 
days after the imposition of pressure overload. At this time point, the level of 
developed hypertrophy was identical for both the adaptive and maladaptive 
hypertrophy phenotypes when compared to control animals.  
Of the 3060 selected features for analysis on the arrays, 179 were significantly 
differentially expressed between the three groups. Clustering of these significantly 
regulated genes revealed distinct clusters with different expression profiles. Some of 
these clusters represented genes that were equally differentially expressed in both 
the adaptive and maladaptive hypertrophy groups relative to control expression 
levels. Two clusters were found that specifically correlated with phenotypical outcome 
of either MCT treated group, i.e., one of these clusters represented genes with 
specifically altered expression levels in the adaptive hypertrophy group only (2 up- 
and 4 downregulated), while the other represented genes with altered expression 
levels for the maladaptive hypertrophy group only (25 up and 6 downregulated). 
Moreover, genes in these specific profiles indicated that processes involving p38-
MAPK signalling and apoptosis could be related to the adaptive or maladaptive 
phenotypical outcome.  
These findings indicated that distinct expression profiles and potentially decisive 
pathways had already been initiated at an early time point during ventricular 
remodelling, which could indicate that the maladaptive and adaptive groups were 
already different very early after the imposition of pressure overload. 
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In Chapter 3 we extended the analysis of gene-expression alterations during adaptive 
or maladaptive hypertrophic remodelling, to include more time points after MCT 
injections. Micro-array experiments were performed at day 10, when RV hypertrophy 
had not yet developed and phenotypes were identical, at day 19 when RV 
phenotypes started to diverge and at day 25 when RV phenotypes were different. 
Force frequency relationship (FFR) determinations from isolated rat trabeculae clearly 
indicated ventricular dysfunction in the CHF group showing a positive FFR response 
for both the CON and HYP animals at day 25, whereas CHF animals did not show this 
potentiation.  
Out of the 3148 selected features for analysis, an analysis of variance statistical 
framework identified 584 significantly regulated genes between the three 
experimental groups over time. When comparing CON to HYP, 8, 123 and 386 genes 
were differentially expressed at day 10, 19 and 25, respectively. When comparing 
CON to CHF, 42, 125 and 454 genes were differentially expressed at day 10, 19 and 
25, respectively. Some of these genes were significantly regulated at more than one 
time point, primarily at days 19 and 25. Also, a considerable number of genes 
existed that were equally regulated in both HYP and CHF group relative to CON. This 
indicated that there is a general increase in the total number of differentially 
expressed genes as ventricular remodelling progressed with time. However, when 
comparing HYP to CHF the number of differentially expressed genes is almost 
constant with 13, 13 and 16 genes differentially expressed on day 10, 19 and 25, 
respectively. 
Self organizing map clustering was used to visualize the changes in expression of the 
584 regulated genes over time. Many of the clusters found represented genes with 
equal significant differential expression in both hypertrophy groups relative to time-
matched control animals, especially at days 19 and 25 after MCT injections. Gene-
ontology (GO) over-representation analyses on these clusters of genes, indicated 
substantial alterations affecting lipid metabolism and the mitochondrial 
compartments, which predominantly represented downregulated genes. In contrast, 
clusters of upregulated genes represented extracellular matrix composition, cell 
adhesion and muscle development. However, for a subset of clusters, the expression 
levels of the genes in the CHF group had a tendency to be altered just prior to those 
same genes in the HYP group. Interestingly, genes with corresponding proteins 
involved in cell-cycle progression control were an over-represented GO classification 
in these latter clusters.  
A gene set enrichment analysis (GSEA) using GenMapp pathways was performed to 
more specifically characterize differences between the HYP and CHF groups at all 
three time points. Several pathways were implicated to predispose adaptive and 
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maladaptive remodelling. Genes with corresponding proteins involved in the 
mitochondrial electron transport chain showed decreased expression in CHF relative 
to the HYP at day 25, while the inverse was observed for this pathway at day 10 after 
imposition of pressure overload. In addition, genes representing the cell cycle control 
pathway showed higher expression in CHF than HYP at day 10. Of these cell cycle 
genes, cyclin B1, cdc2a and p55cdc were confirmed by realtime PCR to be 
differentially overexpressed in the CHF group relative to both HYP and CON. Cyclin 
B1 and cdc2a have important functions in regulating the G2/M cell-cycle transition. 
Furthermore, Gadd45a, an inhibitor of G2/M transition, was shown to be 
overexpressed in the HYP group. This suggested an important role for proper 
regulation of cell-cycle progression to be associated with phenotypical divergence 
between adaptive and maladaptive hypertrophy. 
These findings further challenged the existence of a “transition to heart failure”. More 
specifically, these data indicated that, instead of adaptive and maladaptive 
hypertrophic phenotypes evolving from an common hypertrophic precursor state, the 
myocardial responses in animals developing either of these phenotypes are already 
different from a very early time point after the imposition of pressure overload. 
Furthermore a critical role for proper cell-cycle control at the G2/M transition was 
suggested to be associated with the differentiation between the adaptive and 
maladaptive phenotypes early after the imposition of pressure overload. 
 
Parallel to the gene-expression analyses in Chapter 3, RV myocardial proteome-
expression profiles obtained from animals at 10 days after MCT injections were 
compared using 2-dimensional gel-electrophoresis in Chapter 4. Of the 353 protein 
spots that were analysed, 5, 15 and 23 were significantly differentially expressed 
between the CON to HYP, CON to CHF and HYP to CHF comparisons, respectively. 
Some proteins were significantly regulated in more than one of the pair-wise 
comparisons. Of these proteins, mitochondrial Enoyl-CoA hydratase (Echs1) was 
shown to be specifically downregulated in the CHF group rel. to the HYP and CON 
groups, which was paralleled by a similar significant decrease at the mRNA level. 
Echs1 catalyses the second reaction step in the mitochondrial beta-oxidation of fatty 
acids, suggesting that a change in energy metabolism substrate precedes 
phenotypical divergence.  
These data indicated that not merely specific mRNA levels were different between 
adaptive and maladaptive remodelling early after the imposition of pressure 
overload, but that this was also true for specific proteins. These data further 
substantiated the findings presented in Chapter 3.  
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Adaptive en maladaptive myocardiale remodelling door druk 
overbelasting onstaan niet  vanuit een overeenkomstig hypertroof 
voorloper stadium 
Karakerizatie van ventriculaire proteoom en transcriptoom profielen 
 
Samenvatting 
 
Hart falen was verantwoordelijk voor ongeveer 287.200 sterfgevallen in 1999 in de 
Verenigde Staten, waar er alleen al naar schatting 5 miljoen patiënten met hart falen 
voorkomen. Uit twee recente, op onafhankelijke populaties uitgevoerde 
epidemiologische studies, is gebleken dat hart falen vaker voorkomt bij mannen, 
zonder verminderde incidentie door de tijd. Echter, voor vrouwen bleek uit een van 
deze studies een afgenomen incidentie, terwijl de andere geen verandering aangaf 
voor de laatste twee decennia. In het algemeen gaven beide studies een toegenomen 
overlevings kans aan, met name voor mannen en jongere personen. Doch, deze 
toegenomen overlevingskans was minder evident bij vrouwen en oudere mensen. 
Met een gemiddelde 5-jarige overlevingskans van 52% en de toenemende vergrijzing 
van de bevolking blijft hart falen een groot medisch probleem. 
Hart falen is het klinische eind-punt van een syndroom dat wordt gekarakterizeerd 
door progresief verlies van pomp funktie, dat zich kenbaar maakt door ademhalings 
moeilijkheden, vochtophoping in de benen met ascites, en onverdraagzaamheid van 
lichaamsbeweging. Myocardiale ventrikel hypertrofie is een van de belangrijkste risico 
factoren, die geassocieerd zijn met een hogere frequentie van klinische manifestatie, 
morbiditeit en mortaliteit, die in het algemeen leidden tot hart falen. Hoewel 
myocardiale hypertrofie als gevolg van druk overbelasting gericht is op normalizatie 
van wand spanning, is het afhankelijk van de duur en mate van de overbelasting of 
deze hypertrofe reactie zal doorslaan naar een toestand van belemmerde hart 
funktie, die uiteindelijk zal leidden tot hart falen. Ventrikel hypertrofie is zowel 
geassocieerd met, als te karakterizeren door, vele erkende veranderingen op het 
transcriptoom en proteoom expressie niveau. Bekende voorbeelden hiervan zijn 
veranderde extracellulaire matrix samenstelling, een substraat wisseling mbt. energie 
metabolisme, gewijzigde activiteit van signaal transductie routes en belemmerd 
calcium transport. Echter, er is nog geenszins overeenstemming over welke van deze 
veranderingen kritiek zouden zijn voor de ontwikkeling van enerzijds een adaptief of 
anderzijds een maladaptief fenotype. Bovendien is het tijdspunt waarop de splitsing 
tussen deze twee fenotypes optreed nog altijd onbekend. 
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Het werk dat in dit proefschrift wordt gepresenteerd, is gericht op het ontrafelen van 
veranderingen die optreden op het transcriptoom en proteoom niveau tijdens 
myocardiale hypertrofe remodelling, die geassocieerd zijn met het opsplitsen van de 
adaptive en maladaptive fenotypes. Micro-array analyses en twee-dimensionle gel 
electroforese zijn de gebruikte technieken om de kritieke molekulaire voorvallen op 
respectivelijk het transciptoom en proteoom niveau te bestuderen. Hiervoor zijn eiwit 
en mRNA expressie niveaus vergeleken tussen adaptive en maladaptive hypertrofe 
responsen op druk overbelasting in de tijd.  
In Hoofdstuk 2 wordt eerst het dieren model voor humane pulmonaire hypertensie 
(PH) beschreven. Dit model levert de mogelijkheid voor gecontroleerde inductie van 
hetzij een adaptief of maladaptief fenotype. Rechter ventrikulaire (RV) hypertrofie 
secundair aan PH werd geïnduceerd door een enkele injectie van monocrotaline 
(MCT). Een subcutane MCT injectie van 30 mg/kg leidt tot een stabiele adaptive RV 
hypertrofie (HYP), terwijl 80 mg/kg leidt tot een transiente fase van adaptive 
hypertrofie (dag 14-19) gevolgd door maladaptive hypertrofie en RV falen (CHF) rond 
dag 25-28. Dit model van dosis gecontroleerde RV hypertrofie levert de unieke 
mogelijkheid om de mocelulaire veranderingen gedurende de initiele fase van druk 
overbelasting the karakterizeren en is om die reden gebruikt om ventriculaire mRNA 
en eiwit expressie verschillen te bestuderen ruim voordat fenotypische verschillen 
duidelijk zichtbaar worden.  
RV gen-expressie profielen gegenereerd mbv. een rat oligonucleotide micro-array 
representatief voor 4803 unieke gen-sequenties, werden vergeleken tussen adaptive, 
maladaptive en controle (CON) dieren op 14 dagen na het opleggen van de druk 
overbelasting. Op dit tijdspunt is de mate van ontwikkelde hypertrofie identiek voor 
het adaptive en maladaptive hypertrofe fenotype tov. de controle dieren. 
Van de 3060 voor analyse geselecteerde gen-sequenties waren er 179 met 
significante differentiële expressie tussen de drie groepen. Het clusteren van deze 
significant gereguleerde genen duidde op afzonderlijke clusters met verschillende 
expressie profielen. Sommige van deze clusters waren representatief voor genen met 
gelijke mate van differentiële expressie in zowel adaptive als maladaptive hypertrofie 
tov. de controle expressie niveaus. Twee clusters werden gevonden die specifieke 
correlaties vertoonde met de fenotypische uitslag van de twee gebruikte MCT doses, 
dwz, een van deze clusters was representatief voor genen met specifiek veranderde 
expressie niveaus in de adaptive hypertrofie groep (2 verhoogde- en 4 verlaagde 
expressie), terwijl de andere representatief was voor genen met specifiek veranderde 
expressie niveaus in de maladaptive hypertrofie groep (25 verhoogde- en 6 
verlaagde expressie). Bovendien duidde de genen met deze specifieke expressie 
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profielen op de betrokkenheid van p38-MAPK signalering en apoptose op de 
uiteindelijke gevormde adaptive en maladaptive fenotypes. 
Deze bevindingen gaven aan dat afzonderlijke expressie profielen en potentiëel 
doorslaggevende routes al op een vroeg tijdspunt tijdens ventriculaire remodelling 
geinitiëerd waren, wat zou kunnen betekenen dat de maladaptive en adaptive 
groepen al heel kort na het opleggen van druk overbelasting reeds verschillend zijn. 
 
In hoofdstuk 3 verlengen we de analyse van gen-expressie veranderingen gedurende 
adaptive of maladaptive remodelling met meerdere tijdspunten na MCT injecties. 
Micro-array experimenten werden uitgevoerd voor dag 10, wanneer RV hypertrofie 
nog niet evident was en de fenotypes identiek zijn, voor dag 19, wanneer RV 
fenotypes uiteen beginnen te lopen en voor dag 25, wanneer RV fenotypes 
verschillend zijn. Kracht-frequentie relatie (KFR) bepalingen op geïsoleerde ratten 
trabekels gaven duidelijk gestoorde ventriculaire funktie aan voor de CHF groep. 
Zowel de CON als de HYP groep vertoonde een positieve KFR response voor dieren op 
dag 25, terwijl de CHF dieren deze potentiatie niet weergaven. 
Van de 3148 voor analyse geselecteerde gen-sequenties werden er 584 genen 
geïdentificeerd met significante regulatie tussen de drie groepen in de tijd. Voor de 
CON met HYP vergelijking kwamen 8, 123 en 386 genen differentiëel tot expressie op 
respectivelijk dag 10, 19 en 25. Voor de CON met CHF vergelijking kwamen 42, 125 
en 454 genen differentiëel tot expressie op respectivelijk dag 10, 19 en 25. Een 
aantal van deze genen waren significant gereguleerd op meer dan een tijdspunt, met 
name op dagen 19 en 25. Ook was er een aanzienlijk aantal genen met gelijke mate 
van differentiële expressie in de HYP en CHF groepen tov. de controle expressie 
niveaus. Deze data gaven aan dat er spake is van een globale toename van 
differentiële gen expressie bij het vorderen van de ventriculaire remodelling in de 
tijd. Echter, het aantal differentiële genen voor de HYP met CHF vergelijking was 
vrijwel constant, met 13, 13 en 16 genen differentiële genen op respectivelijk dag 
10, 19 en 25. 
Om de expressie veranderingen van de 584 gereguleerde genen in de tijd weer te 
geven, werd Self organizing map clustering toegepast. Veel van de gevonden clusters 
waren representatief voor genen met gelijke significante differentiële expressie in 
beide hypertrofie groepen tov. de tijds-controle groep. Dit was met name zo voor 19 
en 25 dagen na MCT injecties. Gen-ontologie (GO) over-representatie analyses 
uitgevoerd op deze clusters van genen gaven aan dat er aanzienlijke veranderingen 
optraden mbt. het lipide metabolisme en het mitochondriale compartiment, voor 
genen met voonamelijk verlaagde expressie niveaus. In contrast, clusters met 
vehoogde gen-expressie waren representatief voor veranderingen in extracellulaire 
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matrix samenstelling, cel adhesie en spier opbouw. Echter, in een klein aantal 
clusters was een trend zichtbaar waarbij veranderingen in gen-expressie niveau van 
de CHF groep eerder optraden dan voor deze zelfde genen in de HYP groep. 
Interessant genoeg vertoonde genen met corresponderende eiwitten die een 
regulerende rol spelen in de cel-cyclus progressie, significante GO classificatie over-
gerepresentatie in deze laatst genoemde clusters. 
Een gene set enrichment analysis (GSEA) op GenMapp-routes werd vervolgens 
uitgevoerd om de verschillen tussen HYP en CHF op de drie tijdspunten specifieker te 
karakterizeren. Meerdere routes bleken betrokken bij het predisponeren van adaptive 
en maladaptive remodelling. Genen met corresponderende eiwitten die betrokken 
zijn in de mitochondriale ademhalingsketen vertoonde verlaagde expressie in CHF 
tov. HYP op dag 25, terwijl het ongekeerde werd waargenomen voor deze route voor 
dag 10 na opleggen van de druk overbelasting. Ook kwamen genen die 
representatief zijn voor de cel-cyclus regulatie route hoger tot expressie in de CHF 
groep dan in de HYP groep op dag 10. De significant toegenomen expressie van de 
cel-cyclus genen cyclin B1, cdc2a en p55cdc in de CHF groep tov. HYP en CON, was 
bevestigd met realtime PCR. Cyclin B1 en cdc2a zijn belangrijk bij regulatie van de 
G2/M cel-cyclus transitie. Bovendien kwam de G2/M transitie remmer, Gadd45a 
significant hoger tot expressie in de HYP groep. Dit opperde dat een belangrijke rol 
van correcte regulatie van de cel-cyclus progressie is weggelegd bij de fenotypische 
opsplitsing tussen adaptive en maladaptive hypertrofie. 
Deze bevindingen legde verdere twijfels bij het bestaan van een “transitie naar hart 
falen”. Specifieker gesteld, deze data geven aan dat de myocardiale responsen in 
dieren die een van deze fenotypes ontwikkellen, al verschillen op een heel vroeg 
tijdspunt na te oplegging van druk overbelasting, in paats van dat de adaptive en 
maladaptive hypertrofe fenotypes onstaan uit een overeenkomstige voorloper 
toestand. Bovendien, een kritieke rol voor correcte cel-cyclus controle tijdens de 
G2/M transitie werd geassocieerd met de differentiatie tussen de adaptive en 
maladaptive fenotypes op een vroeg tijdspunt na de oplegging van druk 
overbelasting. 
 
Parallel aan de gen-expressie analyses uit Hoofdstuk 3 worden in Hoofdstuk 4 
myocardiale RV proteoom-expressie profielen van dieren op 10 dagen na MCT 
injecties vergeleken mbv. 2-dimensionale gel electroforese. Van de 353 eiwit spots 
die geanalyseerd zijn, waren er respectivelijk 5, 15 en 23 met significante 
differentiële expressie tussen de CON vs. HYP, CON vs. CHF en HYP vs. CHF 
vergelijkingen. Sommige van deze eiwitten kwamen voor in meer dan een van de 
groeps vergelijking. Van deze eiwitten vertoonde het mitochondriale Enoyl-CoA 
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hydratase (Echs1) specifieke expressie verlaging in de CHF groep tov. de HYP en 
CON dieren, en een parallele verlaging in expressie werd gevonden op het mRNA-
transcript niveau. Het Echs1 katalyseert de tweede stap van de mitochondriale beta-
oxidate van vetzuren, wat inpliceert dat veranderingen in energy metabolisme 
substraat optreden vóór fenotypische opsplitsing. 
Deze data geven aan dat vroeg na de oplegging van druk overbelasting niet alleen 
specifieke mRNA niveaus verschillen tussen adaptive en maladaptive remodelling, 
maar dat dit ook geldt voor specifieke eiwitten. Deze data onderbouwde onze 
bevindingen uit Hoofdstuk 3. 
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